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ABSTRACT 
Current golden standard therapy for bone repair and regeneration involves the use of 
auto grafts. Nevertheless, there are many drawbacks associated with auto grafts 
including donor site morbidity, requirement for an invasive surgery, post-operative 
pain and infection. The use of injectable tissue engineered bone is an attractive 
alternative, providing a minimally invasive approach to regenerate bone. It offers 
faster healing, less pain and exact conformation to irregular defects. The present work 
is designed to achieve injectable formulations of tissue engineered bone that fulfil the 
requirements needed. It involves investigation of potential polymeric binders that are 
biocompatible, biodegradable and allow bone formation when combined with cells. 
Chitosan binders were tested for biocompatibility, biodegradability, gelation, 
angiogenic potential and osteogenic differentiation and bone formation when mixed 
with goat and human bone marrow derived mesenchymal stem cells (gMSCs, 
hMSCs). An in vivo bone formation study was performed to investigate the bone 
formation ability of gMSCs in contact with chitosan binder. Chick chorioallantoic 
membrane assay was carried out to examine the angiogenic potential of the chitosan 
binder combined with/without hMSCs. Furthermore, MC3T3-El cells were employed 
to assess the osteogenic potential of cells exposed to chitosan polymeric systems. 
Chitosan binder was proved to be an attractive polymer to carry cell-scaffold 
combination. hMSCs were able to survive and differentiate along the osteogenic 
lineage when encapsulated with 1.5% (w/v) chitosan-15% (w/v) glycerol phosphate 
(GP)-0.18% (w/v) hydroxyethyl cellulose (HEC) in a 14-day study. Furthermore, 
chitosan-GP-HEC solutions demonstrated fast gelation at 37°C. Chitosan was 
biodegradable following 42 days in the presence/absence of lysozyme. Moreover, 
gMSCs combined with chitosan binder produced 24.6 ± 13.7% bone comparable to 
the control group after a 6-week implantation in mice. Chitosan was shown to be non-
angiogenic unlike hMSCs which showed angiogenic potential. Also, chitosan was 
found to be osteogenic at 2 and 0.05 mg/ml concentrations. 
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1.1 GENERAL INTRODUCTION 
The bone graft and bone graft substitute market is continuously growing mostly due 
to an increase in the population of the elderly. Presently in the UK, the population of 
over 65 age group is more than under 16 age group (Datamonitor-Publications, 2002). 
In addition, there is an increase in the number of osteodegenerative diseases in the 
rapidly aging population present in the developed countries (Heng et aI., 2004). This 
has made bone to be the second most commonly transplanted tissue after blood 
(Angermann and Jepsen, 1991). The current golden standard therapy for bone repair 
and regeneration is autograft (Yaszemski et aI., 1996-a), however, there are certain 
disadvantages associated with their use such as post-operative pain, infection, nerve 
injury and donor-site morbidity (Damien and Parsons, 1991; Gitelis and Saiz, 2002; 
Lane et aI., 1999; Younger and Chapman, 1989). Therefore, a new efficient approach 
is needed to create living autologous equivalent which combines cells (osteogenic 
component), scaffold (to provide volume and attachment sites for cells) and binder 
(for better handling properties) in order to replace auto grafts. Mesenchymal stem cells 
are attracting much attention due to their differentiation potential to many lineages 
including the osteogenic lineage (Haynesworth et aI., 1992; Prockop, 1997). Stem 
cells together with calcium phosphate scaffolds hold great potential to create suitable 
regeneration models which aim at regenerating bone tissue. This thesis investigates a 
cellular therapy approach to repair and regenerate bone through the use of stem cells, 
calcium phosphate scaffolds and an injectable binder, all of which will be explained 
in more detail in this chapter along with the background behind this thesis. 
1.2 THE STRUCTURE AND FUNCTION OF 
BONE 
Bone is a connective tissue which provides an internal support system in vertebrates 
therefore functioning as a structural frame supporting the body. It also offers 
attachment points for muscles and protects the vital organs such as heart, lung, spinal 
cord and brain. It holds the blood forming elements of bone marrow. Furthermore, it 
contains 99% of the body's calcium, 85% of the body's phosphorous and 65% of the 
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body's sodium and magnesium. It participates in maintaining homeostasis of calcium 
and phosphorous in the blood and other body fluids such as extracellular fluid 
(Fawcett and Raviola, 1994; Rosenberg, 1999). Bone is a complex tissue which unites 
the elastic properties of collagen fibers together with the compressive strength of 
hydroxyapatite crystals. 
There are two structural forms associated with bone, cancellous and cortical bone. 
Typically. 800/0 of the adult skeleton is composed of cortical (compact) bone and the 
remaining 200/0 is in fact cancellous (trabecular) bone (Buckwalter et aI., 1995). 
Cortical bone is stiff, dense, smooth and continuous. It forms around the loosely 
organized porous cancellous bones as well as the shaft that surrounds the marrow 
cavity of long bones (Athanasiou et aI., 2000). Cortical bone holds significant 
mechanical and protective roles while cancellous bone is more metabolically active 
(Table 1.1). 
Table 1.1- Tensile/compressive strength and tensile/compressive modulus of cortical 
and trabecular bones (Mistry and Mikos, 2005; Yaszemski et aI., 1996-a). 
Type of Bone Tensile Strength Compressive Strength Tensile/Compressive 
Modulus 
Cortical Bone 79-151 MPa 131-224 MPa 17-20 GPa 
Trabecular Bone 5-10 MPa* 5-10 MPa* 50-100 MPa* 
* The values vary with density but are reported to be within the mentlOned range. 
Both the cortical and cancellous bones contain an extracellular matrix composed of an 
organic component - about 90-95% collagen type I while the rest is comprised of 
non-collagenous proteins (osteocalcin, osteopontin, osteonectin, bone sialoprotein) -
and an inorganic component. The inorganic component contains deposits of crystals 
of calcium phosphate and significant amount of carbonate ions and citrate as well as 
traces of sodium, magnesium, silicone and fluoride. Biochemically, organic matrix 
forms 35% and inorganic matrix forms 65% of the bone dry weight (Fawcett and 
Raviola, 1994; Rosenberg, 1999). The bone cells are surrounded by extracellular 
matrix. Bone cellular composition is explained below in more detail. 
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1.2.1 Cellular Composition 
Bone tissue is composed of four major cell types: 
1. Osteoblasts - derived from mesenchymal stem cells and situated on the 
internal and external surfaces of bone where there is active bone formation 
(Jilka, 2003). They produce collagenous and non-collagenous proteins that 
form the organic matrix of bone called the osteoid (Jilka, 2003). 
2. Bone lining cells - known as inactive osteoblasts. They line bone surfaces 
appearing flatten and are involved in the regulation of passage of calcium in 
and out of bone (Junqueira et al., 1998). 
3. Osteocytes - mature osteoblasts surrounded by osteoid or mineralized bone. 
They stop secreting this matrix and are involved in bone mechanotransduction 
since mechanical loading leads to enhancement of osteocyte metabolic 
activity (Sikavitsas et aI., 2001). 
-t Osteoc1asts - derived from hematopoietic cells of the bone marrow and 
secrete acids and proteolytic enzymes which dissolve mineral salts and digest 
bone's organic matrix (Buckwalter et al., 1995; Jilka, 2003). They are 
involved in bone remodelling process that takes place on the surface and 
within the bone (Buckwalter et aI., 1995). The bone remodelling process is 
performed by both osteoc1asts and osteoblasts through an interaction referred 
to as coupling which is important for keeping a balance between the rate of 
bone resorption and formation. 
All of these cell types are important in the bone formation process which is described 
below in more detail. 
1.2.2 Bone Formation 
Bone is a dynamic living tissue which is constantly being renewed and reconstructed 
throughout the individual's lifetime. Generally bone forms by two mechanisms, 
endochondral and intramembranous ossification. Endochondral bone formation 
occurs by replacement of the pre-existing cartilage whereas intramembranous bone 
formation takes place by direct replacement of the primitive connective tissue (de 
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VemejouL 1996~ Fawcett and Raviola, 1994; Rosenberg, 1999). Intermembranous 
ossification is involved in the formation of flat bones from the skull and the addition 
of bone on the periosteal surfaces of long bones while endochondral ossification is 
associated with the formation of long bones and fracture repair (Junqueira et aI., 
1998~ Yaszemski ef aI., 1996-a). 
There are three key steps associated with bone formation: 
1. Extracellular matrix production 
2. Matrix mineralization 
3. Remodelling of bone by resorption and reformation 
Osteoblasts, osteocytes and osteoclasts are all important in the process of bone 
formation. On the surface of the existing matrix, there are osteoblasts which secrete 
osteoid (Figure 1.1). Osteoblasts are also involved in the mineralization of osteoid 
and while osteoid is changing into a hard matrix through apatite crystal deposition, 
the trapped osteoblasts become osteocytes. Osteocyte cellular processes occupy 
microscopic channels (canaliculi). Since the metabolites cannot diffuse through bone 
calcified matrix, canaliculi have an important role in signal transduction and 
exchanges of nutrients between osteocytes and blood vessels because they perforate 
the bone matrix. Bone is constantly going through dynamic remodelling which is 
essential for bone mechanical function and skeletal growth. This is a joined process 
between osteoclasts and osteoblasts which operate in a balanced manner therefore 
through resorption and reformation of bone, bone remodelling is taken place. 
In order to combine the natural healing response of the body in case of fracture with 
cellular therapy and to benefit from both, a deep knowledge of the healing events that 
occur at the fracture site is crucial. The following section explains in more detail 
about the fracture healing events that take place inside the body. 
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Osteoclast Mesenchyme Newly formed matrix (osteoid) 
Osteocyte 
Figure 1.1- Bone formation events from (Junqueira et aI., 1998). 
1.2.3 Fracture Healing 
A fracture causes a discontinuity within bone as well as causing function loss and 
tissue damage (i.e. blood vessels). Due to the injury, a cascade of healing events takes 
place to start the repair process which sum up some of the steps of embryonic bone 
formation (Yaszemski et aI., 1996-a). There are three stages involved in fracture 
healing: 
• Inflammation 
• Repair 
• Remodelling 
In the inflammatory phase, a hematoma is formed where blood vessels are damaged. 
Neutrophil granulocytes and macrophages arrive and ingest the cellular debris of 
necrosis as well as secreting cytokines and growth factors such as vascular 
endothelial growth factor (VEGF), fibroblast growth factor (FGF), tumour necrosis 
factor (TNF a) and interleukin (IL) (Braddock et aI., 2001). These biochemical signals 
result in migration, differentiation and activation of mesenchymal stem cells from 
neighbouring bone, marrow, endosteum and periosteum. Mesenchymal stem cells 
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produce bone morphogenic proteins (BMPs) which induce proliferation and 
ditlerentiation of these cells into bone-producing cells (Braddock et aI., 200 1). 
A fibrovascular granulation tissue is formed at the site of the injury by capillary 
growth and fibroblast activity. With progenitor cells accumulating and differentiating 
into osteoblasts, a repair blastema is produced. After the relatively short inflammatory 
stage, repair phase begins when osteoblasts rapidly secrete osteoid forming woven 
bone at the injury site. Slowly, the remodelling stage starts during which collagen 
fibers are reorganized resulting in mechanically strong lamellar bone. Also, days 
following fracture, periosteal cells close to the fracture site develop to chondroblasts 
and produce hyaline cartilage. This is then followed by endochondral ossification. In 
terms of time scale for bone healing events, initial inflammatory reaction takes place 
within minutes to hours, chemotaxis and mitosis last hours to days, and osteoid 
production, remodelling and angiogenesis last days to weeks (Braddock et aI., 200 1). 
Although, the remodelling phase may take up to a year in case of severe fractures, it 
will return bone back to its original strength before fracture (Yaszemski et aI., 1996-
a). Nevertheless, if the response of the body to the injury is such that not enough 
active cells are provided or in case a defect is too large for the natural healing 
response of the body, non-union will take place at the site of the fracture (Bancroft 
and Mikos, 2001). Other causes of non-union fractures include infection, insufficient 
blood supply to the bone and inadequate fracture stabilization. 
1.2.4 Bone Related Medical Conditions 
In the field of orthopaedic and oral-maxillofacial surgery, treatment of bone related 
clinical conditions is a significant challenge in case of critical size defects. Critical 
size defects are the type of defects that will not heal during the lifetime of the patient 
through natural healing response of the body (Schmitz and Hollinger, 1986). 
Infections, tumour, trauma and wear are clinical situations that indicate the need for 
augmentation of fracture healing and reconstruction of bone defects. 
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In 2000, approximately 2.2 million bone graft surgeries were carried out throughout 
the world (Lewandrowski et al., 2000). Every year, bone procedures have increased 
by 7-10% since 2001 (Vilquin and Rosset, 2006). In the US, spinal fusion counts for 
more than 50% of the total bone graft procedures (Datamonitor-Publications, 2002) 
(Table 1.2). This is followed by cranio-maxillofacial procedures and non-union 
fractures. 
Table 1.2- Bone graft Procedures performed in the US in year 2001 (Datamonitor-
Publications, 2002). 
Type of Procedure % of Bone Graft Procedures 
Spinal Fusion 51 
Cranio-maxillofacial 12 
Non-union Fractures 8 
Bone Void Filling 6 
Hip Fractures 6 
Total Hip Revisions 6 
Tibial Plateau Fractures 5 
Trauma 5 
Other 1 
Tot~ 100 
Furthermore, there is an increase in the number of osteodegenerative diseases in the 
rapidly aging populations present in the developed countries (Heng et aI., 2004). 
According to South-Paul (2001) and Verzijl et al. (2003), osteoarthritis and 
osteoporosis are major public health issues since they affect quite high proportion of 
the elderly population (South-Paul, 2001; Verzijl et al., 2003). Arthritis is comprised 
of more than 100 different diseases of the joints. Nearly 500 million or one in six 
people worldwide will be affected by arthritis in their life time (Knowledge-
Enterprises, 2002). Osteoarthritis and rheumatoid arthritis are the most frequent types 
of the disease. Arthritis is associated with inflammation, stiffness and degeneration of 
the joints. Osteoarthritis leads to the breakdown of the joint cartilage which functions 
as cushion for the ends of the bones. Hence, bones start contacting each other with 
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subsequent pain and possibly mobility loss. Rheumatoid arthritis is a chronic 
systemic disease causing inflammation of the synovium of articular joints as a result 
of abnormal flIDctioning of the immune system. The patient's own antibodies attack 
the joints which finally lead to reduced mobility, pain and the eventual cartilage, 
tendon and ligament destruction. Approximately 1 7 million people from all age 
groups suffer from rheumatoid arthritis whereas osteoarthritis counts for 190 million 
people throughout the world, most of whom are over 60 years old (Knowledge-
Enterprises, 2002). 
More than 700/0 of all primary knee and hip replacement procedures takes place in 
osteoarthritis patients (Knowledge-Enterprises, 1998). In 2001, more than 1.5 million 
joint replacement procedures were carried out throughout the world (Knowledge-
Enterprises, 2002). The cost of total hip replacement surgeries are about £250 million 
per year however, with the growing trend of the aging population, this figure could 
rise by 500/0 by 2026 (Birrell et aI., 1999; Bolland et al., 2007). Bone grafts are 
potentially used in hip and knee replacement procedures. This is because there is an 
unruet medical need with respect to cartilage repair in patients with osteoarthritis and 
therefore the entire joint should ultimately be replaced. Therefore, such joint 
replacement procedures especially in revision surgeries could possibly require bone 
grafts due to the low quality and quantity of the remaining bone. 
Degenerative disc disease is characterized by progreSSive intervertebral disc 
compression and affects virtually 50% of the US popUlation between forty and sixty 
years of age and about 90% of the population older than sixty years of age 
(Datamonitor-Publications, 2002). In 2001, approximately 2 million spine procedures 
were performed worldwide which include fusion, fracture repair, disectomy and 
laminectomy (Knowledge-Enterprises, 2002). Back pain conditions are responsible 
for more hospitalizations that other musculoskeletal conditions with more than $100 
billion spent annually throughout the world for the treatment of such conditions 
(Knowledge-Enterprises, 2002). Spinal fusion is the largest indication for bone graft 
substitutes as most of these operations need extra bone to confirm the stability of the 
fusion site. Bone grafts alone or in combination with metal implants are used in spinal 
fusion. Presently, the bone graft used for patients requiring spinal fusion is often 
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harvested from the iliac crest which offers many disadvantages as explained in 
section 1.2.5.5. Therefore, there is a great need for more suitable alternatives for 
spinal fusion. 
Approximately 500,000 of the orthopaedic fractures that take place every year in the 
US will ultimately progress to delayed union or non-union fractures (Datamonitor-
Publications. 2002). These delayed unions or non-unions count for about 10% of all 
fractures (Cattermole et at., 1996). This is especially the case in ageing population 
\vhere basic fractures could potentially become more serious. These non-unions in 
critical size defects stop function restoration to the damaged bone (Holy et at., 2000). 
For all the above mentioned medical conditions, bone regeneration is required in 
order to fill in the defect and therefore restore the structure and function of the injured 
tissue. 
1.2.5 Current Treatments 
Generally, bone related injuries can be treated by external and internal fixation 
devices as well as bone growth stimulators (Figure 1.2). Other than fixation devices, 
cell-based therapies, bone growth factors and natural and synthetic bone grafts could 
be used to treat bone defects (Figure 1.3). 
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Bone Growth Stimulators 
• DC Electrical Stimulation 
• Ultrasound 
• Electromagnetic fields 
External Fixation Internal Fixation 
• Bars/Rods • Pins/Wires/Staples 
• Screws/Clamps • Plates/Screws 
• Wires/Pins • 1M Nails 
Fig~re 1.2- Overview of methods to treat bone defects using bone growth stimulators 
and Internal and external fixation devices. 
Bone Growth Factors 
• Bone Morphogenic Proteins (BMPs) 
• Transforming Growth Factors (TGFs) 
• Platelet concentration systems 
Cell-based Therapies Natural Bone Grafts 
• Tissue Engineering 
• Stem Cells 
• Bone Marrow 
• Autografts 
• Allografts 
• Demineralized Bone Matrix (DBM) 
• Xenografts 
Synthetic Bone Graft Substitutes 
• Metals 
• Ceramics 
• Polymers 
• Composites 
Figure 1.3- Overview of methods to treat bone defects using cell-based therapies, 
bone growth factors and natural and synthetic bone grafts. 
These methods are further discussed in the following sections together with the 
shortcomings and advantages associated with them. 
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1.2.5.1 Internal Fixation 
If a fracture is not healed efficiently using closed techniques, it becomes essential to 
invasively open the fracture site using surgery and reposition the bones. The bones 
are then held in place through the use of internal fixation devices. Internal fixation 
devices could consist of rods, screws, wires, nails and plates. Internal fixation is a 
comparatively inexpensive and efficient way to manage a fracture nevertheless, there 
is often a need for a secondary procedure to remove the implanted metalwork. 
However, this could be solved by the development of internal fixation devices that 
have the ability to be slowly absorbed by the body without any adverse tissue 
response. 
1.2.5.2 External Fixation 
External fixation devices (e.g. Ilizarov) function as fracture stabilizers with the use of 
pins and rods on the outer surface of the limb. The fixator is attached to the bone 
through metal pins that are drilled into the bone. External fixation is in fact less 
invasive than internal fixation and is mainly used to treat long bone fractures. With 
regard to the advantages of external fixation, the appliance can be regulated 
throughout the healing process to confirm perfect alignment. When healing is 
complete, the external fixation device can be removed easily without a secondary 
invasive operation. However, infections in the area where pins penetrate the skin 
(percutaneous infection) and also where they enter the bone is the major down side to 
the use of external fixators. Also external fixators can be burdensome as they stick 
out from the body. 
Despite the use of internal and external fixation devices to heal bone fractures, about 
10% of all the fractures lead to delayed unions or non-unions (Cattermole et at., 
1996). This is because natural bone healing using mechanical fixation can generally 
result in sufficient repair of only minor fractures over time (Mistry and Mikos, 2005). 
These non-unions will not heal even when immobilization period is increased. In 
these situations, natural bone grafts can be used in order to bridge the fracture gap and 
to enhance bone formation (Bauer and Muschler, 2000). 
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1.2.5.3 Bone Growth Stimulators 
Bone growth stimulators are an emerging treatment technology. These devices 
produce ultrasonic waves or electromagnetic fields to stimulate bone growth. They 
can either be implanted inside the body or worn externally. For instance, 
electromagnetic fields such as constant direct current (DC) are known to enhance 
bone formation (Baranowski et aI., 1983; Brighton et al., 1976; Brighton and 
Friedenberg, 1974; Friedenberg and Brighton, 1974). More specifically, Friedenberg 
and Brighton (1974) showed the repair of non-union fractures using 20 flA current 
when applied at the non-union site for 14 weeks (Friedenberg and Brighton, 1974). 
Moreover. epiphyseal plate has also been shown to enhance its growth through the 
use of an electrical field of 1500 volts/cm (Brighton et aI., 1976), nevertheless, such 
growth was observed in vitro and its effect in vivo is subject to question. 
1.2.5.4 Bone Growth Factors 
Urist and Strates (1971) observed a distinct protein in demineralized bone matrix 
(DBM) which induced bone formation. This protein was referred to as Bone 
Morphogenic Protein (BMP) (Urist and Strates, 1971). BMPs belong to the 
transforming growth factor ~ superfamily which can stimulate mesenchymal stem cell 
differentiation into chondro and osteogenic lineages (Lane et aI., 1999). These 
proteins produce bone when implanted in animals such as rats and baboons 
(Ripamonti et aI., 2001; Whang et al., 1998). BMPs demonstrated that they have a 
growing potential to become the new golden standard therapy with sales of 
approximately $500 m (Datamonitor-Publications, 2002). Nevertheless, the success 
of BMPs in bone regeneration in vivo depends on the addition of a suitable carrier 
which permits a controlled release (Mendes, 2002). Carriers like collagen (Balk et al., 
1997; Wikesjo et aI., 2001), hyaluronan (Brekke and Toth, 1998), demineralised bone 
matrix (Wikesjo et aI., 2001) have been used for the delivery of BMPs. More 
specifically, freeze-dried Poly (lactide-co-glycolide) (PLG) scaffolds when used 
along with BMP-2 result in controlled release and ectopic bone formation (Ripamonti 
et aI., 2001; Whang et aI., 1998). This confirms the bone formation ability of BMP-2 
and the suitability of PLG as a career in an animal model. Also, Osteogenic protein-l 
(OP-l) which is a morphogenic protein when placed in collagen scaffold and 
implanted into the site of tissue formation result in significantly more bone formation 
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in rabbit hmlbar fusion study after 6 weeks in comparison with the control groups 
(Qian et aI., 2009). This further demonstrates the suitability of collagen scaffolds for 
OP-l delivery and bone formation. 
1.2.5.5 Natural Bone Grafts: Autologous grafts 
Autologous bone grafts are defined as the grafts taken from one site (i.e. iliac crest) 
and transferred to the defect site within the same individual. Autologous grafting is 
considered as the golden standard therapy for bone repair and regeneration 
(Yaszemski et al.. 1996-a). However, there are certain advantages and disadvantages 
associated with their use. 
Autografts offer a source of tissue that is biologically active as they deliver progenitor 
stem cells in the bone marrow for osteogenesis (Lane et aI., 1999). They are 
osteoinductive due to the presence of non-collagenous bone matrix proteins and 
osteoconducti ve because of the existence of bone mineral and collagen (Damien and 
Parsons, 1991; Lane et aI., 1999). The most commonly used donor site for autologous 
bone harvest is the iliac crest as bone obtained from this site has demonstrated the 
highest osteogenic potential (Prolo and Rodrigo, 1985). 
Despite the advantages mentioned, autografts are less efficient in defects with 
irregular shapes and may even be resorbed before complete healing occurs (Mistry 
and Mikos, 2005). Autografts require an invasive surgical procedure to harvest bone 
from the iliac crest of the hip which is associated with complication rates as high as 
45% consisting of post-operative pain, infection, fracture, nerve injury, paresthesia, 
permanent gait disturbances, cosmetic disability and donor-site morbidity (Damien 
and Parsons, 1991; Gitelis and Saiz, 2002; Lane et al., 1999; Younger and Chapman, 
1989). The operation and recovery time is also longer when autologous bone graft 
procedure is performed. 
Limited availability of harvest site without causing loss of function is another concern 
associated with auto grafts (Brown and Cruess, 1982; Enneking et al., 1980). This is 
especially the case for young patients with limited donor sites or in situations where 
large quantities of bone are required. All these drawbacks indicate the necessity to 
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find a suitable alternative to autografts. An alternative which offers the advantages of 
auto grafts without the disadvantages associated with them is therefore preferred. 
1.2.5.6 Natural Bone Grafts: Allogenic grafts 
Allogenic bone grafts are the grafts harvested from a donor of the same species. 
These grafts can resolve some of the drawbacks associated with autografts but offer 
their own limitations when applied. Allografts are more readily available compared to 
autografts and the secondary harvest procedure and the amount of tissue available are 
not concerns for patients anymore. Also, due to the elimination of the harvest 
procedure, the operation time is reduced. Nevertheless, they carry the risk of immune 
rejection and disease transmission (Strong et al., 1996) as well as having minimal 
osteoinductivity (Bauer and Muschler, 2000), therefore, they cannot replace 
auto grafts for bone regeneration purposes. 
1.2.5.7 Natural Bone Grafts: Demineralized Bone Matrix 
Processed allograft is known as demineralized bone matrix (DBM). DBM is obtained 
using cortical allograft bone which has surface lipids removed followed by 
dehydration with ethanol and ethyl ether. The bone is further treated with 
hydrochloric acid to remove the mineralized component but leaving behind proteins, 
collagen and growth factors. DBM could be available in different forms such as 
putties, granules, gels and blocks and could be used alone or in combination with 
autologous and allogenic bone grafts. Also, it is believed that the acid 
demineralization process eliminates cellular components present in the graft that 
express transplantation antigens. As a result, the demineralization process may assist 
in reducing the likelihood of implant rejection. DBM is widely used to repair skeletal 
defects since in vivo osteoinductivity of DBM has been demonstrated by various 
researchers (Bernick et al., 1989; Bolander and Balian, 1986). However, the 
inductivity between various DBMs vary and is reduced by the treatments due to 
growth factor inactivation (Lane and Sandhu, 1987). 
1.2.5.8 Natural Bone Grafts: Xenogenic grafts 
Xenografts are the bone grafts derived from different species commonly having 
porcine or bovine origin however, the most frequent xenograft material is processed 
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bovine collagen. Unfortunately, xenografts offer the possibility of disease transfer and 
immtIDologic rejection (Erbe et al., 2001). Partial deproteination can reduce severe 
antigenic response related to these implants but this process eliminates osteoinductive 
proteins (Lane and Sandhu, 1987). Moreover, when implanted into soft or hard 
tissues, xenografts do not induce bone formation (Damien and Parsons, 1991), hence, 
they cannot substitute autografts for bone repair. 
1.2.5.9 Synthetic Bone Graft Substitutes: Synthetic Biomaterials 
The problems related to the application of autologous bone grafts led to the 
investigation of several products in order to find an alternative without the 
disadvantages. There are various synthetic biomaterials currently available. Synthetic 
biomaterials offer the advantage of increased storage time and lack of disease 
transmission. 
Two of the most important requirements for in vivo application of biomaterials are 
biocompatibility and biofunctionality. Biocompatibility is referred to as the non-toxic 
effects of a material on biological systems and biofunctionality is the ability of a 
biomaterial to carry out the purpose for which it was designated for. There are four 
groups of synthetic biomaterials concerning bone reconstruction applications: 
• 
• 
• 
• 
Metals like stainless steel, cobalt chrome alloys (Co-Cr), titanium alloys 
(Ti-6AI-4V) and ceramics such as zirconia (Zr02) and alumina (Ah0 3) 
Calcium phosphate ceramics and bioglass 
Polymers such as poly(methyl methacrylate) (PMMA), polyethylene and 
polylactide 
Composites such as polymers filled with hydroxyapatite 
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Metals have been used successfully for hip and knee replacement procedures 
nevertheless, since they demonstrate poor integration with bone, they are often coated 
with a layer of calcium phosphate in order to promote integration (de Groot et aI., 
1987). Mechanical properties of metals are considerably higher when compared to 
natural bone, thus resulting in stress-shielding effect by absorbing much of the 
mechanical stimuli required for bone re-growth (Bobyn et aI., 1992). This in fact 
leads to bone resorption around the implant which may ultimately necessitate whole 
implant removal (Mistry and Mikos, 2005). 
Ceramic materials especially calcium phosphates such as hydroxyapatite (HA) and B-
tricalcium phosphate (B-TCP) have been investigated for applications as bone graft 
substitutes since they have similar composition to bone and teeth mineral (Damien 
and Parsons, 1991; Jarcho, 1981; Yuan et aI., 2000). However, calcium phosphate 
ceramics are too brittle with respect to providing structural support to load-bearing 
bones (Mistry and Mikos, 2005). Ceramic bone grafts contain cements and biphasic 
mixtures with calcium phosphate content. It is interesting to note the relation between 
the CaIP ratio, acidity and solubility of the mixture such that the lower the Ca/P ratio, 
the higher the acidity and solubility of the mixture. Ca/P <1 shows high acidity and 
solubility while CaIP ratios close to 1.67 demonstrate considerable reduction in 
acidity and solubility. Table 1.3 illustrates various calcium phosphate ceramics based 
on their CaIP ratio. 
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Table 1.3- Showing different calcium phosphate ceramics wI'th th . d' 
CaIP t 
. t' (V 11 . elf correspon lng 
a omlC ra lOS a et-Regl and Gonzalez-Calbet, 2004). 
CalP Ceramic name Formula Acronym 
2.00 Tetracalcium phosphate Ca40(P04)2 TetCP 
1.67 Hydroxyapatite Ca\O(P04)6(OH)2 HAp 
1.50 Tricalcium phosphate (a,~,y) Ca3(P04)2 TCP 
1.33 Octacalcium phosphate CaSH2(P04k5H2O OCP 
1.00 Dicalcium phosphate dihydrate CaHP04.2H2O DCPD 
1.00 Dicalcium phosphate CaHP04 DCPA 
1.00 Calcium pyrophosphate (a,~,y) Ca2P207 CPP 
1.00 Calcium pyrophosphate dihydrate Ca2P207.2H20 CPPD 
0.70 Heptacalcium phosphate Ca7(P5016)2 HCP 
0.67 Tetracalcium dihydrogen phosphate Ca4H2P6020 TDHP 
0.50 Monocalcium phosphate monohydrate Ca(H2P04)z. H2O MCPM 
0.50 Calcium metaphosphate (a,~,y) Ca(P03)2 CMP 
The in vitro bioactivity of bone replacement materials like calcium phosphates is 
defined as their ability to form an apatite-like layer when soaking the materials in a 
simulated body fluid (SBF) (Filgueiras et a!., 1993). Bioactive ceramics such as 
sintered hydroxyapatite bond to living bone through a biologically active bone like 
apatite layer (Hench and Wilson, 1984; larcho, 1981; larcho et a!., 1977). This apatite 
layer is produced on the surface of the materials in the body (Ohtsuki et a!., 1991) 
through which they bond to living bone (Kokubo, 1991). Apatite layer formation on 
bioactive ceramics which occurs inside the body was demonstrated to be reproducible 
in acellular simulated body fluid having ion concentrations about equal to that of 
human blood plasma (Filgueiras et al., 1993). It should be noted that bioactive 
materials such as calcium phosphate ceramics and glass ceramics demonstrate 
bonding osteogenesis which is bone formation initiating at the implant surface and 
progressing away from the surface (de Bruijn, 1993). 
Several polymeric materials have been used as bone graft substitutes however, 
amongst them, non-biodegradable polymers such as ultra high molecular weight 
polyethylene (UHMWPE) and poly (methyl methacrylate) (PMMA) have been 
widely applied in bone reconstruction (Mendes, 2002; Oreffo and Triffitt, 1999). 
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UHMWPE has been used to produce acetabular cups in total hip prostheses whereas 
PMMA has been applied as bone cement and dental prosthesis (Oreffo and Triffitt, 
1999). With respect to degradable polymers, poly(hydroxy esters) such as 
poly(glycolic acid) (PGA) and poly(L-lactic acid) (PLLA) have been extensively 
studied (Mistry and Mikos, 2005). Since degradation rates can vary based on the 
amorphous and crystalline parts of the polymer, at the time of in vivo degradation, the 
presence of non-degraded polymer particles might cause foreign body inflammatory 
reactions (Bostman, 1991; Bostman et al., 1992; Temenoff et aI., 2000). 
An overview of the presently used bone graft and bone graft substitutes together with 
their associated advantages and disadvantages are demonstrated below in Table 1.4. 
Autografts which are the golden standard therapy having osteoconductive, 
osteoinductive and osteogenic properties (presence of cells that can ultimately 
produce bone), are still associated with serious drawbacks (Damien and Parsons, 
1991; Lane et aI., 1999). On the other hand, none of the other bone graft and bone 
graft substitutes offer the advantages of auto grafts therefore, there is a need for 
autograft equivalents without their inherent drawbacks. There is thus an unmet 
medical need which needs to be solved. 
Table 1.4- An overview of the currently used bone substitutes and their related 
advantages and disadvantages. 
Bone grafts and bone graft substitutes 
Factors Autografts Allografts Synthetic Xenografts DBMs Growth 
Biomaterials factors 
Availability X / / / / / 
Osteogenesis (i.e. / X X X X X presence of cells) 
Osteocond uctivity / / * / X X 
Osteoinductivity / X * X / / 
Donor site morbidity / X X X X X 
Immune reaction X / X / § § 
* varies depending on the material used. § immune reaction is possible depending on the type of carrier used. 
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1.2.6 Unmet Medical Need 
All procedures that repair missing tissue need some kind of replacement structure for 
the defect or injury region (Vacanti and Langer, 1999). The unmet medical need in 
the field of orthopaedics and bone related conditions with regard to large bone defects 
require an alternative which lacks all the drawbacks associated with autografts. There 
is therefore a need for a new golden standard. Bone tissue engineering provides a 
promising treatment solution by enhancing the natural healing response of the body 
through the combination of bone forming cells, growth factors and three-dimensional 
scaffolds (Figure 1.4) (Langer and Vacanti, 1993). The tissue engineered bone 
constructs have the potential to replace the existing bone graft technologies. 
Tissue Engineering 
Figure 1.4- Tissue engineering approach using cells, scaffolds and growth factors 
combination. 
Ideally, a treatment solution should mimic or improve the natural healing response of 
the body to bone injury by using cells and bioactive growth factors which will 
eventually result in natural bone with correct mechanical properties (Mistry and 
Mikos, 2005). Therefore, knowledge of the fracture healing events -section 1.2.3- that 
takes place inside the body is necessary to appropriately design therapeutic solutions 
to repair the injured bone. 
1.3 TISSUE ENGINEERING 
Tissue engineering could become a potential alternative to autografts. It is applied to 
replace living tissue with living tissue that is designed for the. need~ ~f .each 
individual patient (Vacanti and Langer, 1999). It is defined as "an Interdisciphnary 
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field that applies the principles of engineering and the life sciences toward the 
development of biological b f t t h . . 
su S lues t at restore, maIntaIn, or improve tissue 
function" (Langer and Vacanti, 1993). Tissue engineering has broadened the search 
for less invasive and better tr t t h . 
ea men approac es for many dIsease processes. 
Living tissue equivalents have the potential to regenerate bone tissue at a defect using 
cells which provide dynamics (osteogenic potential to produce bone) and scaffolds 
which offer volume (surface for cells to attach). Therefore, most research in the field 
of tissue engineering utilizes cell/scaffold combination to form new tissue (Vacanti 
and Langer. 1999). Addition of a cellular element within a scaffold may help to repair 
tissue at a more enhanced rate and to repair larger defects (Elisseeff et aI., 2005). 
Ideal tissue engineered bone substitutes should possess osteogenic properties (cells to 
form bone) and porous structure (to permit vascularization and bone ingrowth) as 
well as being biocompatible, osteoinductive and osteoconductive (Bancroft and 
Mikos, 2001; Goldstein, 2002; Temenoff and Mikos, 2000). 
Bone tissue engineering substitutes containing cell (tissue )-scaffold combination 
could be prepared in different ways. The cells can either be seeded onto the scaffolds 
just prior to implantation or they can be cultured on the scaffolds before implantation 
to allow extracellular matrix formation and differentiation of cells (Mankani et aI., 
2001; Ohgushi and Caplan, 1999; Yoshikawa et al., 2000). Several comparative 
studies have demonstrated the benefits of cell culturing before implantation (Kruyt et 
aI., 2004-b; Kruyt et aI., 2006; Mendes et aI., 2002-a). More specifically, Yoshikawa 
et al. (1996), observed faster bone formation in rat marrow stromal cell/HA scaffolds 
which were triggered to osteogenic differentiation before subcutaneous implantation 
in rats compared with fresh bone marrow or undifferentiated mesenchymal stem cells 
(Yoshikawa et aI., 1996). Differentiated mesenchymal stem cells can start building 
new osteoid immediately after arrival at the defect site. Despite the advantages 
associated with the cell cultured scaffolds, this technique takes longer because of the 
cell culture needed and requires more strategic planning with regard to clinical 
applications. Figure 1.5 demonstrates a possible bone tissue engineering approach 
where in stage 1 bone marrow cells are harvested from a patient followed by culture 
expansion in vitro. Following proliferation, the cells are cultured on biomaterial 
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scaffolds and triggered to differentiate into the osteogenic lineage by particular 
stimulatory factors like dexamethasone, ascorbic acid and ~-glycerophosphate 
(Maniatopoulos et al., 1988). In stage 4 the resulting tissue engineered construct is 
then implanted in the bone defect of the same patient. 
It should be noted that different cell types from both autologous and allogeneic 
sources could be used for bone tissue engineering nonetheless, the most commonly 
used source of osteogenic cells is the bone marrow (Johansson and Persson, 2003). 
The procedure taken to obtain the bone marrow from the iliac crest or other parts of 
the skeleton is less invasive when compared to the harvest procedure associated with 
the collection of autologous bone. Cell sources for bone tissue engineering will be 
discussed further in section 1.6 of this chapter. 
o 
4 - Implantation into patient's defect site 
1- Bone marrow harvest (~ 
(i' C~ oJ' 
! 
2 - Proliferation of mesenchymal stem cells 
3 - Cells cultured on biomaterial scaffolds and triggered to 
differentiate to osteogenic lineage 
Figure 1.5- Bone Tissue Engineering using cells and scaffolds. 
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The cell (tissue)-scaffold combination described requires the addition of an injectable 
binder so that it could be applied to the defect site in a minimally invasive manner. 
Injectable formulations of tissue engineered bone provide a step forward in 
technology compared to non-injectable functional tissue engineered bone. Minimally 
invasive application of tissue engineered bone is the focus of this thesis which will be 
discussed in the following section. 
1.4 INJECTABLE TISSUE ENGINEERED 
BONE 
Tissue engineered formulations that can be injected straight into a bone defect in a 
minimally invasive manner provide a major advancement in the field of bone tissue 
engineering. Injectable formulations of tissue engineered bone could be used for 
variety of applications such as spinal fusion which indicates about 50% of the total 
bone graft procedures (Datamonitor-Publications, 2002). Using this technique, the 
surgeon will leave out the invasive bone harvest procedure required for obtaining 
autologous bone grafts since the osteogenic cells are obtained through minimal 
invasive procedure from bone marrow. 
Injectable tissue engineered bone formulations offer less invasive surgery at 
implantation therefore resulting in less pain for patients, faster healing, reduced post-
operative complications and surgery time. In addition, they conform to the shape of 
the defect and provide easy handling properties for physicians. 
Injectable formulations consist of osteogenic cells combined with biomaterial 
scaffolds like most bone tissue engineering techniques but they also need a binder to 
hold the components together (Figure 1.6). The major functions of the binder are the 
provision of injectability and fixation. Injectability is the ability to inject the tissue 
engineered cell/particle combination while fixation refers to the ability of the binder 
to fix the cell/particle mixture in the bone defect such that they would remain in the 
injection site until the extracellular matrix formation. To provide for injectability, the 
scaffolds should be sub-millimetre size particles. Many researchers demonstrated that 
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the shape and size of the microparticles affect bone formation in vivo (Malard et aI., 
1999; Mankani et aI., 2001). Mankani et al. (2001) showed that microparticles with 
1 00-250 ~m diameter when mixed with human bone marrow cells and implanted 
ectopically in nude mice produce abundant bone formation. Moreover, Fischer et al. 
(2003) investigated the influence of size (212-300 ~m versus 500-706 ~m 
microparticles) and microporosity (dense versus microporous) on bone formation for 
injectable formations of tissue engineered bone (Fischer et aI., 2003). Goat bone 
marrow cells were cultured on hydroxyapatite microparticles of different sizes and 
implanted subcutaneously in nude mice for 4 weeks. Abundant bone formation was 
observed in the 212-300 ~m diameter particle range in both dense and microporous 
microparticles. The results of these studies suggest that the optimal particle size for 
bone formation lies in the range of 100-300 Jlm. Therefore, the microparticles used in 
this thesis were in the size range of212-300 ~m. 
Cells attached to 
scaffolds 
Binder 
Particle 
Figure 1.6- Injection device for injectable tissue engineered bone. 
Polymers which undergo in situ polymerization via thermal cross-linking offer a 
major advantage for injectable formulations. These polymers can be added to 
cell/scaffold mixture and then injected through minimal invasive surgery to the injury 
site. These polymers should be biocompatible and degrade in a controlled manner to 
allow bone ingrowth into the defect. Moreover, they should gel at 37°C when applied 
to the defect site so that cell-scaffold combination would remain in the defect. 
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Various polymeric binders have been used previously in combination with cells. For 
instance, Weinand et al. (2006) combined collagen type I, alginate, fibrin glue and 
pluronic F127 with differentiated mesenchymal stem cells and ~-tricalcium phosphate 
and examined bone formation through gene expression and histological analysis 
(Weinand et aI., 2006). The result of this study showed that collagen type I and fibrin 
produce the highest bone formation and are therefore suitable binders to carry cell-
scaffold mixtures. In a different study, platelet rich plasma was used together with 
mesenchymal stem cells and applied to 10 mm diameter bone defect in dogs (Yamada 
et aI., 2004). Histological observations showed mature bone formation in cell-platelet 
rich plasma group after 2 and 4 weeks. Eight weeks following implantation, there was 
significantly more bone formation in cell-platelet rich plasma group compared to the 
defect only and platelet-rich plasma controls. This study indicates the potential of 
platelet-rich plasma to encapsulate stem cells. The potential binder materials for bone 
tissue engineering will be discussed further in section 1.8 of this chapter. 
It should be noted that the studies in this thesis focus on the biological and material 
aspects of injectable bone tissue engineering as opposed to the mechanical aspects. It 
is of paramount significance that the cells inside the injectable tissue engineered bone 
constructs survive and produce bone when implanted in defects. In line with this 
requirement, the biological and material aspects of such constructs were the subject of 
investigation in this thesis. Therefore, the potential use for these constructs would be 
non load-bearing applications such as spinal fusion and skull defects. The current 
golden standard therapy for bone repair and regeneration (auto grafts) are applied to 
the defects in the form of bone chips without having high tensile strength and fracture 
toughness. Even though these bone chips lack sufficient mechanical properties, they 
are still the best solution available for bone regeneration. It is the subject of 
discussion how relevant mechanical properties are with regard to bone defects. 
Nonetheless the ideal solution is when tissue engineered bone constructs perform , 
well both biologically and mechanically. 
Injectable tissue engineered bone formulations in this thesis contained three elements 
which include: 
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• Bone marrow derived mesenchymal stem cells 
• Sub-millimetre (microparticle) size calcium phosphate scaffolds 
• An injectable binder 
In this thesis, mesenchymal stem cells attached to calcium phosphate microparticles 
will be combined with a suitable binder to create a tissue engineered bone 
formulation. Various studies with regard to suitability of the potential binders and 
more generally the performance of cell-scaffold-binder combination in vitro and in 
vivo will be performed. All these elements (cells, scaffolds, binder) are influential in 
injectable tissue engineered bone formulations and are discussed further in sections 
1.6, 1.7 and 1.8 of this chapter. 
1.5 CELL SURVIVAL PROBLEM 
Clinical use of tissue engineering techniques is the ultimate aim in the field of 
regenerative medicine. With this in mind, Meijer et al. (2008) performed a study in 
which the potential of bone tissue engineering to treat jaw defects was examined in 6 
patients (Meijer et al., 2008). Mesenchymal stem cells were seeded onto 
hydroxyapatite particles and cultured for 7 days in osteogenic medium. Following 
this, the tissue engineered bone substitutes were implanted in each patient. Also, the 
tissue engineered bone constructs were subcutaneously implanted in mice to confirm 
their osteogenic potential. The results showed bone formation in mice however, tissue 
engineered bone constructs were able to produce bone in only 1 patient. In other 
words, tissue engineered bone constructs formed bone in ectopic site but not in 
orthotopic location. This study shows that clinical success of tissue engineered bone 
in osseous defects is still a major challenge. This is mainly due to the cell survival 
problem in such defects since the diffusion limit of oxygen is around 100-200 Ilm and 
therefore formation of new blood vessels is essential for the tissue to grow further , 
than this limit (A wwad et al., 1986; Carmeliet and Jain, 2000). Vascularization is the 
major problem in bone tissue engineered constructs that are primarily employed to 
regenerate large bone defects. 
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Addition of an angiogenic binder to cell-scaffold combination in order to enhance 
vascularization is a potential way to overcome the cell survival problem in injectable 
bone tissue engineering. This is further examined in chapter 6 of this thesis. 
1.6 CELL SOURCES 
Cell sources that have the potential to differentiate into the osteogenic lineage are 
necessary in a tissue engineered construct to restore the biological function of bone 
(Hee et aI., 2006). Stem cells provide a promising cell source for bone reconstruction 
purposes since they have the ability of dividing to form equal daughter cells (self-
renewal) and (multi) lineage differentiation with the provision of appropriate cues 
(Shamblott et aI., 1998; Smith, 2001; Thomson et aI., 1998; Weissman, 2000). More 
specifically, stem cells from mesenchymal and embryonic origins have been used for 
therapeutic purposes in tissue engineering (Czyz et aI., 2003). These cells provide a 
potential source for bone regeneration which will be discussed in more detail in the 
following section. 
1.6.1 Embryonic Stem Cells 
Embryonic stem cells are pluripotent cells that when placed in clusters and left to 
differentiate form embryoid bodies (EBs) that possess cell types from all three germ 
layers (Figure 1.7, Figure 1.8) (Smith, 1998; Smith, 2001; Weiss and Orkin, 1996). 
This resulted in a growing interest in their use (Reubinoff et aI., 2000; Thomson et 
aI., 1998) as a supply of differentiated cell types for cell transplantation therapy and 
drug discovery applications despite controversial ethical issues surrounding them 
(Smith, 1998; Solter and Gearhart, 1999). These cells are isolated from the inner cell 
mass of a blastocyst or from the primordial gonadal ridge of the fetus (Shamblott et 
aI., 1998; Thomson et aI., 1998). They can be multiplied infinitely in culture while 
still maintaining their ability for multilineage differentiation (Smith, 2001). Despite 
the fact that these cells have the potential of indefinite expansion in an 
undifferentiated status and differentiate into all tissues inside the body, isolation of 
homogenous cell populations from embryonic stem cells needs selection strategies so 
that a pure cell type is selected. Moreover, due to the plasticity of these cells, the 
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purity of any isolated cell population is subject to question since embryonic stem cells 
are at different stages of differentiation (Elisseeff et aI., 2005). 
Inner cell mass 
/j\ 
Mesoderm Endoderm Ectoderm 
• liver, lung, gut 
... 
muscle, connective tissue, bone, blood vessels brian, spinal cord, skin 
Figure 1.7- Schematic presentation of embryonic stem cells differentiating into three 
germ layers (Thomson et aI., 1998). 
Embryonic stem cells can be genetically modified to reduce their immunogenicity as 
immunosuppressive drugs are associated with many unwanted side-effects. The 
genetic modification can take place in different ways such as removing immunoactive 
proteins such as B7 antigens and inserting immunosuppressive molecules like Fas 
ligand (Harlan and Kirk, 1999; Walker et aI., 1997). Also, foreign major 
histocompatibility complex (MHC) genes can be eliminated and genes coding for the 
recipient's MHC can be inserted (Hardy and Malissen, 1998; Westphal and Leder, 
1997). The major challenge in the field of embryonic stem cells is in fact efficient and 
reliable control of the differentiation process into specific cell types. Some 
investigations performed on embryonic stem cells contain manipulation of the culture 
conditions such as addition of biochemical factors or co culture with specific cells or 
tissues (Gepstein, 2002; Soria et al., 2001). Buttery et al. (2001) showed 
differentiation of murine embryonic stem cells into osteoblasts using both coculture 
with fetal murine osteoblasts and osteogenic differentiation medium containing 
dexamethasone, ascorbic acid and ~-glycerophosphate (Buttery et al., 2001). 
Furthennore, Kawaguchi et al. (2005) derived osteogenic and chondrogenic cells 
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from mouse embryonic stem cells treated with bone morphogenic protein (BMP-4) 
and transforming growth factor (TGF-B) respectively (Kawaguchi et a!., 2005). In a 
different study, Jukes et a!. (2008) examined the differentiation of embryonic stem 
cells into osteoblasts through the process of endochondral bone formation (Jukes et 
aI., 2008). Murine derived embryonic stem cells were seeded on ceramic particles of 
2-3 mm and cultured in serum-free chondrogenic differentiation medium for a period 
of 21 days. Following the culture period, the tissue engineered constructs were 
implanted in nude mice for 21 days. The results showed bone formation in all 
constructs which were differentiated in vitro into chondrogenic as opposed to 
osteogenic lineage. This study indicates that a cartilage matrix is necessary for bone 
production by embryonic stem cells. Moreover, it demonstrates new facts with regard 
to the way in which bone tissue engineering is performed since most current tissue 
engineering strategies for bone repair and regeneration involve direct osteogenic 
differentiation of stem cells. Nevertheless, the natural healing response of the body in 
case of fracture is also through endochondral bone formation and as discussed above, 
Jukes et al. (2008) observed bone tissue formation through endochondral ossification 
(Jukes et a!., 2008). It is therefore reasonable to combine tissue engineering 
techniques with natural healing response of the body (endochondral bone formation) 
when devising strategies to regenerate bone defects in future. 
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Figure 1.8- Schematic presentation of pluripotent embryonic stem cells versus 
multipotent adult stem cells (e.g. mesenchymal stem cells from (Caplan and Bruder, 
2001». 
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1.6.2 Bone Marrow Derived Mesenchymal Stem Cells 
Considering a different cell source for bone production, osteoblasts, which are the 
native bone producing cells, are difficult to isolate and expand in vitro thus they result 
in a non-ideal source for bone tissue engineering applications (Notingher et aI., 
2004). An alternative cell type is therefore required for bone formation. Cell-based 
approaches to bone tissue engineering need a great number of cells to seed onto 
scaffolds (Elisseeff et aI., 2005). Hence cells must be capable of extensive 
proliferation while still retaining their differentiation ability as well as their ability to 
maintain tissue forming activities such as secretion of extracellular matrix (ECM) and 
mineralization. 
Mesenchymal stem cells from mesodermal germ layer were discovered in 1966 
(Friedenstein et aI., 1966). Following their discovery, Friedenstein et al. (1970) 
showed the presence of colony-forming unit fibroblasts (CFU-F) within adult bone 
marrow which had the ability to differentiate to bone forming cells (Friedenstein et 
aI., 1970). Further studies demonstrated that mesenchymal stem/progenitor cell 
populations are able to differentiate into multiple mesenchymal lineages which 
include cartilage (Y 00 et aI., 1998), bone (Haynesworth et aI., 1992; Prockop, 1997), 
ligament (Altman et aI., 2002), adipose (Beresford et al., 1992), muscle (Ferrari et aI., 
1998), tendon and stroma (Pittenger et aI., 1999) (Figure 1.8). This multi-lineage 
differentiation is particularly interesting since these cells could be used for variety of 
applications. Also, MSCs in the body are employed for repairing injured tissues thus 
making these cells good candidates for cell-based applications in musculoskeletal 
tissue engineering (Musaro et aI., 2004). 
Postnatal mammalian bone marrow consists of two distinct developmental systems: 
the stromal and hematopoietic cell networks. The hematopoietic system includes 
mainly CD34 - positive stem and progenitor cell populations which are able to 
differentiate into all the mature blood cell phenotypes of an adult (Civin et aI., 1996; 
Ema et aI., 1991; Spangrude et aI., 1988; Uchida and Weissman, 1992). The stromal 
cell network predominantly consists of vascular endothelial and mesenchymal 
stem/progenitor cell (MSC) populations (Prockop, 1997; Seshi et aI., 2000; Strobel et 
aI., 1986). Despite the fact that different cell types from various tissues and locations 
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have been studied for bone tissue engineering applications, the most commonly used 
source of osteogenic cells is the bone marrow (Johansson and Persson, 2003). 
Practically, bone marrow seems to be an appropriate source of osteogenic cells since 
it can be obtained through a fairly simple aspiration technique (Elisseeff et aI., 2005; 
Johansson and Persson, 2003; Tuli et al., 2003). Apart from the bone marrow, recent 
studies showed that MSCs are also present in subcutaneous fat (Zuk et aI., 2002), 
umbilical cord blood (Lee et aI., 2004), amniotic fluid (In 't Anker et aI., 2003), 
synovial membrane of the knee (De Bari et aI., 2001) and foetal liver (Gotherstrom et 
al., 2003). MSCs for cell-based therapies could be either obtained autologously from 
patient's own bone marrow aspirates or other locations as explained above, or even 
allogenic ally from a cell bank (Elisseeff et aI., 2005). Interestingly, it was 
demonstrated that these cells exhibit immuno-privileged status which gives new 
hopes for their allogenic applications since both differentiated and undifferentiated 
MSCs do not cause all ore active lymphocyte response (Le Blanc et al., 2003). 
In tenns of drawbacks associated with MSCs, it should be noted that there is no 
single exclusive marker available for these cells however, using flow cytometry, 
antigens on MSCs could be identified. Human MSCs are positive for SH2, SH3, 
CD29, CD44, CD71, CD90, CD106 and CD120a markers and negative for CD14, 
CD34 and CD45 markers (Pittenger et al., 1999). In addition, the concentration of 
mesenchymal stem cells in the adult bone marrow aspirates are less than 1 in 
100,000-500,000 nucleated cells (Caplan, 2005) which is quite low and therefore 
leads to possible concerns regarding clinical application of these cells. 
1.6.3 Multipotent Adult Progenitor Cells (MAPCs) 
Multipotent Adult Progenitor Cells (MAPCs) form a new class of stem cells that are 
derived from adult tissues such as bone marrow, brain and muscle (Jiang et aI., 2002-
a; Jiang et aI., 2002-b; Reyes and Verfaillie, 2001; Schwartz et aI., 2002). They are 
pluripotent stem cells with a wide differentiation potential such that when a single 
MAPC is injected into a blastocyst, it contributes to all tissues from three genn layers 
including skeletal muscles, liver, lung, cardiac muscle, skin, spleen, blood, marrow, 
central nervous system and intestine (Jiang et aI., 2002-a; Reyes and Verfaillie, 
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2001). Nonetheless, not much is known regarding the phenotype and genotype of 
these cells, their function in vivo or their differentiation potential following 
transplantation (Reyes and Verfaillie, 2001). 
The cell type used in this thesis for majority of the studies involved mesenchymal 
stem cells. Individual results chapters (chapters 3-7) in this thesis explain more about 
the use of these cells in different experimental studies. 
1.7 BIOMATERIAL SCAFFOLDS FOR 
BONE TISSUE REGENERATION 
Early challenges to produce potential alternatives to traditional allografts and 
xenografts led to the creation of synthetic bone replacement materials (Elisseeff et a!., 
2005). In an attempt to find synthetic bone replacement materials, various research 
groups throughout the world performed studies which resulted in a list of biomaterials 
with osteoconductive properties such as porous hydroxyapatite and calcium 
phosphates (Eggli et a!., 1988), bioglass (Hench and Wilson, 1984; Oonishi et a!., 
1997) and titanium (Vehof et a!., 2002). 
Synthetic bone replacement materials have also been used as scaffolds in tissue 
engineering applications. For instance, polymers such as poly(a-hydroxy acids) and 
collagen (Burg et a!., 2000; Middleton and Tipton, 2000), and osteoconductive 
ceramics like synthetic calcium phosphates (Frayssinet et a!., 1993; Yuan et al., 
2001) have previously been used for bone regeneration. The scaffold is designed to 
generate a three-dimensional environment which enhances tissue development from 
the cells that were seeded on or within the scaffold (Elisseeff et al., 2005). The 
following sections explain about different polymers and ceramics that have been used 
as scaffold material for bone formation. 
1.7.1 Poly( a-hydroxy esters) 
Poly(a-hydroxy esters), such as poly(L-lactic acid) (PLLA), Poly(glycolic acid) 
(PGA) and poly(DL-lactic-co-glycolic acid) (PLGA) have been frequently used in 
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bone tissue engineering (Mistry and Mikos, 2005). This is because PLLA, PGA and 
their copolynler, PLGA are FDA- approved for certain applications. Previously, PGA 
meshes were employed to engineer bone tissue successfully in vitro and in vivo 
(Freed et aI., 1994; Vunjak-Novakovic et aI., 1999). Montjovent et al. (2005) made 
three-dimensional bioresorbable foams of PLLA alone or filled with hydroxyapatite 
or ~-tricalcium phosphate (~-TCP) and studied the effect of alkaline phosphatase 
activity, in vitro mineralization and osteocalcin synthesis on human primary 
osteoblasts (Montjovent et aI., 2005). They observed that the cells adhere, proliferate 
and differentiate towards osteoblasts. The cells also formed a mineralized 
extracellular Inatrix which indicates osteoblastic differentiation. Moreover, Ishaug et 
al. (1996) reported that osteoblasts have the ability to migrate on PLGA films which 
indicates that PLGA is a promising scaffold material for bone tissue regeneration 
(Ishaug e t aI., 1996). 
Altering the proportions of lactic and glycolic acid in the copolymer formulation can 
change the hydrophobicity and crystallinity of the system, therefore the degradation 
time for the scaffold will vary as a result (Temenoff et aI., 2000). It has been reported 
that a modified copolymer of poly(lactic acid) and poly(lactic acid-co-Iysine) could 
give attachment sites for specific peptides such as Arg-Gly-Asp (RGD) sequences in 
order to control adhesion and growth of the cells (Cook et al., 1997). Interestingly, 
inflammatory reactions and poor incorporation in bone were observed in some cases 
when PLA and PGA were applied in vivo (Bostman, 1991; Bostman et al., 1992), 
however the inflammatory reactions observed depended on the amount of material 
used. Therefore, it is not correct to generally assume that these polymers cause 
immune reactions. Nonetheless, it should be noted that polymeric materials are not 
osteoconductive which provides a major drawback to their use as scaffolds in bone 
tissue engineering. 
1.7.2 Poly(propylene fumarate) 
Poly(propylene fumarate) (PPF) scaffolds have previously shown to enhance 
proliferation and differentiation of primary rat stromal osteoblasts when cultured in 
vitro for four weeks (Peter et aI., 2000). Furthermore, when PPF scaffolds were 
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ilnplanted in rat's tibial defects, the outer margins of the material was replaced by 
bone in 5 weeks (Yaszemski et aI., 1995). These studies indicate that PPF scaffolds 
are promising for bone tissue engineering applications. 
1.7.3 Collagen 
Collagen scaffolds have been used with marrow stromal cells (Farrell et aI., 2007; 
Glowacki et aI., 1998) and osteoblasts (Mueller et aI., 1999) and were demonstrated 
to interact positively within 3-dimentional collagen lattices. Contact dependent cells 
such as mesenchymal stem cells and osteoblasts migrate along the fibers and result in 
a uniform distribution all over the collagen lattice structure (Glowacki et aI., 1998; 
Mueller et al.. 1999). Purified type I collagen has been applied in different forms for 
three-dimensional growth of osteoblast-like cells ex vivo (Mueller and Glowacki, 
2000). They therefore provide an interesting scaffold material for bone tissue 
. . 
englneenng. 
1.7.4 Calcium Phosphates 
Many different scaffold materials have been used for bone tissue engineering 
applications. However, one commonly used scaffold material is calcium phosphate 
ceramic because of its biocompatibility and osteoconductivity (Hench and Wilson, 
1984; Jarcho, 1981). Calcium phosphate materials containing ~-tricalcium phosphate 
have been able to enhance bone formation when implanted with (Dong et aI., 2002; 
Fredericks et aI., 2004; Knabe et aI., 2000; Liu et al., 2008; Wang et al., 2004) or 
without cells (Frayssinet et aI., 1993; Yuan et al., 2001). 
Depending on the application, calcium phosphate scaffolds could be made degradable 
or non-degradable. It was observed that different types of calcium phosphate 
scaffolds such as hydroxyapatites and tricalcium phosphates have different 
characteristics in vivo. Generally, hydroxyapatites were known to have a slower 
degradation rate whereas tricalcium phosphates were found to degrade much faster 
(Daculsi et aI., 1989; Klein et aI., 1983). Combination of hydroxyapatites and 
tricalcium phosphate results in biphasic calcium phosphates with a wide range of 
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resorption rates that can be tailored to the specific application (Daculsi, 1998; Klein et 
at.. 1989). It is possible to inject or use these materials as coatings or in the bulk form 
to till bone defects (Grimandi et al., 1998). 
1.7.4.1 Calcium phosphate scaffolds 
Biodegradable calcium phosphate (CaP) ceramics have been used in orthopaedic 
surgery as bone replacement materials (Jarcho, 1981; Jarcho, 1986). A biphasic 
calcium phosphate (BCP) composition containing 85% hydroxyapatite (HA) and 15% 
~-tricalcium phosphate (~-TCP) has been shown to enhance new bone formation once 
applied in periodontal osseous defects (Nery et al., 1992). Furthermore, porous HA 
scaffolds combined with rat marrow stromal cells and cultured with osteogenic 
supplements produced rapid bone formation following subcutaneous implantation in 
rats (Yoshikawa et at., 1996). In a different study, bone tissue engineering was 
evaluated clinically using bone marrow derived mesenchymal stem cells seeded on 
porous HA scaffolds which were custom made based on the shape and size of the 
critical size bone defect in patients (Marcacci et aI., 2007). Follow-up studies showed 
a complete fusion between the host bone and the implant after 5 to 7 months without 
any pain, swelling or infection. Moreover, following 6-7 years, good implant 
integration was observed. This study is promising in terms of the clinical application 
of bone tissue engineering using calcium phosphate scaffolds. 
When BCP implants are used in bulk or granule form, invasive surgery becomes 
necessary to implant them in patients. However, sub-millimetre size CaP scaffolds 
together with an injectable binder is needed to develop minimally invasive 
formulations. Previously, a system composed ofbiphasic calcium phosphate particles 
mixed with 2% methyl cellulose carrier gel was produced such that the system was 
easily injectable (Gauthier et aI., 1999-a). Moreover, in vivo studies demonstrated 
higher bone ingrowth in BCP particles/cellulose groups than that of the BCP 
blocks/particles alone (Dupraz et aI., 1998; Gauthier et aI., 1999-a). This could be due 
to the cellulose which is spacing the BCP particles apart therefore creating a ceramic 
scaffold with free space in between (macropores) that support the formation of bone 
and blood vessels (Gauthier et aI., 1999-b; Grimandi et al., 1998). 
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In this thesis, biphasic calcium phosphate microparticles were used. When powder 
form materials are used for bone filling instead of granules, one of the key advantages 
is their superior adaptability to the shape of the defect. However, such materials are 
hard to place and secure in the defect region because of the movement of these 
particles. The solution is to mix these powder-like particles with a suitable injectable 
binder (Dupraz et aI., 1999). Injectable binders and potential materials that could 
serve as injectable binders are discussed in more detail in section 1.8. 
1.8 DELIVERY SYSTEMS: BINDERS 
Polymeric binders are necessary for injectable formulations of tissue engineered 
bone. They hold the cell/microparticle scaffolds together as well as providing 
injectability and fixation. They also provide better handling properties. Binders 
should be biocompatible and allow bone ingrowth. Furthermore, they should be 
biodegradable and gel quickly at 37°C (i.e. in a few minutes). 
Researchers have previously used binders to carry stem cells into the defect area. For 
instance, Richards et al. (1999) cultured mesenchymal stem cells in a collagen gel 
carrier and injected the cell-collagen combination into distraction gaps of rat femora 
(Richards et al., 1999). A significantly higher amount of bone was observed in gaps 
which were treated with mesenchymal stem cell injections compared with the gaps 
with cell-free injections. Also, Collett et al. (2007) used thermally responsive poly(N-
isopropyl acrylamide) (polyNIP AM) in combination with chondrocytes and showed 
that chondrocytes attach and survive (Collett et aI., 2007). In addition, it was possible 
to release the chondrocytes by just lowering the temperature. PolyNIP AM could be 
used with polyelectrolyte microcapsules while retaining its thermally responsive 
behaviour (Prevot et al., 2006). This combination could be useful for targeted drug 
delivery applications. 
1.8.1 Hydrogels 
An ideal division of polymeric materials are hydro gels which have several 
applications in the biomedical field. They only include small amounts of polymeric 
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material typically in the scale of 1-30 % weight in aqueous solvent, have high 
tl10lecular and oxygen permeability and possess mechanical properties similar to 
physiological soft tissues (Ratner and Hoffman, 1976). Basically, hydrogels are cross-
linked polymeric systems that absorb large amounts of aqueous solution (Elisseeff et 
al..2005). 
1.8.2 Thermosensitive Polymers 
Thermosensitive polymers are certain group of polymers which demonstrate 
temperature dependent sol-gel transition. These polymeric solutions can be injected 
whilst kept below or above their transition temperature and form a gel in situ upon 
reaching a particular temperature for instance 37°C (body temperature). 
The following pages explain about different binders that have been used previously 
\vith the potential to carry cell/scaffold combination for bone tissue engineering 
purposes. Table 1.5 describes some of the potential binders for injectable tissue 
engineered bone and their inherent drawbackslbenefits. As polymers that are 
mentioned in Table 1.5 are associated with drawbacks such as non-degradability, low 
gelation temperatures, high erosion rates and high polymer concentrations, they 
therefore provide non-optimal binders for injectable tissue engineered bone 
applications. 
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T,able 1.5-, S,howing the advantages/disadvantages associated with some potential 
bInders for Injectable tissue engineered bone, 
Binders Authors Advantages Disadvantages 
Poloxamers (Johnston et aL 1992); * One of the mostly * Gelation at 15°C 
(Pec et aI., 1992); studied thermo- limits room 
(Johnston and Miller, 1989); sensitive polymers; temperature handling; 
(Rue I-Gariepy et aI., 2000); * Present in the form of * High polymer 
(Desai and Blanchard, 1998); a viscous liquid at low concentration needed 
(Bhardwaj and Blanchard, temperatures but forms e.g. 20-30% (w/v); 
1996); a rigid semisolid gel * Rapidly erodable, 
(Jarry et aI., 2001); upon temperature * Non- biodegradable 
(Palmer et aI., 1998) Increase 
N- (Dinarvand and D'Emanuel, * Gelation at 3TC * Non-biodegradable; 
Isopropylacrylamide 1995; Okano et aI., 1990) * Limited toxicity data 
Poly(Ethylene (J eong et aI., 1997) * Gelation at 3TC; * Need to heat the 
Oxide) and * Biodegradable; system to 45°C to get a 
poly(Lactic Acid) * Biocompatible liquid phase before 
incorporating drugs or 
cells 
Xyloglucan (Miyazaki et aI., 1998) * Gelation at low * Low transition 
concentrations e.g. 1- temperature limits 
2% (w/w) with room temperature 
temperature above 22- handling 
27°C 
With respect to the in vitro/in vivo performance of the materials, natural binders such 
as alginate, plasma, fibrin glue, hyaluronic acid and chitosanlglycerol phosphate are 
promising candidates for use as injectable binder. These polymeric binders are 
explained below in more detail. 
1.8.3 Chitosan 
Chitosan, an aminopolysaccharide derived from alkaline de acetylation of chitin, is a 
natural polymer which is present in fungal cell walls and exoskeletons of arthropods 
such as shrimps and crabs (Khor and Lim, 2003; Montembault et aI., 2005; Pelletier 
et aI., 1990). Chitosan is a cationic copolymer composed of glucosamine and N-
acetyl-glucosamine (Figure 1.9) (Crompton et aI., 2005; Jarry et aI., 2001). The 
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properties of chitosan are mainly governed by the degree of deacetylation, DDA, 
which is based on the relative amount of acetyl and amine groups and also its 
molecular weight (Mw) (Crompton et aI., 2005). These factors are determined 
depending on the conditions selected during the preparation process; however 
additional modification at a later stage is still possible. For instance, the DDA can be 
lowered through reacetylation (Sorlier et aI., 2001). 
Deproteinisation 
CHITIN 
Acetylic group 
Minerals 
113 
Demineral isation 
CHITOSAN 
CH20H NH2 
HO ~~o~\ H~ O/ 
___ o~\ HO )-~\' ) o NH2 CH20H 
CH2 0H 
Figure 1.9- Illustrating the derivation process of chitosan. After deproteinisation and 
deminiralisation of shrimp's exoskeleton, chitin is obtained which is then 
deacetylated to result in chitosan. 
Chitosan is attracting a great deal of attention due to its abundance in nature, its low 
cost production and its interesting intrinsic properties (Berger et aI., 2004). Indeed, 
chitosan is a biocompatible (Chandy and Sharma, 1990; Hirano and Noishiki, 1985; 
Park et aI., 2005) and biodegradable (Muzzarelli, 1997) biopolymer playing an 
important role in biomedical and pharmaceutical applications (Sandford, 1989). 
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Biocompatibility of chitosan resulted in its use in numerous medical applications such 
as topical ocular application (Felt et aI., 1999), injection (Song et aI., 2001) and 
implantation (Patashnik et aI., 1997). Chitosan can be metabolized by certain 
enzymes within the human body such as lysozyme thus giving it biodegradability 
(Muzzarelli, 1997). It possesses a positive charge at the physiological pH therefore 
making it bioadhesive which enhances retention at the site of application (Calvo et 
aI., 1997). One of the main advantages of applying chitosan as a carrier is that 
chitosan gel is formed at very low polymer concentration (e.g. < 2% w/v) therefore 
high aqueous contents of the gel increases its biocompatibility (Jarry et al., 2001). It 
has been reported by Ueno et al. (2001-a) that chitosan encourages and supports 
wound-healing (Ueno et al., 200 I-a). In addition, chitosan possesses bacteriostatic 
effects (Felt et al., 2000). 
Apart from the interesting properties mentioned, chitosan possesses other useful 
properties. With respect to the angiogenic potential of chitosan, there have been 
suggestions that chitosan is angiogenic (Biagini et al., 1989; de Castro-Bernas, 2003). 
De Castro-Bernas (2003) reported chick chorioallantoic membrane (CAM) assay 
results showing that chitosan stimulated neovascularization in a dose-dependent 
manner at even higher levels than the known angiogenic growth factor b-FGF (basic 
fibroblastic growth factor). In a study by Biagini et al. (1989), N-Carboxymethyl 
chitosan placed into the cornea of 10 adult rabbits induced neovascularisation in 7 
rabbits after 30 days whereas control rabbits did not show any new vasculature. In 
their paper, Biagini et al. (1989) referred to the biochemical effects of chitosan or the 
foreign body reaction caused by chitosan as potential reasons behind chitosan's 
induced neoangiogenesis. 
Also, chitosan has been reported to stimulate bone healing in different animal models 
(Klokkevold et al., 1996; Malette et al., 1986; Muzzarelli et al., 1994; Pang et al., 
2005). In an in vivo study, Muzzarelli et al. (1994) reported the use of chitosan 
containing imidazolyl groups in a 7 mm diameter defect in the femoral condyle of 
sheep. Following 40 days there was more bone formation in the defects treated with 
chitosan whereas the control group demonstrated no indication of bone formation. 
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Chitosan polymers have an average molecular weight of 50 kDa < Mw < 2000 kDa 
and the degree of deacetylation of 40% < DDA < 98% (Chenite et a!., 2001). 
Chitosan is not soluble in water and at neutral and alkaline pH but chitosan solutions 
are made in acidic aqueous media that protonate chitosan amino groups, therefore 
tnaking the polymer positively charged (Chenite et a!., 2001; Ruel-Gariepy et a!., 
2000). With the addition of a strong base like NaOH, chitosan is in the solution form 
up to a pH in the vicinity of 6.2 however, extra basification to pH of> 6.2 causes 
hydrated gel-like precipitates to form which is due to chitosan phase-separation 
(Chenite et a!., 2001). This gel is formed because of the neutralization of the amine 
groups of chitosan and subsequent elimination of repulsive interchain electrostatic 
forces that permit massive hydrogen bond formation and hydrophobic interactions 
between the chains (Chenite et a/., 2001). Nevertheless, upon the addition ofa polyol 
counterionic salt like glycerol phosphate (GP) to chitosan solution, the pH is changed 
to neutral without phase-separation (Chenite et a!., 2001; Chenite et a!., 2000). The 
liquid can maintain its sol state for a long time at or below room temperature (Ruel-
Gariepy et a!., 2000). This system turns into thermally sensitive thus creating a gel 
above a particular temperature (37°C), therefore it is only the temperature of the 
milieu that decides the sol or gel state (Chenite et a!., 2000; Crompton et a!., 2005). 
ChitosanlGP system has shown great potential for drug delivery and cell 
encapsulation (Chenite et a!., 2000; Ruel-Gariepy et a/., 2000). Chondrocytes 
encapsulated within chitosan-GP were capable of maintaining more than 80% 
viability over an extended period of time in vitro (Chenite et al., 2000). Moreover, 
chitosan-GP systems have also been applied in vivo (Molinaro et a!., 2002). For 
instance, Molinaro et al. (2002) implanted 50 JlI of 1.8% (w/w) chitosan - 45% (w/w) 
GP in the hindpaw of the rat and observed an acute inflammatory response. 
All the information mentioned indicates that chitosan is an interesting hydrogel for 
injectable applications of tissue engineered bone. 
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1.8.4 Alginate 
Sodium alginate has been used in vanous biotechnology applications mostly to 
encapsulate and immobilize several cell types for immunoisolatory and biochemical 
processing applications since cells maintain their viability when in contact with the 
cross-linked gel (Park and Chang, 2000; Trivedi et aI., 2001). The term alginate 
refers to a family of polyanionic copolymers which are derived from brown sea algae 
and are composed of ~-D-mannuronic (M) and a-L-guluronic (G) residues in altering 
proportions. 
Sodium alginate is soluble in aqueous solutions and produces stable gels that can be 
processed into any shape at room temperature with the aid of non-cytotoxic divalent 
cations such as Ca2+ and Ba2+ through the ionic interaction between the guluronic 
acid groups (Wang et aI., 2003-b). This leads to the formation of three-dimensional 
structures which can be loaded with viable cells. Calcium cross-linked sodium 
alginates are therefore able to immobilize cells and bioactive factors (Augst et aI., 
2006). Moreover, alginate can be uncross-linked with the use of mild chelating agents 
that can result in the release of entrapped cells (Lindenhayn et al., 1999). However, 
large variations exists in degradation rates of calcium cross-linked sodium alginates 
which could be a possible disadvantage (Ishikawa et al., 1999). 
Although Wang et al. (2003-b) demonstrated that rat bone marrow stromal cells 
(rMSCs) attach, proliferate and differentiate on unmodified calcium cross-linked 
sodium alginate gels (Wang et aI., 2003-b), Lawson et al. (2004) observed little or no 
attachment with human bone marrow derived stromal cells (hMSCs) (Lawson et aI., 
2004). Nevertheless, when calcium cross-linked sodium alginate gels were modified 
through the addition of collagen type I and ~-tricalcium phosphate, which are 
materials similar to bone extracellular matrix, successful attachment and proliferation 
of hMSCs were obtained (Lawson et aI., 2004). This shows that sodium alginate gels 
might need modification before hMSCs attach and proliferate within the gel. 
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1.8.5 Fibrin GluelPlasma 
Fibrin glue is widely used as biological sealant for hemostasis and wound dressing 
applications but because of its biomimetic and physical properties, it is frequently 
used as a carrier for different cell types such as chondrocytes and osteoblasts (Kneser 
et aI., 2005; Sims et aI., 1998). 
Plasma could also be used as binder in tissue engineering applications. It was shown 
to be biocompatible when used with hMSCs (Trombi et aI., 2008). In combination 
with chondrocytes, platelet-rich plasma demonstrated great potential as a carrier 
material since new cartilage formation was detected after 2 months subcutaneous 
injection in the dorsal tissue of rabbits (Wu et al., 2007). Moreover, plasma can be 
obtained from the patients at the time of operation and centrifuged. This provides 
fresh autologous plasma thus eliminating possible immune reactions. 
1.8.6 Hyaluronic Acid 
Hyaluronic acid - also known as hyaluronan - is a non-sulfated glycosaminoglycan 
containing repeated disaccharide units of N-acetyl-glucosamine and D-glucuronic 
acid and is found in the extracellular matrix and the synovial fluid (Luo et aI., 2001). 
Hyaluronan is associated with water homeostasis of tissues as well as being the 
lubricating molecule of the musculoskeletal system (Fraser et aI., 1997). It plays an 
important role in cartilage matrix stabilization (Fraser et aI., 1997) and the regulation 
of motility and cell adhesion (Collis et al., 1998; Hardwick et aI., 1992). Hyaluronic 
acid receptors were observed on the cell surfaces since CD44 which is a broadly 
distributed cell surface glycoprotein, belongs to hyaluronan cell surface receptors 
(Johansson and Persson, 2003; Luo et al., 2001). 
Hyaluronic acid has great potential for drug delivery and tissue engineering 
applications since it is biocompatible (Luo et aI., 2001). When used with 
mesenchymal stem cells and chondrocytes, hyaluronan based scaffolds demonstrated 
positive tissue formation (Solchaga et al., 1999; Solchaga et aI., 2002). However, the 
molecular weight of hyaluronan which is the crucial factor in physical properties can 
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vary when obtained from different sources (Luo et aI., 2001). This could result in 
different physical properties depending on the source ofhyaluronan. 
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1.9 AIMS AND OBJECTIVES OF THE 
THESIS 
The drawbacks associated with the use of the current golden standard therapy for 
bone repair and regeneration (autografis) and the potential of tissue engineering 
principles to enhance bone repair has been discussed in this chapter. The addition of 
an injectable angiogenic binder which holds the cell-scaffold combination could have 
the additional advantage of repairing bone defects in a minimally invasive fashion. 
Therefore, the general aim of this project is to contribute towards better 
understanding of the use of mesenchymal stem cells in combination with calcium 
phosphate ceramic microparticles for injectable bone tissue engineering application. 
With this in mind, this thesis concentrates on the use of chitosan binders In 
combination with cell-scaffold mixture as well as analysing various aspects of 
injectable tissue engineered bone construct. This aim will be achieved by realising the 
following objectives: 
• Investigating the biocompatibility and gelation of chitosan-GP hydrogels 
• Analysing the effect of degradation, gelation, cell survival, growth and 
osteogenic differentiation when chitosan-based hydrogels are used 
• Assessing the in vivo bone formation ability of cultured mesenchymal stem 
cells on calcium phosphate ceramic microparticles when combined with 
• 
• 
chitosan-based hydrogels 
Examining the angiogenic potential of chitosan-based matrices with/without 
mesenchymal stem cells using chick chorioallantoic membrane assay 
Measuring the osteogenesis by MC3T3-E1 cells through chitosan-based 
hydrogels 
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CHAPTER II 
GENERAL CELL CULTURE TECHNIQUES 
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2.1 INTRODUCTION 
This chapter is devised to explain the materials and methods regularly used during the 
experimental part of this thesis. Materials and methods for specific experimental 
works are described within the materials and method section of the relevant chapters. 
2.2 CELL CULTURE TECHNIQUES 
2.2.1 Monolayer Culture of Cells 
Human mesenchymal stem cells (hMSCs) (from female, age 36 (iliac crest); male, 
age 44 (acetabulum); female, age 55 (iliac crest); Xpand Biotechnology BV, The 
Netherlands), MC3T3-E1 cells (Murine cell line, Department of Tissue Regeneration, 
Twente University, The Netherlands) and goat mesenchymal stem cells (gMSCs) 
(from iliac crest of adult Dutch milk goats, 2-4 years old, Xpand Biotechnology BV, 
The Netherlands) were expanded in a monolayer culture in a-MEM (Gibco 
Invitrogen, UK) supplemented with different concentrations of fetal bovine serum 
(FBS, Gibco Invitrogen, UK) as shown in Table 2.1. More specific supplements 
added to the culture media are explained in individual chapters. Cell suspensions 
were added to the culture media in relevant sized polystyrene culture flasks and 
expanded in monolayer at different seeding densities as demonstrated in Table 2.1. 
Based on the number of cells to be seeded, culture flasks of different sizes were 
employed (Table 2.2). The cells were then incubated at 37°C, 5% CO2 and 95% 
humidity. The FBS was chosen through batch-testing according to the maximum cell 
growth and alkaline phosphatase (ALP) activity levels. This is because cell 
proliferation and osteogenic differentiation (ALP activity) were involved in most 
studies in this thesis and hence a serum that enhances proliferation of cells and their 
osteogenic differentiation is the most suitable. 
The colourimetric indicator Alamar Blue (SeroTec, Oxford, UK) was employed to 
evaluate cell proliferation at days 1, 3, 7, 10 and 14 for the batch-testing. The medium 
was composed of a-MEM (Gibco Invitrogen, UK) supplemented with 10% vlv fetal 
bovine serum from different batches (FBS, Gibco Invitrogen, UK), 100 Ulml 
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penicillinJl 00 ~lg/ml streptomycin, 1 ng/ml basic fibroblast growth factor (b-FGF, 
SeroTec, Oxford, UK), 2 mM L-glutamine and 0.2 mM AsAP. At days 1, 3, 7, 10 and 
14, hMSCs were washed three times with pre-warmed PBS solution. Consequently, 1 
ml of a 5% Alamar Blue solution in culture medium (Lawson et al., 2004) was added 
to each well-plate. The plates were then incubated for 3 hours in a humidified 
atmosphere at 37°C/5% CO2. Fluorescence of 1 00 ~l aliquots of the extracted dye 
from each sample was determined using a Fluorimeter (FLUOstar Galaxy 
Fluorimeter, JENCONS-PLS, Germany) at excitation and emission wavelengths of 
544 nm and 590 nm respectively. A standard calibration curve according to known 
numbers of hMSCs reacting with the Alamar Blue solution was used in order to 
quantify the number of cells present in each sample (Lawson et aI., 2004; Li et aI., 
2005). 
The osteogenic differentiation was measured through the alkaline phosphatase (ALP) 
activity and protein content at days 1, 3, 7, 10 and 14 for the batch-testing. For this, 
the human mesenchymal stem cells were cultured in the basic medium which was 
composed of a-MEM (Gibco Invitrogen, UK) supplemented with 10% v/v fetal 
bovine serum from different batches (FBS, Gibco Invitrogen, UK), 100 Ulml 
penicillinJl 00 ~g/ml streptomycin, 2 mM L-glutamine and 0.2 mM AsAP as well as 
the osteogenic medium which was composed of the basic medium supplemented with 
10 mM ~-glycerophosphate and 10-8 M dexamethasone. In brief, the samples were 
washed with pre-warmed PBS and stored at -80°C freezer (New Brunswick 
Scientific, USA). The samples from all time points were defrosted all at once, lysed 
by the addition of 1 ml of 0.2% Triton X-I00 followed by sonification (Decon 
Ultrasonics, UK). The ALP activity in the supernatant was measured as the release of 
p-nitrophenol from p-nitrophenylphosphate substrate over a period of 1 hour (AP 307 
kit, Randox Laboratories, UK) by assessing the absorbance at 405 nm wavelength on 
a ELx808 Ultra Microplate Reader (Bio-Tek Instruments, USA). A standard 
calibration curve based on the absorbance measurements of known concentrations of 
p-nitrophenol standard solution were used to compare the values obtained. The total 
protein content was evaluated with bicinchoninic acid (BCA) protein assay kit 
(product no: 23227, Pierce, USA) following manufacturer's instructions to normalize 
the ALP activity levels. This assay applies a reactive solution of bicinchoninic acid 
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(BCA) and CUS04. Proteins of the cells reduce Cu2+ ions into Cu +1 ions, which make 
a complex with BCA. The absorbance was measured at 562 run wavelength on a 
ELx808 Ultra Microplate Reader. A series of bovine serum albumin (BSA) was used 
as standards. The ALP activity levels were normalized to the total protein content at 
the end of the experiment (expressed as runol P-nitrophenol/mg protein/hr). 
Table 2.1- Summary of FBS concentration and seeding density for different cell 
types. 
Cell type FBS concentration (v/v) 
hMSCs 10% 
gMSCs 15% 
MC3T3-E 1 cells 10% 
Seeding density (cells/cm2) 
5000 
2000 
2000 
Table 2.2- Summary of culture flasks used and relevant growth medium, Trypsin and 
PBS volumes. 
Culture flask/Reagent Surface area of flasks 
25 cm2 80 cm2 175 cm2 225 cm2 
Flask manufacturer Coming Nunclon Nunclon Coming 
Neck Angled Angled Straight Angled 
Cap Filtered Filtered Filtered Filtered 
Volume of growth medium 6ml 14 ml 35 ml 50ml 
Volume of PBS wash 4ml 7 ml 10 ml 12 ml 
Volume of Trypsin used 1 ml 3 ml 5 ml 5 ml 
2.2.2 Passaging Monolayer Cell Cultures 
When cells reached approximately 95% confluency, as detected by light microscopy, 
the growth medium was removed and the cells were washed with pre-warmed 
phosphate buffered saline (PBS) such that the surface of the culture flask was 
covered. This was performed to remove any medium (calcium) from the flask since 
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medium (calcium) neutralizes the action of Trypsin. After the removal of PBS an 
, 
appropriate amount of Trypsin-EDT A (Invitrogen, UK) was added to the culture 
flasks to detach the cells from the flasks such that they can be replated (Table 2.2). 
The culture flasks were then transferred to the incubator (Heraeus, Germany) for 
about 10 minutes. Growth medium containing a-MEM + FBS at least twice the 
volume of Trypsin was added to each culture flask to neutralize the action of Trypsin. 
The cell suspension was then centrifuged at 300 x g (Centrifuge ALC 4218, Italy). 
The medium containing Trypsin was then removed and the cell pellet was mixed with 
a known volume of medium to count the number of cells. 
2.2.3 Cell Quantification and Determination of Viability by 
Trypan-blue Exclusion Assay 
Trypan-blue staining assay (Sigma-Aldrich, UK) was used along with a 
haemocytometer (Burker-Turk, Germany) to determine the number of viable cells. 
Ruptured membrane causes Trypan-blue stain to enter the dead cells thus allowing to 
distinguish between the dead cells and live transparent cells. For this, well mixed cell 
suspension (10 f..11) was combined with Trypan blue (10 f..11) and then mixed 
thoroughly. Cell-Trypan blue combination (20 f..11) was then added to the 
haemocytometer. Haemocytometer is a glass chamber which holds known volume of 
fluid (1 x 10-4 ml) having a grid structure. Cells were counted from different grid 
areas (Figure 2.1) and then incorporated into the following formula to obtain the total 
number of viable cells: 
N = M x D x 104 x V 
N = Total number of viable cells in original cell suspension 
M = Mean cell number counted using haemocytometer 
D = Dilution factor for Trypan-blue 
V = Volume of original cell suspension 
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~ Cells in this region were counted 
Figure 2.1- Schematic presentation of a haemocytometer. Cells were counted from 4 
different grid areas shown above. 
2.2.4 Cryo-preservation and Resuscitation of Cell Suspensions 
After obtaining cell suspension from monolayer cultures, the cells were centrifuged at 
300 x g and suspended in 1 ml of a-MEM + 20% FBS + 10% Dimethyl sulphoxide 
(DMSO, Sigma-Aldrich, UK) which is a cryo-protective agent. The number of cells 
per vial was 2 million for hMSCs and 10 million for gMSCs and MC3T3-El cells. 
Cryo-vials (Nalgene, USA) were used for long term storage of cell suspensions in a 
liquid nitrogen cryo-bank. Nalgene cryo-freezing container (Nalgene, USA) was used 
to achieve a cooling rate of approximately -1°C/min in -80°C freezer (New 
Brunswick scientific, USA) overnight. The samples were then stored in liquid 
nitrogen. 
To defrost the cells, the cryo-preserved samples were thawed in a 37°C waterbath 
(GFL 1092, Germany). When all the ice was thawed, the cell suspension was mixed 
with pre-warmed a-MEM + FBS followed by centrifugation at 300 x g. Total number 
of viable cells was assessed (2.2.3) before seeding the cells in culture flasks (2.2.1). 
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CHAPTER III 
BIOCOMPATIBILITY AND GELATION OF 
CHITOSAN-BASED HYDROGELS 
Published in the Journal of Biomedical Materials Research Part A (more details 
in the List of publications and conference proceedings section). 
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3.1 INTRODUCTION 
Thermo-sensitive binders have attracted great deal of interest in cell encapsulation, 
drug delivery, and tissue engineering (Chen and Hoffman, 1995; Jeong and 
Gutowska, 2002). These polymers can be added to cells, drugs, scaffolds, or a 
combination thereof and then injected through minimal invasive surgery to the injury 
site. The mixture can then set in situ upon change in temperature. Development of a 
tissue engineered formulation that can be injected straight into the injury site such as 
a bone defect is a major advancement in the field of tissue engineering. The injectable 
formulations offer several advantages compared to the conventional solid implants 
such as lower cost, easy handling by the physicians, reduced scarring and healing 
period, less pain to the patient, minimized surgery time, less complications, and exact 
conformation to irregular defects. 
Polymers like poloxamers which are poly( ethylene oxide )-poly(propylene oxide)-
poly( ethylene oxide) block copolymers have been widely investigated as temperature 
dependent reversible polymers (Johnston and Miller, 1989; Johnston et aI., 1992; Pec 
et al., 1992). Some reported disadvantage of poloxamer gels is that they have 
demonstrated rapid erosion (Bhardwaj and Blanchard, 1996). Bhardwaj and 
Blanchard (1996) have reported that a 25 wt% poloxamer 407 gel is completely 
dissolved in 4 h at 37°C, which would limit its potential as an injectable system that 
would have to remain for days, not hours (Bhardwaj and Blanchard, 1996). 
Chitosan is an aminopolysaccharide derived from alkaline deacetylation of chitin; a 
natural polymer material which is present in fungal cell walls and exoskeletons of 
arthropods like shrimps and crabs (Khor and Lim, 2003; Montembault et al., 2005; 
Pelletier et al., 1990). Due to its biocompatibility (Hirano and Noishiki, 1985), 
biodegradation properties (Muzzarelli, 1997), wound healing support (Ueno et aI., 
2001-a) and bacteriostatic effects (Felt et al., 2000), the natural biopolymer chitosan 
has been used in the biomedical field for a long time. Chitosan provides a biologically 
renewable non-toxic polymeric source (Li et aI., 2005) offering a hydrophilic surface 
which encourages proliferation, differentiation, and adhesion of cells (Hutmacher et 
aI., 2001; Suh and Matthew, 2000). In combination with glycerol phosphate (GP -
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disodium salt), this cationic polyelectrolyte becomes thermo-sensitive in diluted acids 
and can undergo gelation around body temperature (Chenite et aI., 2000). These 
properties make chitosan-based materials promising for a variety of applications such 
as drug delivery, cell encapsulation, and injectable tissue engineering. 
When GP is added to chitosan solution, the pH of the solution increases as a result of 
the neutralizing phosphate groups. Interestingly, chitosan-GP solutions can maintain 
their liquid state at physiological pH and then gel when heated at 37°C, also it was 
suggested that hydrogen bonding, hydrophobic and electrostatic interactions are the 
three forces which are potentially involved in the gelation process (Chenite et aI., 
2000). 
ChitosaniGlycerol phosphate (GP) systems have shown potential to be used for drug 
delivery and cell encapsulation (Chenite et al., 2000; Ruel-Gariepy et aI., 2000). The 
addition of 2% (w/v) chitosan-5.6% (w/v) GP to chondrocytes has been evaluated 
before by Chenite et al. (2000). Chondrocytes encapsulated within chitosan-GP were 
capable of maintaining more than 80% cell viability over an extended period of time 
in vitro. Cartilage formation was observed within chondrocytes-chitosan-GP gels 
after three weeks in vitro and in vivo. Furthermore, chitosan-GP systems have been 
also applied in vivo (Molinaro et aI., 2002). According to an study performed by 
Molinaro et al. (2002), 50 f.ll of 1.8% (w/w) chitosan with deacetylation degrees in 
the range of 84-95% mixed with 45% (w/w) GP resulted in an acute inflammatory 
response when injected in the hindpaw of the rat. Solutions containing chitosan of 
higher deacetylation degrees, however, cause a lesser inflammatory response. 
Interestingly, increasing GP concentration speeds up the gelation process (Cho et aI., 
2006). As reported by Zan et al. (2006), the higher the pH of the chitosan-GP 
solutions, the faster the gelation (Zan et aI., 2006). Higher GP content will result in 
higher pH. An increase in GP amount causes more chitosan amino groups to combine 
with GP by ionic interaction, resulting in the weakening of electrostatic repulsive 
force between amino groups that lead to easier aggregation of polymer chains and 
therefore faster gelation (Wu et aI., 2006). Higher GP concentration in chitosan-GP 
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systems which results in faster in situ gelation is desirable provided that it does not 
afTect cell viability. 
3.1.1 Aims and Objectives 
In this study, sixteen different combinations of 0.5-2% (w/v) chitosan mixed with 5-
20% (w/v) GP were prepared. To our knowledge, nothing is known with regard to the 
biocompatibility and reaction of chitosan-GP to mesenchymal stem cells. Therefore, 
the aim of this study was to evaluate the cytotoxicity of the different combinations of 
chitosan-GP gels by monitoring the growth rate of goat bone marrow derived 
mesenchymal stem cells (gMSCs). In addition, the osmolality and pH of the extracts 
from different combinations of chitosan-GP and the effect of extracts from 0.5-2% 
(\v/v) chitosan without GP on gMSC proliferation was assessed in order to understand 
the response of gMSCs towards the extracts. Furthermore, the pH and the gelation 
times of all chitosan-GP combinations were monitored. 
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3.2 MATERIALS AND METHODS 
All chemicals were ordered from Sigma-Aldrich, UK unless otherwise indicated. The 
experiments were repeated twice and all the measurements were performed in 
triplicates. 
3.2.1 Preparation of ChitosanlGP Solutions 
Chitosan powder (Bright Moon Seaweed Industrial Co. Limited, Qingdao, China) 
with an 800/0 degree of deacetylation (DDA) and a molecular weight (Mw) of 1000 
kDa was sterilized by autoclaving at 126°C for 20 minutes. Sterile chitosan powders 
with quantity ofO.075g and 0.15g were dissolved in 8 ml of 0.1 M hydrochloric acid 
while 9 ml of 0.1 M hydrochloric acid was used to dissolve 0.225g and 0.3g of sterile 
chitosan powders. Subsequently, 0.75g, 1.5g, 2.25g, and 3g of ~-glycerol phosphate 
disodium salt (GP) was dissolved in deionized water in order to make the total 
hydrochloric acid and deionized water volume in the solutions to 15 m!. The GP-
deionized water mixtures were then sterilized using a 0.2 f.lm filter (Triple Red 
Laboratory, UK). Solutions of chitosan-hydrochloric acid and GP-deionized water 
were chilled in an ice bath for 15 minutes in order to avoid gelation when mixed 
together. The ice cold GP-deionized water was then added drop-wise to the ice cold 
chitosan solution with continuous stirring to form a clear solution. Sixteen different 
combinations of chitosan-GP were prepared. The final concentration of chitosan in 
the solutions was 0.5%, 1 %, 1.5%, and 2% (w/v) while the concentration of GP was 
5%,10%,15%, and 20% (w/v) (Table 3.1). 
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Table 3.1- Sixteen different concentrations of chitosan GP solutl' d C . - ons were rna e 
oncentrattons are based on percentage weight/volume. . 
Chitosan (w/v) + GP (w/v) 
0.5% + 5% 1.0% + 5% 1.5% + 5% 2.0%+5% 
0.5% + 10% 1.0% + 10% 1.5% + 10% 2.0% + 10% 
0.5% + 15% 1.0% + 15% 1.5% + 15% 2.0% + 15% 
0.5% + 20% 1.0% + 20% 1.5% + 20% 2.0%+20% 
3.2.2 Cytotoxicity Tests 
After preparing 16 different combinations of chitosan-GP solutions, O.S ml of each 
solution was placed in sterile 12 well-plates (Falcon, VWR international, UK). The 
well-plates were then left at 37°C/5% CO2 incubator overnight in order to obtain gel 
films of more than 1 mm thickness. Cytotoxicity of the gels was evaluated by an 
extraction test according to ISOI0993-S. In brief, the chitosan-GP gels were 
immersed in 2.S ml of culture medium composed of a-MEM (Gibco Invitrogen, UK) 
supplemented with 15% v/v fetal bovine serum (FBS, Gibco Invitrogen, UK), 100 
U/ml penicillin! 1 00 J.lg/ml streptomycin (Sigma Aldrich, UK) and 0.2 mM L-ascorbic 
acid 2-phosphate (AsAP) (Sigma Aldrich, UK) and placed for 24 hours at 37°CIS% 
CO2. The ratio of culture medium to gel surface area was set at Iml/1.2Scm2. The 
culture medium added to empty well-plates served as control. Passage 2-3 goat bone 
marrow derived mesenchymal stem cells (gMSCs) (Kruyt et ai., 2004-b) (from iliac 
crest of adult Dutch milk goats, 2-4 years old, Xpand Biotechnology BV, The Netherlands) 
were seeded at a density of 40,000 cells/cm2 in sterile 12 well-plates and kept in a 
humid atmosphere at 37°C/5% CO2 for 24 hours until the cells reached 80-90% 
confluency. Before the addition of 0.5 ml of extraction fluids from different mixtures 
of chitosan-GP gels and the control medium to 80-90% confluent layer of gMSCs, the 
extraction fluids were passed through an sterile 0.2 J.lm filter (Triple Red Laboratory, 
UK). Cell proliferation was measured using the colourimetric indicator Alamar Blue 
assay (SeroTec, Oxford, UK). After 48 hours of incubation, extraction medium was 
removed from the well-plates and gMSCs were washed three times with pre-warmed 
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phosphate buffered saline solution. Subsequently, 1 ml of a 50/0 Alamar Blue solution 
in culture medium (Lawson et aI., 2004) was added to each well-plate and the plates 
were incubated for 3 hours in a humidified atmosphere at 37°C/5% CO2. 
Fluorescence of 100 /-11 aliquots of the extracted dye from each sample was 
determined using a Fluorimeter (FLUOstar Galaxy Fluorimeter, JENCONS-PLS, 
Germany) at excitation and emission wavelengths of 544 nm and 590 nm 
respectively. A standard calibration curve based on known numbers of gMSCs 
reacting with the Alamar Blue solution was employed to quantify the number of cells 
present in each well (Lawson et aI., 2004; Li et al., 2005). 
3.2.3 Gelation Time of Chitosan-GP 
The gelation time of 16 different mixtures of chitosan-GP solutions was measured 
using an AR 2000 Rheometer (Advanced Rheometer AR 2000, TA Instruments, UK) 
fitted with a plate-plate tool. The diameter of the plates was 25 mm. The elastic 
modulus (G') and the viscous modulus (G"), as a function of time at 37°C, were 
evaluated from the oscillatory measurements at a frequency of 1 Hz. The gelation 
time was determined at the intersection of G' and G" (Luginbuehl et al., 2005; Tung 
and Dynes, 1982). 
3.2.4 pH Measurements 
The pH of the ice cold chitosanlGP solutions and extraction medium were measured 
using an electronic pH meter (Fisherbrand Hydrus 300, Orin Research Incorporation, 
USA). 
3.2.5 Osmolality of Extraction Medium from Chitosan-GP 
From all sixteen different combinations of chitosan-GP solutions, 0.5 ml of each type 
was placed in sterile 12 well-plates (VWR international, UK). The well-plates were 
then left at 37°C/5% C0 2 incubator overnight in order to get gel films of more than 1 
mm thickness. The chitosan-GP gels were immersed in 2.5 ml of culture medium 
with the same composition as before and placed for 24 hours at 37°C/5% C02. 
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Osmolality of 200 J.d aliquots of the filter-sterilized extraction medium from different 
combinations of chitosan-GP gels was measured by the Advanced Osmometer 
(Model 3250, Advanced Instruments Inc., USA), in order to assess the concentration 
of leaching ions in the extraction fluids. Culture medium in empty well-plates was 
used as control. The osmolality of the extraction media from 0.5-2% (w/v) chitosan 
solutions without GP with pH neutralized with 1 M NaOH as described earlier were 
also evaluated in the same manner. 
3.2.6 Effect of Chitosan Degradation on Proliferation of gMSCs 
Chitosan powder with quantities of 0.075g, 0.15g, 0.225g and 0.3g were sterilized 
through autoc1aving at 126°C for 20 minutes before being dissolved in 8 ml (the first 
two concentrations) and 9 ml (the last two concentrations) of 0.1 M hydrochloric 
acid. The pH was neutralized to 7.4 with the addition of 1 M NaOH solution followed 
by the addition of deionized water to make the final solution volume to 15 ml. The 
final concentration of chitosan in the solution was 0.5%, 1 %, 1.5%, and 2% (w/v). 
Extraction cytotoxicity of the gels was evaluated in exactly the same way as 
described earlier. 
3.2.7 Statistical Analysis 
Results were analysed using two sample two-tail Student's (-test and one-way 
analysis of variance (ANOVA) followed by a post hoc least significant difference 
(LSD) test for multiple comparisons. All measurements were performed in triplicate. 
Data are presented in mean ± standard deviation. A p value of <0.05 indicated 
statistical significance. 
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3.3 RESULTS 
3.3.1 Gelation of Chitosan-GP Hydrogels 
The chitosan-GP is solution at room temperature i.e. 22°C, however the solution sets 
at 37°C (Figure 3.1 a, b). The colour of the solution changes from transparent to 
opaque upon gelation at 37°C. 
Different chitosan concentrations (0.5-2% (w/v)), with 5-200/0 (w/v) GP all gel around 
physiological temperature but in different time periods (Figure 3.2). Chitosan in 
combination with 15-200/0 (w/v) GP gels in less than 2 minutes whereas 5-10% (w/v) 
GP leads to longer gelation times of around 10 minutes. The gelation time decreases 
with increasing GP concentration. Chitosan concentration also influences the gelation 
time such that higher chitosan concentrations lead to reduced gelation time when 
combined with the same quantity of GP. Statistically, within one group, the gelation 
times of different GP concentrations are significantly different from one another 
(p<0.05). At 15-20% (w/v) GP, chitosan concentrations of 1-2% (w/v) have similar 
gelation rates. Nevertheless, 0.5 % (w/v) chitosan mixed with 15-20% (w/v) GP 
illustrates longer gelation time with respect to 1-2% (w/v) chitosan mixed with 15% 
or 20% (w/v) GP. 
Figure 3.1- Chitosan (1 % w/v)-GP (20% w/v) solution before gelation (a) and after 
gelation (b). 
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3.3.2 Cytotoxicity of Chitosan-GP Hydrogel Extracts 
Extracts of 0.5-2% (w/v) chitosan mixed with 5% GP (w/v) enhance gMSC 
proliferation compared to the control (Figure 3.3). Extracts of 2% (w/v) chitosan 
combined with 10% (w/v) GP also result in an improved cell proliferation relative to 
the control while the rest of the extracts from other chitosan concentrations mixed 
with 10% (w/v) GP result in reduced cell growth compared to the control. Extracts 
from all chitosan concentrations mixed with 20% (w/v) GP lead to 100% cell death 
except for 2% (w/v) chitosan for which a less significant toxic response was 
observed. Extracts from 0.5-1 % (w/v) chitosan mixed with 15% (w/v) GP caused 
around 93% cell death but that of 1.5-2% (w/v) chitosan produced a lower toxic 
response. The highest proliferation belongs to extracts of 2% (w/v) chitosan-5% (w/v) 
GP. This combination results in up to 34% more cells relative to the control. 
Generally, the cytotoxicity of the extracts from chitosan mixed with more than 10% 
(w/v) GP increases, while in case of 2% chitosan this phenomenon holds true when 
the quantity of GP is higher than 15% (w/v) (Figure 3.3). Considering the extracts of 
0.5-2% (w/v) chitosan combined with 5% (w/v) GP, the higher the concentration of 
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chitosan, the higher the percentage cell growth relative to control. Similarly, when 
combined with the same quantity of GP, higher concentrations of chitosan create 
lower extract cytotoxicity response. 
Taking 1.50/0 (w/v) chitosan experimental group as an example, the cytotoxic 
response of the extracts from this chitosan concentration mixed with 5% and 20% 
(w/v) GP is demonstrated in Figure 3.4. Clearly, an improved cell proliferation for the 
extracts from 1.50/0 (w/v) chitosan-50/0 (w/v) GP is observed when compared to the 
control (Figure 3.4 a and b respectively). Considerable cell death with a OP 
concentration of 20% (w/v) is visible where the cells appear to have shrunk (Figure 
3.4 c). 
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20 "'" 
Figure 3.4- gMSCs after incubation with a) extraction medium from 1.5% (w/v) 
chitosan-5% (w/v) GP; b) control medium; c) extraction medium from 1.5% (w/v) 
chitosan-20% (w/v) GP. 
3.3.3 pH Measurements 
The pH of all different combinations of chitosan-GP solutions and the extraction 
media are around physiological range (Table 3.2). There is a general decrease in pH 
values of the extraction media compared to the chitosan-GP solutions. For each 
concentration of chitosan solution, the pH values increase with increasing quantities 
ofGP. 
Table 3.2- pH values of chitosan-GP solutions (bold) and of chitosan-GP extraction 
medium (italic). Based on an average of three measurements. The standard deviation 
is less than 0.1. 
~) 0.5% 1.0% 1.5% 2.0% GP (w/v) 
5% 
7.1 Z1 6.9 7.0 6.9 7.2 6.9 Z1 
10% 
7.4 7.0 7.3 7.2 7.1 7.2 7.3 7.0 
15% 
7.6 Z1 7.4 Z1 7.3 Z1 7.4 7.0 
20% 
7.7 Z1 7.6 7.0 7.5 Z1 7.6 Z1 
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3.3.4 Osmolality of Extraction Medium from Chitosan-GP 
Increasing the GP concentration of the gels mixed with any of the chitosan 
concentrations results in a linear increase in osmolality of the extraction media 
relative to the control as illustrated in Figure 3.5. However, there is not a significant 
difference in the osmolality of the extraction media obtained from different chitosan 
concentrations combined with the same GP concentration. 
The osmolality of the extracts from 0.5-20/0 (w/v) chitosan solutions increase steadily 
with an increase in chitosan concentration compared with the control indicating the 
contribution of the chitosan degradation products towards increased osmolality 
(Figure 3.6). Statistically, there is a significant difference between the osmolality of 
the extracts from 2% (w/v) chitosan and that of 0.5 and 1 % (w/v) chitosan (p<0.05). 
Extracts of 10/0, 1.5%, and 2% chitosan are statistically significantly higher relative to 
the control (p<0.05). 
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3.3.5 Effect of Chitosan Degradation on Proliferation of gMSCs 
Extracts from chitosan solutions without GP demonstrate up to 17% increase in 
gMSC proliferation relative to the control (Figure 3.7). All the groups show 
significantly higher cell growth as compared with the control. Cell growth obtained 
from exposure of extracts of 1.5-2% (w/v) chitosan are statistically significantly 
higher in comparison with the cell proliferation observed with 0.5-1 % (w/v) chitosan 
(p<O.05). 
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3.4 DISCUSSION 
The results of this study show that extracts from 0.5-2% (w/v) chitosan containing 
5% (w/v) GP are not only biocompatible but lead to high gMSCs proliferation 
relative to the control. Extracts from 0.5-2% (w/v) chitosan mixed with 10-20% (w/v) 
GP cause reduced cell growth compared to the control except for the extract of 2% 
(w/v) chitosan combined with 10% (w/v) GP for which an enhanced cell proliferation 
relative to the control is observed. The chitosan-GP is a solution at room temperature 
i.e. 22°C, but sets at 37°C (Figure 3.1). As shown in Figure 3.2, the gelation or setting 
time of the chitosan-GP solutions depend on GP concentration; the higher the 
concentration of GP, the lower the gelation time. The pH values of 0.5-2% (w/v) 
chitosan combined with 5-20% (w/v) GP are all in the physiological range. The 
extraction media also had pH around physiological range. For each concentration of 
chitosan solution, the pH values increase with increasing quantities of GP. This is due 
to neutralizing action of the phosphate groups in GP (Cho et aI., 2006). There is up to 
17% increase in cell proliferation compared to the control when extracts from 0.5-2% 
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(w/v) chitosan solutions without GP were used. Furthermore, a linear increase in 
osmolality of the extracts from chitosan-GP with increasing GP content is observed. 
The osnl0lality of the extracts from 0.5-2% (w/v) chitosan solutions raise gradually 
with an increase in chitosan concentration in comparison with the control. 
The gelation time decreases with increasing GP concentration. This is in agreement 
with the observations performed by Ganji et al. (2007) however, in their paper, the 
gelation time was measured based on the inverted test tube method which is not as 
accurate as using rheometery for measuring gelation time (Ganji et al., 2007). When 
15-20% (w/v) GP was added to 1-2% (w/v) chitosan, gelation time was reduced to 
less than 1 minute but lower GP concentrations led to increased gelation time. High 
GP concentrations of 15% and 20% (w/v) produce similar gelation rates when 
combined with 1-2% (w/v) GP however, 0.5% (w/v) chitosan combined with 15% 
and 20% (GP) demonstrates lower gelation rate relative to 1-2% (w/v) chitosan. 
Chitosan concentration also influences the gelation time such that higher chitosan 
concentrations lead to lower gelation time when mixed with the same quantity of GP. 
This trend was also observed by Ganji et al. (2007) whereby 2% (w/v) chitosan 
resulted in reduced gelation time compared to 1 % (w/v) chitosan when combined 
with similar GP quantities. Increasing GP and chitosan concentration speeds up the 
gelation process due to an increase of intermolecular interactions and entanglements 
(Cho et aI., 2006). This is in agreement with the findings in this study. Montembault 
et al. (2005) compared the effect of chitosan concentration on gelation time without 
any external cross-linking agents in acetic acid-water-propanediol solution and found 
that higher chitosan concentrations result in lower gelation time, similar to the results 
presented in this study (Montembault et al., 2005). It was then suggested that more 
entangled polymer chains are responsible for faster gelation in case of higher polymer 
concentrations. 
Chenite et al. (2001), investigated the effect of gelation temperature as a function of 
pH and GP concentration on chitosan-GP solution and found that higher GP 
concentration results in higher pH which in tum leads to lower gelation temperature 
(Chenite et aI., 2001). They suggested that the number of charged ammonium groups 
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on the chitosan chain is influential in terms of controlling the gelation. A decrease in 
charge density on chitosan chains causes reduction of interchain electrostatic 
repulsion therefore leading to smaller amount of thermal energy needed to initiate the 
gelation. This is again in accordance with the observation in the present study since 
higher OP concentration and thus higher pH leads to smaller addition of thermal 
energy required to start the gelation. This would result in faster gelation but chitosan 
solutions with lower OP concentrations need more thermal energy which can be 
achieved by increasing the gelation temperature or increasing the gelation time. 
According to Chenite et al. (2000), when chondrocytes were added to 2% (w/v) 
chitosan-5.6% (w/v) OP, they were able to maintain more than 80% viability over an 
extended period of time in vitro and give rise to cartilage and proteoglycan formation 
(Chenite et aI., 2000). In this study, the response of gMSCs to extracts from various 
concentrations of chitosan-OP gels was evaluated as this was not performed in the 
literature before. Extracts of 0.5-2% (w/v) chitosan mixed with 5% OP (w/v) enhance 
gMSCs proliferation compared to the cells cultured in control medium. Improved 
cell proliferation relative to the control ranging from 18-34% was observed with the 
extracts from 0.5-2% (w/v) chitosan combined with 5% (w/v) OP (Figure 3.3). 
Chitosan-OP extracts with higher concentrations of chitosan result in more cell 
proliferation. For instance, in the case of extracts from 10% (w/v) OP mixed with 
chitosan, there is enhanced cell proliferation with 2% (w/v) chitosan and reduced cell 
proliferation with 0.5-1.5% (w/v) chitosan. This could potentially be due to two 
reasons. Firstly, it could be due to higher chitosan concentrations needing more OP to 
react with the amine group as the electrostatic interactions between the chitosan and 
the OP is one of the forces involved in gel formation (Chenite et al., 2000). When 
more OP is reacting with the chitosan, there would therefore be less leaching to the 
outside medium i.e. extraction medium and thus better cell growth response. 
Secondly, higher chitosan concentrations lead to higher degradation products and thus 
stimulating higher cell growth based on the possible theories discussed later on in the 
discussion section. To investigate this further, the osmolality of the extraction media 
obtained from different concentrations of chitosan-OP hydrogels was studied as well 
as the osmolality of the extraction media exposed to chitosan solutions without OP. 
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The proliferation of the cells exposed to the extracts of chitosan solutions without GP 
was also examined. 
As demonstrated in Figure 3.5, there is not a significant difference in the osmolality 
of the extraction media obtained from different chitosan concentrations combined 
with the same GP concentration. This rules out the first theory reason of getting more 
enhanced cell growth with higher chitosan concentrations. After gelation GP is 
diffusing out of the physically cross-linked network (Chenite et aI., 2001). Ruel-
Gariepy et al. (2000) also suggested that there is a significant leaching of excess GP 
\vhich do not contribute to the physical cross-linking of the chitosan-GP gels (Ruel-
Gariepy et aI., 2000). But the extra GP is needed for raising the pH and in tum the 
gelation rate. But according to the osmolality results, even though more GP is needed 
to react with increased amine groups present in higher chitosan concentrations, the 
extra GP leaching out to the medium is similar for all conditions. Extracts from 
chitosan of 0.5-2% (w/v) without GP have shown an increase in gMSC proliferation 
compared to the control (Figure 3.7). This proves that GP is not responsible for the 
enhanced growth seen with certain extracts and it is in fact due to the degradation 
products of chitosan in the extraction media through the possible mechanisms 
described below. All the groups have shown significant difference relative to the 
control. Cell growth obtained from exposure of extracts of 1.5-2% (w/v) chitosan are 
statistically significantly higher in comparison with the cell proliferation observed 
with 0.5-1 % (w/v) chitosan (p<0.05). This result proves the second theory reason of 
getting more enhanced cell growth with higher chitosan concentrations, indicating 
that higher chitosan concentrations cause higher degradation products and therefore 
leading to higher cell proliferation. This is further evidenced by the fact that the 
osmolality of the extracts from 0.5-2% (w/v) chitosan solutions increase 
progressively with a raise in chitosan concentration compared with the control 
indicating more chitosan degradation products with higher chitosan concentrations 
(Figure 3.6). There is a significant difference between the osmolality of the extracts 
from 2% (w/v) chitosan and that of 0.5 and 1 % (w/v) chitosan (p<0.05). Extraction 
media from 1 %, 1.5%, and 2% chitosan are significantly higher relative to the control 
(p<0.05). 
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As shown in Figure 3.5, a linear increase in osmolality of the extracts is seen with 
higher levels of GP in gels containing 0.5-20/0 (w/v) chitosan in comparison with the 
control. This illustrates that there is more GP in the extracts exposed to higher GP 
content hydrogels. The osmolality for bioencapsulation should be ideally around 270-
340 mOsmlkg H20 (Chenite et aI., 2002). Extracts from all chitosan concentrations 
mixed with 5% (w/v) GP all show osmolality less than 340 mOsmlkg H20. 
Nevertheless, osmolality of the extraction media from all chitosan concentrations 
mixed with 10-20% (w/v) GP are more than 400 mOsmlkg H20 and since the 
physiological osmolality is around 285 mOsmlkg H20 (Davies et aI., 2001) this 
could be a possibility for resultant cell death obtained with extracts from 0.5-2% 
(w/v) chitosan mixed with 10-20% (w/v) GP causing the cells to shrink as they are 
trying to reach an isotonic environment with the extraction medium. Figure 3.4c 
illustrates the shrunk cells which are exposed to the extracts from 1.5% (w/v) 
chitosan-20% (w/v) GP. However, there is an increase of more than 20% relative to 
the control in the proliferation of the cells in contact with extracts from 2% (w/v) 
chitosan-100/0 (w/v) GP despite the known high osmolality of the extract. The extracts 
from 2% (w/v) chitosan-10% (w/v) GP possess higher chitosan degradation products 
compared to the extracts of 0.5-1.5% (w/v) chitosan-lO% (w/v) GP. The relatively 
high polymer degradation in extracts exposed to 2% chitosan overrules the high 
osmolality resulting in increased cell growth compared to the control. 
Chitosan has been observed to cause improved cell proliferation response as Howling 
et al. (2001), investigated the effect of chitin and chitosan on the proliferation of 
human skin fibroblasts and keratinocytes (Howling et aI., 2001). They observed about 
50% increase in the proliferation rate of fibroblasts over the control group when they 
were treated with an initial chitosan concentration of 50 ~g/ml in culture media. The 
mechanism by which chitosan stimulates cell growth is unknown however, chitosan 
may indirectly enhance fibroblast proliferation through the formation of poly-
electrolyte complexes with serum components like heparin (Mori et aI., 1997), or 
potentiating growth factors like platelet derived growth factor (Inui et aI., 1995). 
According to Howling et al. (2001) the effect of chitosan on the growth of fibroblasts 
depended on the presence of serum in the medium. It was shown by Inui et al. (1995), 
that chitosan oligosaccharides interact with a receptor present on the surface of 
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vascular smooth muscle cells (VSMC). Based on their observations, four or more D-
glucosamine units were needed for activation. They also pointed out that chitosan 
oligosaccharides play a role as progression factor in mitogenesis induced by platelet 
derived growth factor in vascular smooth muscle cells. Platelet derived growth factor 
is known as a competence factor that needs the existence of progression factors like 
insulin in order to induce cell proliferation (Howling et al., 2001). As shown by Inui 
et al. (1995), platelet derived growth factor induced cell proliferation was in fact 
stimulated by chitosan and insulin therefore chitosan may imitate insulin in terms of 
action as progression factor. 
As reported by Howling et al. (2001), chitosan might bind with serum components 
thus activating them. This suggests that chitosan by binding to serum components 
may present the components to the cells in an activated form. As mentioned before, 
only extracts from certain concentrations of chitosan-GP resulted in improved cell 
growth relative to control despite the presence of chitosan in all groups. This could 
potentially be due to high GP concentrations leaching to the extraction medium 
leading to high osmolality and the subsequent toxicity. 
All the above information suggests that chitosan may activate the serum components 
present in goat bone marrow derived mesenchymal stem cell medium used in this 
study by binding/interacting with the serum components thus the extraction medium 
was able to produce higher proliferation rates compared to the control. 
3.5 CONCLUSION 
Extracts of all chitosan concentrations mixed with less than 10% GP (w/v) are 
biocompatible and result in enhanced cell growth compared to the control group. 
Extracts from other chitosan-GP combinations lead to reduced cell proliferation in 
comparison with the control. 
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Chitosan 0.5-20/0 (w/v) containing 5-200/0 (w/v) GP all gel around physiological 
temperature but in different time periods. 
The gelation time decreases with increasing GP concentration. Higher chitosan 
concentrations result in faster gelation time. The pH values of 0.5-2% (w/v) chitosan 
combined with 5-200/0 (w/v) GP are all in the physiological range. Extracts from 
chitosan solutions without GP demonstrate up to 17% increase in gMSC proliferation 
relative to the control. A linear increase in osmolality of extraction media with 
increasing GP content was also observable. Chitosan-GP can act as a potential future 
vehicle for cell encapsulation and injectable tissue engineering applications. 
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CHAPTER IV 
CHITOSAN-BASED HYDROGELS: GEL 
COMPOSITION, PHYSICAL PROPERTIES AND 
BIOLOGICAL EVALUATION 
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4.1 INTRODUCTION 
Presently, autologous bone grafts are regarded as the golden standard therapy to 
repair and regenerate bone (Yaszemski et aI., 1996-a). However, autograft harvesting 
leads to many complications including donor site morbidity (Banwart et al., 1995) 
therefore, a substitute technology is needed. Bone tissue engineering which combines 
osteoprogenitor cells with a suitable scaffold to form bone holds the promise to be a 
possible solution (Kruyt et aI., 2006). This is because osteoprogenitor cells attached 
to scaffolds and derived from the patient could produce bone with no immunological 
issues (Johansson and Persson, 2003). 
Minimal invasive surgery is today's advancement in the field of medicine. To 
improve the bone tissue engineering technique even further and to apply the minimal 
invasive surgery in bone repair and regeneration, a method that reduces intrusion and 
scar formation is required. Minimally invasive injectable tissue engineered bone is 
therefore a promising solution since it provides faster healing, easier handling for 
physicians and less pain. 
In previous chapter, cytotoxicity studies on chitosan-glycerol phosphate (GP) extracts 
were performed using goat bone marrow derived mesenchymal stem cells (gMSCs). 
The results showed that chitosan-GP extracts were biocompatible at certain 
concentrations. In addition, gelation of chitosan-GP was carried out which 
demonstrated that chitosan-GP was able to gel within minutes. Based on the work 
done by Roughley et al. (2006), it was shown that chitosan-GP has a weak structure 
(Roughley et aI., 2006). The weak structure by chitosan-GP is problematic since BCP 
microparticles are relatively heavy and they will be likely to settle at the bottom of 
the gel causing inhomogeneity within the chitosan-GP-microparticle structure. 
Therefore, there is a need to enhance the integrity of the structure in order to prevent 
this from happening. Addition of hydroxyethyl cellulose (HEC) allows cross-linking 
of chitosan and thus enhancing gel rigidity (Hoemann et al., 2002; Hoemann et al., 
2005; Roughley et aI., 2006). With chitosan-GP-HEC hydrogel having a firmer 
composition, BCP microparticles can be mixed with the gel and remain 
homogeneously distributed within the gel structure. Therefore, in the current study, 
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HEC was added to chitosan-GP and the effect of gelation and degradation of 
chitosan-GP-HEC hydrogels was examined. Additionally, the survival and growth of 
human bone marrow derived mesenchymal stem cells (hMSCs) encapsulated with 
chitosan-GP-HEC was investigated together with their osteogenic differentiation 
since in previous chapter only extract cytotoxicity test was carried out. It should be 
mentioned that hMSCs were used in this study as opposed to gMSCs in previous 
chapter since hMSCs are closer to the final application of the injectable tissue 
engineered bone. Furthermore, in terms of osteogenic differentiation, hMSCs will 
produce higher ALP activity in comparison with control when in contact with 
osteogenic medium (Mendes et aI., 2004) therefore making it easy to examine 
osteogenic tendency. This is further explained in the discussion section of this 
chapter. 
To allow injectability, sub-millimetre SIze particles should be used. Calcium 
phosphate ceramICS are commonly used as scaffold material due to their 
biocompatibility and osteoconductivity (Hench and Wilson, 1984; Jarcho, 1981). 
Many researchers demonstrated that the size of ceramic particles affect bone 
formation in vivo with the optimal diameter size lying in the range of 100-300 J..lm 
(Fischer et aI., 2003; Malard et aI., 1999; Mankani et aI., 2001). This has been related 
to the three-dimensional microenvironment produced by the optimal size 
microparticles such that the macroporosity created (the free space created in between 
the microparticles) allowed entry of blood vessels, body fluids and nutrients whereas 
bigger microparticles produced a different macroporosity unsuitable for bone 
formation (Fischer et aI., 2003). The created macroporosity should be such that there 
is some empty space for blood vessel ingrowth without fibrous tissue development. 
Mankani et al. (2001) and Kruyt et al. (2006) have successfully used biphasic 
calcium phosphate (BCP) microparticles consisting of hydroxyapatite (HA) and 
tricalcium phosphate (TCP) in bone tissue engineering (Kruyt et aI., 2006; Mankani 
et aI., 2001). Therefore, in the study described herein, biphasic calcium phosphate 
microparticles of 212-300 J..lm diameter were used. In general, two different 
approaches have been used regarding injectable bone tissue engineering which 
consists of osteoprogenitor cells, ceramic microparticles and an injectable binder. The 
cells can either be seeded onto the scaffolds just prior to implantation or they can be 
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cultured on the scaffolds for a few days before implantation to allow extracellular 
matrix formation and differentiation of cells (Kruyt et al., 2004-a; Mankani et aI., 
2001; Ohgushi and Caplan, 1999; Yoshikawa et aI., 2000). With respect to bone 
formation, cell culturing on the scaffolds has shown to be more beneficial compared 
to the cells seeded onto scaffolds prior to implantation (Kruyt et aI., 2004-b; Kruyt et 
aI., 2006; Mendes, 2002). More specifically, Yoshikawa et al. (1996), observed faster 
bone formation in rat marrow stromal cell/HA scaffolds which were triggered to 
osteogenic differentiation before subcutaneous implantation in rats compared with 
fresh bone marrow or undifferentiated mesenchymal stem cells (Yoshikawa et aI., 
1996). Differentiated mesenchymal stem cells can start building new osteoid 
immediately after arrival at the defect site. Moreover, bone marrow-derived stromal 
cells (BMSCs) have been successfully used with ceramic particles to produce 
osteogenic constructs through the cell culturing approach (Fischer et aI., 2003; 
Mankani et aI., 2001). Therefore, the cell culturing approach was used in the present 
study together with BMSCs. 
With regard to the application of minimal invasive surgery to patients, methods to 
easily apply tissue engineered bone constructs such as injection are required. A binder 
is therefore needed to offer injectability and fixation. Fixation of the cell-ceramic 
microparticles at the defect site can be achieved by gelation of the carrier binder at 
body temperature. As discussed in previous chapter, chitosan has great potential to be 
used as injectable binder mainly due to its biocompatibility (Hirano and Noishiki, 
1985; Vande Vord et aI., 2002), biodegradability (Muzzarelli, 1997) and thermo-
sensitivity in combination with glycerol phosphate (GP) at 37°C (Chenite et aI., 
2000). The use of chitosan-GP in drug delivery and cell encapsulations has been 
demonstrated before (Chenite et aI., 2000; Cho et al., 2008; Ruel-Gariepy et al., 
2000). Cho et al. (2008) studied the attachment and proliferation of rat bone marrow 
mesenchymal stem cells when suspended in 1.8% (w/v) chitosan mixed with 20% GP 
(w/v) (Cho et aI., 2008). Immunohistochemical visualization confirmed that the cells 
remained viable in the gel for at least 28 days following implantation. As explained in 
the preceding chapter, chitosan-GP was found to be biocompatible at certain 
concentrations when used in combination with gMSCs. Nevertheless, it is important 
to examine the biocompatibility of chitosan-GP in the presence of hMSCs in order to 
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use this hydrogel system for injectable bone tissue engineering involving hMSCs. 
Nothing is known with regard to biocompatibility and reaction of chitosan-GP to 
hMSCs and even though chitosan-GP has been shown to be biocompatible at certain 
concentrations when used with gMSCs (previous chapter) however, it is more 
appropriate to confirm the biocompatibility of chitosan-GP when in contact with 
hMSCs. 
Several investigators have applied chitosan-GP-HEC for tissue engineering and cell 
encapsulation purposes (Hoemann et aI., 2007; Hoemann et aI., 2005; Roughley et 
al.. 2006). Hoemann et al. (2005) encapsulated chondrocytes in 1.5% (w/v) chitosan-
3.3% (w/v) GP-2.5% (w/v) HEC-18 mM glucosamine followed by subcutaneous 
injection in nude mice for 3, 6 and 9 weeks. The results showed that chitosan gel 
support chondrocyte viability, phenotype and cartilage matrix accumulation in vivo. 
Moreover, HEK293 cells (a transformed epithelial cell line derived from human 
embryonic kidney) remained viable after 4 days of culture in 1.6% (w/v) chitosan-
2.9% (w/v) GP-0.25% (w/v) HEC (Hoemann et aI., 2007). In another study, 
Roughley et al. (2006) examined the behaviour of intervertebral disc cells consisting 
of nucleus pulposus and annulus fibrosus encapsulated within 1.5% (w/v) chitosan-
2.9% (w/v) GP-0.36% (w/v) HEC for 20 days. Chitosan-GP-HEC hydrogels were 
able to retain around 70% of the proteoglycan produced by nucleus pulposus cells. 
Furthermore, nucleus pulposus and annulus fibrosus cells survived and continued to 
proliferate during the 20 day culture period when cultured with fetal calf serum and 
TGF-~. For the final application of injectable tissue engineered bone, it is necessary 
to assess the viability, growth and osteogenic differentiation of hMSCs encapsulated 
within chitosan-GP-HEC. 
Regarding chitosan-GP-HEC gelation, it is known that increasing concentration of 
HEC leads to enhanced chitosan-GP-HEC gelation (Hoemann et aI., 2007; Li and Xu, 
2002). According to Hoemann et al. (2007), 1.5% (w/v) chitosan- 2.9% (w/v) GP 
mixed with HEC concentrations of 0.1 %-0.5% (w/v) demonstrated faster gelation 
with higher HEC concentrations. Furthermore, Li and Xu (2002) examined the 
influence of HEC content on the gelation rate and elastic strength of chitosan-GP 
hydro gels. Hydrogels with higher concentrations of HEC had considerably higher 
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storage modulus (strength) compared to those with lower levels. Also, increasing 
HEC content enhanced the gelation rate. It was then suggested that higher number of 
hydrogen bonding in the hydrogel network leads to enhanced hydrogel strength. 
Higher storage modulus (strength) corresponding to stiffer hydrogels is more suited 
for applications in bone defects compared to hydrogels with lower storage modulus. 
As explained in previous chapter, higher GP contents result in faster gelation. Higher 
concentration of GP and HEC which corresponds to faster gelation is therefore 
preferable in the chitosan-GP-HEC hydrogel system without compromising cell 
viability. For injectable bone tissue engineering purposes, the gelation time in the 
range of a few minutes should be adequate to permit rapid hardening inside the body. 
Other than having rapid gelation properties, an injectable binder should be degradable 
in order to provide space for bone formation. However, injectable binders should not 
have rapid degradation since they have to remain for days and not hours to offer 
stability to the cell (tissue)-scaffold combination in the defect site until the cells start 
producing extracellular matrix and forming bone. Chitosan (2% w/v)-GP (S.6% w/v) 
was shown to be degradable with about 60% of the dry weight remaining after 72 
hours (Wu et aI., 2006). Moreover, chitosan-GP/blood implants remained for about 3 
weeks after implantation in chondral defects (3.S x4.S mm) in rabbits (Chevrier et al., 
2007). These studies demonstrate that chitosan-GP does not have rapid degradation 
rate, which is useful for injectable applications of tissue engineered bone. However, 
addition of HEC could possibly affect the degradation rate of chitosan-GP, which will 
be investigated in the current study. 
4.1.1 Aims and Objectives 
In previous chapter, chitosan-GP extract cytotoxicity and gelation studies were 
successfully performed. Nonetheless, due to the weak structure of chitosan-GP 
(Roughley et aI., 2006), it was necessary to enhance the gel structure such that BCP 
microparticles could be homogenously distributed within the gel network. Therefore, 
the aim of the present study was to evaluate the optimal chitosan binder composition 
for injectable tissue engineered bone purposes. For this, HEC was added to chitosan-
GP hydro gels. The biocompatibility and pH of various concentrations of chitosan-GP 
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mixed with and without HEC when in contact with hMSCs were assessed by means 
of biochemical assays. A temporal assessment of hMSCs survival, growth and 
osteogenic differentiation when encapsulated with chitosan-GP-HEC using live/dead 
staining and biochemical assay techniques were performed. Moreover, gelation and 
degradation properties of different compositions of chitosan-GP-HEC were 
examined. 
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4.2 MATERIALS AND METHODS 
All chemicals were ordered from Sigma-Aldrich, UK unless otherwise indicated. The 
experiments were repeated three times and all the measurements were performed in 
triplicates unless otherwise stated. 
4.2.1 Preparation of Chitosan-GP Solutions 
Chitosan powder (Kitomer, Marinard Biotech, Quebec, Canada) with a 94% degree of 
deacetylation (DDA) and a molecular weight (Mw) of 679 kDa was sterilized by 
autoclaving at 126°C for 20 minutes. Sterile chitosan powder (0.225g) was dissolved 
in 9 ml of 0.18 M hydrochloric acid. Subsequently, 0.75g, 1.5g, 2.25g and 3g of ~­
glycerol phosphate disodium salt (GP) was dissolved in deionized water in order to 
bring the total hydrochloric acid and deionized water volume in the solutions to 15 
ml. A 0.2 /lm filter (Triple Red Laboratory, UK) was used to sterilize the GP-
deionized water mixtures. Chitosan-hydrochloric acid and GP-deionized water 
solutions were placed in an ice bath to chill for 15 minutes to avoid gelation when 
combined together. The ice cold GP-deionized water was then added drop by drop to 
the ice cold chitosan solution with constant stirring in order to create a clear solution. 
F our different combinations of chitosan-GP were prepared. The final concentration of 
chitosan in the solutions was 1.5% (w/v) while the concentration of GP was 5%, 10%, 
15%, and 20% (w/v). 
4.2.2 Cytotoxicity Tests 
After preparing 1.5% (w/v) chitosan solution combined with 5-20% (w/v) GP, 0.5 ml 
of each solution was added to sterile 12 well-plates (Falcon, VWR international, UK). 
The well-plates were then kept at 37°C/5% CO2 incubator overnight to obtain gel 
films of more than 1 mm thickness. Cytotoxicity of the gels was assessed by an 
extraction test based on ISOI0993-5. Briefly, the chitosan-GP gels were immersed in 
2.5 ml of proliferation culture medium composed of a-MEM (Gibco Invitrogen, UK) 
supplemented with 10% v/v fetal bovine serum (FBS, Gibco Invitrogen, UK), 100 
U/m! penicillinll00 f.lg/ml streptomycin, 1 ng/ml basic fibroblast growth factor (b-
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FGF, SeroTec, Oxford, UK), 2 mM L-glutamine, and 0.2 mM AsAP and kept for 24 
hours at 37°C/50/0 CO2. The ratio of culture medium to gel surface area was 
1m1/1.25cm2. The culture medium in empty well-plates was used as control. Passage 
2 hMSCs (from female, age 36 (iliac crest); male, age 44 (acetabulum); female, age 
55 (iliac crest); Xpand Biotechnology BV, The Netherlands) were seeded at a density 
of 50.000 cells/cm2 in sterile 12 well-plates (Falcon, VWR international, UK) and 
placed in a humid atmosphere at 37°C/5% CO2 for 24 hours until the cells reached 
80-900/0 cont1uency. The extraction t1uids from different mixtures of chitosan-GP gels 
were sterilized using an sterile 0.2 /-lm filter (Triple Red Laboratory, UK). This was 
then followed by the addition of 0.5 ml of such extraction t1uids to hMSCs with 80-
900/0 cont1uency. The control medium was also added to hMSCs in a similar way. 
The colourimetric indicator Alamar Blue (SeroTec, Oxford, UK) was employed to 
evaluate cell proliferation. The extraction medium was removed from the well-plates 
following 48 hours of incubation, and hMSCs were washed three times with pre-
wanned PBS solution. Consequently, 1 ml of a 5% Alamar Blue solution in culture 
medium (Lawson et aI., 2004) was added to each well-plate. The plates were then 
incubated for 3 hours in a humidified atmosphere at 37°C/5% CO2. Fluorescence of 
100 /-ll aliquots of the extracted dye from each sample was determined using a 
Fluorimeter (FLUOstar Galaxy Fluorimeter, JENCONS-PLS, Germany) at excitation 
and emission wavelengths of 544 nm and 590 nm respectively. A standard calibration 
curve according to known numbers of hMSCs reacting with the Alamar Blue solution 
was used in order to quantify the number of cells present in each sample (Lawson et 
al., 2004; Li et aI., 2005). 
4.2.3 Preparation of Chitosan-GP-HEC Solutions 
HEC was added to a-MEM (Gibco Invitrogen, UK) at the concentration of 0.0125, 
0.025, and 0.05 glml (Roughley et aI., 2006). The HEC solutions were sterilized 
using a 0.2 flm filter and then added to the chitosan-GP solution at the ratio of 0.8 ml 
to 4.8 ml respectively. The final concentration of chitosan and GP in the solutions 
was 1.5% (w/v) and 15% (w/v) respectively while the concentration of HEC was 
0.18%,0.36%, and 0.72% (w/v). 
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4.2.4 Direct Contact Biocompatibility Tests 
Passage 2 hMSCs (from female, age 36 (iliac crest); male, age 44 (acetabulum); 
female, age 55 (iliac crest); Xpand Biotechnology BV, The Netherlands) were seeded 
at a density of 20,000 cells/cm2 in sterile 24 well-plates (Falcon, VWR international, 
UK) after obtaining ethical approval and kept in a humid atmosphere at 37°C/5% CO2 
for 24 hours until a subconfluent monolayer is observed. Direct contact 
biocompatibility tests were performed based on ISOI0993-5. A one mm-thick layer 
of 1.5% (w/v) chitosan-15% (w/v) GP mixed with HEC concentrations of 0%, 0.18% 
(\v/v), 0.36% (w/v) , and 0.72% (w/v) was placed on top of a subconfluent layer of 
hMSCs. hMSCs exposed to tissue culture plastic were used as control. The 
proliferation culture medium mentioned above was used to feed the cells and was 
refreshed every two days. Following 1, 3, and 7 days of incubation, the DNA 
contents of the cells were evaluated using the cyquant assay kit (Molecular Probes, 
USA) following manufacturer's instructions and a Fluorimeter (FLUOstar Galaxy 
Fluorimeter. JENCONS-PLS, Germany). To perform the analysis, the samples were 
washed with pre-warmed PBS and stored at -80°C freezer (New Brunswick 
Scientific, USA). The samples from all time points were defrosted at once, lysed by 
the addition of 1 ml of 0.2% Triton X-I00 followed by sonification (Decon 
Ultrasonics, UK). The supernatants were then used to carry out the assay. The DNA 
solution obtained was spectrometric ally analysed using emissions measured at 485 
and 520 nm by a Hitachi U- 2000 Spectrophotometer. A standard calibration curve 
based on the DNA measurements of known numbers of hMSCs was used in order to 
quantify the number of cells present. 
4.2.5 pH Measurements 
The pH of the ice cold chitosan-GP solutions and extraction medium from the 
cytotoxicity tests above were assessed using an electronic pH meter (Fisherbrand 
Hydrus 300, Orin Research Incorporation, USA). Also, the pH of 1.5% (w/v) 
chitosan-15% (w/v) GP combined with HEC concentrations of 0% (w/v) , 0.18% 
(w/v), 0.36% (w/v) and 0.72% (w/v) were measured. 
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4.2.6 hMSCs Survival, Growth and Osteogenic Differentiation 
within Chitosan-GP-HEC 
4.2.6.1 hMSCs Survival and Growth Study 
Passage 2 hMSCs (from female, age 36 (iliac crest); male, age 44 (acetabulum); 
female, age 55 (iliac crest); Xpand Biotechnology BV, The Netherlands) with a 
seeding density of 30,000 cells/cm2 were added to 212-300 J.lm BCP microparticles 
that were sintered at 1150°C and were composed of 80% ± 3 HA and 20% ± 3 ~-TCP 
(Figure 4.1, Siemens D5000 x-ray diffractometer, Germany) with a porosity of 70.8 
% (Xpand Biotechnology BV, The Netherlands). The seeding density of 30,000 
cells/cm2 was used since after 7 days, 85-95% cell coverage around the BCP 
microparticles were observed based on previous experiments. The medium used was 
the proliferation culture medium and was refreshed every two days. hMSCs attached 
to BCP microparticles were cultured for 7 days in non-tissue culture (cells do not 
attach) 25 square well-plates (Greiner Bio-one, Germany) at 37°C/5% CO2 incubator 
after which 1.5% (w/v) chitosan-15% (w/v) GP-0.18% HEC was added such that the 
final BCP/gel ratio was 20% (w/v). The optimal BCP/gel ratio was 20% (w/v) as it 
involves the maximum amount of BCP microparticles while the binder is still 
injectable. The celIlBCP/Chitosan-GP-HEC mixture was then cultured for another 7 
days. hMSCs attached to BCP microparticles without chitosan-GP-HEC and hMSCs 
in contact with tissue culture plastic were the control groups. 
The viability of the cells was evaluated before and after gel addition at days 1, 3, 7, 8, 
10, and 14 through live/dead viability staining using Ca1cein AM and Ethidium 
homodimer-2 (Molecular Probes, USA). Briefly, the samples were washed with pre-
warmed PBS. Subsequently, 2.5 J.lI of both stains were mixed with 1 ml of a-MEM 
and applied to the samples in 250 J.lI volume such that the samples were covered by 
the staining solution. Following this, the samples were kept at 37°C/5% CO2 
incubator for 15 minutes after which they were washed three times with pre-warmed 
a-MEM and viewed under Nikon Eclipse fluorescent microscope (Nikon Eclipse 
TE200, Japan) equipped with an UltraPix camera (UltraPix, model: 41 OOV /002, 
PerkinElmer, UK). In the live/dead viability assay, metabolically active cells, covert 
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Calcein AM into green fluorescent Calcein by intracellular esterases, whereas 
Ethidium homodimer enters the dead cells and binds to deoxyribonucleic acid (DNA) 
through danlaged membranes. Viable and dead cells are presented as green and red 
respectively. The DNA contents of the samples were also measured at days 1,3,7,8, 
10, and 14 using the supernatant of the samples obtained as explained before. The 
cyquant assay kit was employed to measure the DNA contents following 
manufacturer's instructions and using a Fluorimeter. The DNA solution obtained was 
spectrometrically analysed using emissions measured at 485 and 520 nm by a Hitachi 
U- 2000 Spectrophotometer. A standard calibration curve based on the DNA 
measurements of known numbers of hMSCs was used for quantification of the 
number of cells present. 
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Figure 4.1- X-ray diffraction (XRD) spectra ofBCP microparticles. Arrow indicates 
the main ~-TCP peak while dashed arrow shows the main HA peak. 
4.2.6.2 hMSCs Osteogenic Differentiation Study 
The alkaline phosphatase (ALP) activity and protein content were measured at days 1, 
3, 7, 8, 10, and 14. For this, the cells were cultured in the basic medium which was 
composed of the proliferation culture medium without b-FGF as well as the 
osteogenic medium which was composed of the basic medium supplemented with 10 
mM ~-glycerophosphate and 10-8 M dexamethasone. In brief, the samples were 
washed with pre-warmed PBS and stored at -80°C freezer (New Brunswick 
Scientific, USA). The samples from all time points were defrosted at once, lysed by 
the addition of 1 ml of 0.2% Triton X-I00 followed by sonification (Decon 
Ultrasonics, UK). The ALP activity in the supernatant was measured as the release of 
p-nitrophenol from p-nitrophenylphosphate substrate over a period of 1 hour (AP 307 
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kit, Randox Laboratories, UK) by assessing the absorbance at 405 run wavelength on 
a ELx808 Ultra Microplate Reader (Bio-Tek Instruments, USA). A standard 
calibration curve based on the absorbance measurements of known concentrations of 
p-nitrophenol standard solution were used to compare the values obtained. The total 
protein content was evaluated with bicinchoninic acid (BCA) protein assay kit 
(product no: 23227, Pierce, USA) following manufacturer's instructions to normalize 
the ALP activity levels. This assay applies a reactive solution of bicinchoninic acid 
(BCA) and CUS04. Proteins of the cells reduce Cu2+ ions into Cu+1 ions, which make 
a complex with BCA. The absorbance was measured at 562 run wavelength on a 
ELx808 Ultra Microplate Reader. A series of bovine serum albumin (BSA) was used 
as standards. The ALP activity levels were normalized to the total protein content at 
the end of the experiment (expressed as run 0 I P-nitrophenol/mg protein/hr). The 
sample size for all the measurements in this experiment was 6. 
4.2.7 Gelation Time and Storage Modulus ofChitosan-GP-HEC 
The gelation time of 1.5% (w/v) chitosan-15% (w/v) GP combined with HEC 
concentrations of 0% (w/v) , 0.18% (w/v) , 0.36% (w/v) and 0.72% (w/v) mixed with 
and without 20% (w/v) BCP microparticles was examined using an AR 2000 
Rheometer (Advanced Rheometer AR 2000, TA Instruments, UK) fitted with a plate-
plate tool. The diameter of the plates was 25 mm. The elastic (G') and viscous 
modulus (G") as a function of time at 37°C, were measured from the oscillatory 
measurements at a frequency of 1 Hz. The intersection of G' and G" was known as 
the gelation time (Luginbuehl et al., 2005; Tung and Dynes, 1982). In addition, the 
elastic modulus (G') at complete gelation was assessed for all the above mentioned 
gel compositions. Complete gelation is reached when G' levels off. 
4.2.8 Chitosan-GP-HEC Degradation 
Chitosan 1.5% (w/v)-15% (w/v) GP solutions combined with 0% (w/v), 0.18% (w/v), 
0.36% (w/v) and 0.72% (w/v) HEC were prepared and kept at 37°C incubator to gel 
overnight. Subsequently, 10 ml of phosphate buffered saline (PBS) with or without 
10 mg/L of lysozyme (50,000 U/mg form chicken egg white) were added to 2 ml of 
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the gels. This concentration of lysozyme was used to imitate lysozyme levels in 
plasma which is around 4-13 mg/L (Henry, 1991). The degradation behaviour of the 
gels were examined in terms of wet and dry weight measurements at days 1, 7, 14, 21, 
28. 35, and 42 and compared to day 0 measurements and expressed as % dry/wet 
weight remaining. For dry weight measurements, the samples were washed three 
times with distilled water, snap freezed in liquid nitrogen at -196°C for 2 minutes and 
then dried using a freeze dryer (Biopharma process systems, UK) for 24 hours. For 
wet weight lneasurements, the gels were washed with distilled water and gently 
blotted. The PBS with or without lysozyme was changed weekly until the end of the 
experiment. The samples from 1.5% (w/v) chitosan-15% (w/v) GP mixed with 0% 
and 0.18% (w/v) HEC following exposure to PBS with or without lysozyme were 
prepared for scanning electron microscopy after 1,7, 14,21,28,35 and 42 days. The 
samples prepared for dry weight measurements were coated with a layer of gold 
(Agar Auto Sputter Coater, UK) and placed into the JEOL JSM 6300 Scanning 
Electron Microscope (JEOL, JSM-6300F, Japan). 
4.2.9 Statistical Analysis 
Results were analyzed using two sample two-tail Student's {-test and one-way 
analysis of variance (ANOV A) followed by a post hoc least significant difference 
(LSD) test for multiple comparisons. All measurements were performed in triplicate 
unless otherwise stated. Data are presented in mean ± standard deviation. A p value of 
<0.05 indicated statistical significance. 
4.3 RESULTS 
4.3.1 Cytotoxicity Tests 
Extracts of 1.5% (w/v) chitosan combined with 5-15% (w/v) GP improve hMSCs 
proliferation compared to the control (Figure 4.2). They can therefore be regarded as 
not only biocompatible but also a stimulatory material for hMSCs proliferation. There 
are however no significant differences in terms of hMSCs percentage normalized to 
the control medium when exposed to extracts of 1.5% (w/v) chitosan in combination 
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with 5-150/0 (w/v) GP. Chitosan concentration of 1.5% (w/v) mixed with 15% (w/v) 
GP was chosen as the preferred composition for future studies since based on the 
results from previous chapter, higher GP concentrations demonstrate higher gelation 
rates. 
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Figure 4.2- hMSCs proliferation after 48 h of exposure to extraction medium from 
1.5% (w/v) chitosan mixed with 5-20% (w/v) GP, normalized to control medium. 
(percentage of cells compared to control). * Statistically higher compared to control 
(P<0.05). t Statistically lower compared to control (P<0 .05). 
4.3.2 Direct Contact Biocompatibility Tests 
hMSCs were exposed to various gel compositions for a period of 7 days. Initially at 
day 1, there are no significant differences between different groups (Figure 4.3). 
hMSCs continue to grow between days 1 and 3 in all the groups and the differences 
in cell number are significantly different. Nevertheless, after 3 days the number of 
cells in 1.5% (w/v) chitosan-15% (w/v) GP-0.72% (w/v) HEC group is significantly 
lower relative to all the other groups. After 7 days of exposure, the cells in the control 
group as well as the groups containing 1.5% (w/v) chitosan-15% (w/v) GP combined 
with 0 and 0.18% (w/v) HEC have grown significantly in number compared to day 3 
and there are no significant differences between any of these groups at day 7 which 
demonstrates that the mentioned concentrations of chitosan-GP-HEC are 
biocompatible relative to the control. Interestingly, cells exposed to higher 
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concentrations of HEC are not growing as well as the control and the groups 
containing 0 and 0.18% (w/v) HEC as observed by the significantly lower number of 
cells in these groups (Figure 4.3). Chitosan concentration of 1.5% (w/v) mixed with 
15% (w/v) GP and 0.18% (w/v) HEC was selected as the ideal composition for 
hMSCs survival, growth and osteogenic differentiation studies since it is 
biocompatible. 
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Figure 4.3- hMSCs in direct contact with different gel compositions. * Statistically 
significantly different (P<0.05). 
4.3.3 pH Measurements 
The pH of all the chitosan-GP solutions and the extraction media are around the 
physiological levels (Figure 4.4). For the chitosan concentration of 1.5% (w/v) used 
in this study, the pH values increase with increasing quantities of GP. Statistically, 
there are no significant differences between the pH values of the chitosan-GP 
solutions and that of the extraction media for all four groups (P<0.05). Also, the pH 
values of 1.5% (w/v) chitosan-15% (w/v) GP combined with HEC concentrations of 
0% (w/v) , 0.18% (w/v), 0.36% (w/v) and 0.72% (w/v) are around the physiological 
range (Figure 4.5). 
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4.3.4 hMSCs Survival, Growth and Osteogenic Differentiation 
within Chitosan-GP-HEC 
4.3.4.1 hMSCs Survival Study 
Viable and dead cells are presented as green and red respectively when the cells are 
stained with Calcein AM and Ethidium homodimer-2. During the first 7 days of 
culture, the number of viable cells increases in both tissue culture plastic control as 
well as the BCP microparticles groups (Figure 4.6). There are no dead cells in any of 
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these groups in the first 7 days. After 7 days of culture, the BCP microparticles are 
almost covered with cells and a confluent layer of cells is also observed in tissue 
culture plastic control (Figure 4.6). Following 7 days of incubation, 1.5% (w/v) 
chitosan-150/0 (w/v) GP-0.180/0 HEC is added to hMSCs attached to BCP 
microparticles. hMSCs attached to BCP microparticles exposed to 1.5% chitosan-
150/0 GP-O.180/0 HEC proliferate and remain viable after 7 days (Figure 4.7). There is 
only limited nwnber of dead cells observed when the cells are surrounded by 
chitosan-GP-HEC. Similarly, cells attached to BCP microparticles without chitosan-
GP-HEC continue to grow and expand with only a few dead cells as shown in Figure 
4.7. 
Figure 4.6- hMSCs on tissue culture plastic at a) day 1, d) day 3, g~ day 7;. hMSCs 
attached to BCP microparticles at b) day 1, e) da~ 3, h) day 7; BCP m1cropart1cle only 
(i.e. non-fluorescent image) at c) day 1, f) day 3, 1) day 7. 
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Figure 4.7- hMSCs on tissue culture plastic at a) day 8, s) day 14; dead hMSCs on 
tissue culture plastic at t) day 14; hMSCs attached to BCP microparticles at b) day 8, 
g) day 10, m) day 14; dead hMSCs attached to BCP microparticles at h) day 10, n) 
day 14; BCP microparticles only for the hMSCs combined with BCP groups (i.e. non-
fluorescent image) at c) day 8, i) day 10, 0) day 14; hMSCs attached to BCP 
microparticles and surrounded by chitosan-GP-HEC at d) day 8, j) day 10, p) day 14; 
dead hMSCs attached to BCP microparticles and surrounded by chitosan-GP-HEC at 
e) day 8, k) day 10, q) day 14; BCP microparticles only for the hMSCs combined 
with BCP and chitosan-GP-HEC groups (i.e. non-fluorescent image) at f) day 8, 1) 
day 10, r) day 14. 
4.3.4.2 hMSCs Growth Study 
The number of cells exposed to different conditions was quantified (Figure 4.8). The 
cells grow in tissue culture plastic and BCP microparticles groups mixed with or 
without chitosan-GP-HEC. After day 7, the cells in all groups were proliferating at 
slower rate since they were reaching confluency. There are significant differences 
between cells attached to tissue culture plastic and BCP microparticles at days 7 and 
8. At days 8, 10, and 14, there was no significant differences between the number of 
hMSCs attached to BCP in the presence or absence of chitosan-GP-HEC (Figure 4.8). 
At days 10 and 14, the cells continue to proliferate but there are no significant 
differences between any of the groups indicating that hMSCs in contact with 
chitosan-GP-HEC are viable and proliferating at rates similar to both control groups. 
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Figure 4.8- hMSCs proliferation in different groups. * Statistically significantly 
different (P<0.05). 
4.3.4.3 hMSCs Osteogenic Differentiation Study 
With respect to the osteogenic differentiation of hMSCs attached to tissue culture 
plastic and BCP microparticles, addition of the osteogenic medium results in 
significantly higher ALP activity compared to the basic medium for all different time 
points as shown in Figure 4.9 (P<0.05). Similarly, hMSCs attached to BCP 
microparticles surrounded by chitosan-GP-HEC when exposed to osteogenic medium 
produce significantly higher ALP activity relative to the basic medium at all time 
points (Figure 4.9). More importantly, the presence of chitosan-GP-HEC does not 
negatively influence osteogenic differentiation of hMSCs as the ALP activities are 
similar to when the cells are attached to tissue culture plastic and BCP microparticles. 
There are no significant differences between the ALP activities of the cells in any of 
the three different groups at each individual time point after the first 7 days of culture 
(i.e. days 8, 10, and 14) whether the cells are in contact with basic or osteogenic 
medium. When the cells are in contact with the osteogenic medium, the ALP activity 
reaches its peak between days 8 and 10 followed by a reduction at day 14. 
Furthermore, addition of chitosan-GP-HEC does not change this pattern of ALP 
activity over time. 
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ALP activity per protein content per hour. * Statistically significantly different 
(P<0.05). 
4.3.5 Gelation Time and Storage Modulus ofChitosan-GP-HEC 
Chitosan concentration of 1.5% (w/v) combined with 15% (w/v) OP and 0-0.72% 
(w/v) HEC all gel at 37°C however at different time points (Figure 4.10). The gelation 
time decreases significantly with increasing concentrations of HEC. Nevertheless, 
there is not much difference in the gelation rate when the HEC concentration is 
increased above 0.36% (w/v). Furthermore, in the presence of BCP microparticles, 
the gelation is even more enhanced however, for HEC concentration of 0.36% (w/v) 
and 0.72% (w/v) the gelation time is the same in the absence or presence of BCP 
microparticles. For chitosan-OP without HEC, there is no significant different in the 
gelation rate in the absence or presence of BCP. 
Additionally, the storage modulus of different gel compositions at complete gelation 
was measured (Figure 4.11). Once more, the storage modulus increases with 
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increasing HEC concentrations. The storage modulus increases significantly when 
BCP microparticles are mixed with the chitosan-GP-HEC hydrogels indicating that 
the hydrogel is becoming stiffer. 
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4.3.6 Chitosan-GP-HEC Degradation 
The degradation rate of chitosan-GP-HEC is faster with lower HEC concentrations 
whether exposed to PBS or PBS mixed with lysozyme (Figures 4.12 and 4.13). 
Generally, the degradation rate is higher when the gels are in contact with lysozyme 
compared to PBS (Figures 4.12, 4.13 and 4.14). The dry and wet weight 
measurements show similar degradation profiles for different gel compositions. The 
percentage dry and wet weight remaining for all different gel compositions decreases 
throughout the 42 day period of this experiment (Figures 4.12 and 4.13). This is 
further evidenced by scanning electron microscopy images showing the external 
morphology of the gels over the 42 days (Figure 4.14). When the gels are degrading, 
the structure becomes more porous. Chitosan-GP mixed with 0-0.72% (w/v) HEC 
exposed to lysozyme demonstrate significantly faster degradation rates initially in the 
first 7 days followed by a steady reduction of percentage dry and wet weight 
remaining throughout the experiment. Nevertheless, with regard to the gels in PBS 
solution, there is almost similar rate of weight loss all through the experiment 
although the weight loss becomes insignificant towards the end. As shown in Figures 
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4.14 i and L after 42 days of contact with lysozyme, the hydrogels are degraded 
however. chitosan-GP has a faster degradation rate compared to chitosan-GP-HEC as 
evidenced by higher removal of the gel structure. When chitosan-GP is exposed to 
PBS after 42 days, the degradation is faster compared to chitosan-GP-HEC since the 
gel is having a slightly more open and porous morphology in comparison with 
chitosan-GP-HEC (Figures 4.14 c and f). 
I t should be noted that dry weight measurements presented in this chapter were 
obtained after freeze drying under vacuum however since before measuring the 
weight at each time point, the lid in which the gels were kept was opened, the 
moisture from the air could have had an effect on the dry weight measurements. 
Nevertheless, such change in weight is not expected to make a significant effect on 
dry weight measurements. Also, wet weight measurements were obtained by blotting 
the samples and measuring the weight however, the weight of the water is measured 
in fact as well which could introduce a variable in the measurements. Nonetheless, 
the samples were treated consistently throughout the experiment which should reduce 
such an effect. Moreover, wet weight measurements were sensitive enough to show 
reduction as a result of chitosan degradation (Figure 4.12) despite the possible 
inconsistency from the water component. 
Such dry/wet weight measurements performed in this chapter is a basic approach to 
degradation which is commonly used however, it gives just an indication on the 
degradation behaviour of chitosan-GP-HEC in vivo. In fact, in vivo degradation will 
be significantly different to the in vitro degradation observed in this chapter and it 
will most likely be faster. 
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Figure 4.14- Scanning electron microscopy images of different gel compositions 
subject to degradation. Chitosan 1.5% (w/v) - OP 15% (w/v) in contact with PBS at a) 
day 1 , b) day 21 , c) day 42; chitosan 1.5% (w/v) - OP 15% (w/v) - HEC 0.18% (w/v) 
in contact with PBS at d) day 1, e) day 21, t) day 42; chitosan 1.5% (w/v) - OP 15% 
(w/v) in contact with PBS + lysozyme at g) day 1, h) day 21, i) day 42; chitosan 1.5% 
(w/v) - OP 15% (w/v) - HEC 0.18% (w/v) in contact with PBS + lysozyme at j) day 
1, k) day 21, 1) day 42. 
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4.4 DISCUSSION 
In this study. the effect of different chitosan-GP ± HEC compositions on hMSCs 
proliferation was evaluated. Moreover, survival, growth and osteogenic 
differentiation of hMSCs in contact with chitosan-GP-HEC hydrogel was assessed in 
order to determine if chitosan-GP-HEC allows cell survival, growth and osteogenic 
differentiation. In addition, pH, gelation and degradation behaviour of chitosan-GP-
HEC binders was examined to verify if such binders gel fast at body temperature and 
degrade to create free space for bone formation. 
The results of this study demonstrated that extracts of 1.5% (w/v) chitosan containing 
5-15% (w/v) GP have physiological pH levels and enhance hMSCs proliferation 
relative to the control. They are therefore not only biocompatible but also stimulate 
hMSCs proliferation. Stimulation of cell proliferation was also observed in previous 
chapter using gMSCs which was followed by discussion of potential reasons behind 
this observation. In previous chapter, 0.5-2% (w/v) chitosan mixed with 15-20% 
(w/v) GP led to reduced gMSCs proliferation and cell death. In this study, the same 
cytotoxic response was observed although only extracts from GP concentration of 
20% (w/v) were associated with cell death and the rest resulted in improved cell 
growth. It should be noted that chitosan with a 94% DDA was used in this study 
compared to 80% in previous study. This was due to the fact that chitosan with higher 
DDA has proved to be more biocompatible (Molinaro et aI., 2002). Chitosan of 
higher DDA need more concentrated hydrochloric acid to solubilise because of the 
more amine groups present in the chitosan chains that need to be protonated in acidic 
solutions (Chenite et aI., 2002). This leads to chitosan requiring more GP to interact 
with the amine groups in case of 94% DDA as compared to 80% DDA since the 
electrostatic interactions between the GP and the chitosan is one of the forces 
responsible for gel formation (Chenite et al., 2000). As discussed in previous chapter, 
when more GP is reacting with the chitosan, there would be less leaching to the 
outside extraction medium therefore leading to higher cell growth when tested for 
cytotoxicity. As a result, when a similar GP concentration is added to both 80% and 
94% DDA chitosan, there is less GP leaching to the medium in contact with the cells 
in case of 94% DDA chitosan compared to 80% DDA. Therefore, 15% (w/v) GP 
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mixed with 94% DDA chitosan is not toxic while the same GP concentration 
combined with 80% DDA chitosan was shown to be toxic in previous chapter. For all 
the remaining experiments in the present study, chitosan-GP concentration of 1.5% 
and 15% (w/v) respectively was chosen as the preferred composition. This was based 
on the results from previous chapter indicating that higher GP concentration leads to 
higher gelation rate which is preferable as long as it does not compromise cell 
survival. 
Despite the fact that chitosan-GP is promISIng as a binder for injectable tissue 
engineered bone applications, it is difficult to obtain homogenous distribution of BCP 
microparticles in chitosan-GP hydrogels due to mass differences. To overcome this, 
an agent was introduced into the chitosan-GP gel structure to increase gel strength so 
that the BCP microparticles can be approximately uniformly distributed inside the 
gel. HEC is a non-ionic macromolecule that can be added to chitosan-GP in order to 
increase gel strength (Hoemann et aI., 2002; Hoemann et aI., 2005; Li and Xu, 2002; 
RougWey et aI., 2006). 
With regard to addition of HEC, chitosan 1.5% (w/v)-15% (w/v) GP containing 0 and 
0.18% (w/v) HEC has physiological pH levels and is biocompatible based on hMSCs 
proliferation when in direct contact with the materials for 7 days. The rate of cell 
growth is similar to the control group. Chitosan-GP mixed with HEC concentrations 
higher than 0.18% (w/v) are not biocompatible and cause significant cell death when 
exposed to hMSCs. As suggested by Hoemann et al. (2007), HEC contains glyoxal. 
Glyoxal is a toxic by-product of advanced glycation endproducts (AGE) (Shangari et 
aI., 2003) which has caused apoptosis following extended contact with lung epithelial 
cells at 0.1 mM concentration (Kasper et aI., 2000). In a study, Hoemann et al. (2007) 
encapsulated HEK293 cells in chitosan-GP hydrogels containing different 
concentrations of glyoxal (Hoemann et al., 2007). Glyoxal concentration of 0.6 mM 
demonstrated the highest toxicity response whereas 0.15 mM concentration was 
associated with the highest cell viability. This observation is in agreement with the 
direct contact biocompatibility results obtained in this chapter since higher HEC 
concentrations therefore having higher glyoxal levels give rise to higher cytotoxicity 
response and thus cell death. This is the reason for the dose-dependent reduction in 
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hMSCs number observed in this study when exposed to HEC concentrations of 0.36 
and 0.72% (w/v). Chitosan concentration of 1.5% (w/v) in combination with 15% 
(w/v) GP and 0.180/0 (w/v) HEC was selected as the optimal binder composition for 
hMSCs survival, growth and osteogenic differentiation studies performed in this 
chapter since it is biocompatible. 
With respect to survival and growth study, hMSCs encapsulated within 1.5% (w/v) 
chitosan-150/0 (w/v) GP-0.180/0 HEC remain viable and proliferate at levels similar to 
the controls with minimum number of dead cells present based on quantification of 
the number of cells as well as live/dead staining using Calcein AM and Ethidium 
homodimer-2. This observation further confirms the results obtained from the direct 
contact biocompatibility tests with regard to suitability of 1.5% (w/v) chitosan-15% 
(w/v) GP-0.180/0 HEC to carry cells for the purpose of injectable bone tissue 
engineering. Scanning electron microscopy images obtained in this study prove the 
existence of a porous structure that permits penetration of biological nutrients through 
the hydrogel network, therefore justifying the viability and growth of the cells. 
In order to examine osteogenic differentiation of hMSCs in the present study, the 
ALP activity was measured. ALP is the most commonly known osteogenic marker 
(Cheng et aI., 1994; Jaiswal et aI., 1997; Martin et al., 1997; Weinreb et al., 1990). 
Pre-osteoblasts in bone as well as osteogenic cells in culture are associated with high 
ALP activity levels (Weinreb et al., 1990). The osteogenic medium that was used in 
the current study contained 10-8 M dexamethasone and 10 mM B-glycerophosphate 
since based on previous studies, osteogenic differentiation in vitro has been enhanced 
with these two components present (Maniatopoulos et al., 1988). As demonstrated in 
the present study, osteogenic medium gives rise to significantly higher ALP actively 
relative to the basic medium for all different groups at all time points. It should be 
noted that the existence of chitosan-GP-HEC does not negatively affect hMSCs 
osteogenic differentiation, since the ALP activities are similar to when hMSCs are in 
contact with tissue culture plastic and BCP microparticles. For hMSCs exposed to 
osteogenic medium in the presence/absence of chitosan-GP-HEC, the ALP activity 
reaches its peak between days 8 and 10 followed by a decrease at day 14. Mendes et 
al. (2004) also observed the same pattern of ALP activity over time since the relative 
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atnount of cells positive for ALP increased followed by a peak and then a decrease 
(Mendes et aI., 2004). 
hMSCs unlike gMSCs were used in this study owning to their clinical relevance. 
Also, in terms of osteogenic differentiation, hMSCs will produce higher ALP activity 
in comparison with control when in contact with osteogenic medium (Mendes et al., 
2004) therefore making it easy to examine osteogenic tendency. However, we 
previously observed that gMSCs do not respond to osteogenic differentiation medium 
by enhancing ALP activity (unpublished). Furthermore, after 1 and 2 weeks of culture 
in osteogenic differentiation medium only 10% and 12% of gMSCs were stained 
positive for ALP respectively (Vermonden et al., 2008) indicating that the marker 
ALP is not a reliable marker to assess osteogenic differentiation of gMSCs. 
Therefore, using ALP activity measurement to evaluate osteogenic differentiation, 
hMSCs are a more suitable cell type to study osteogenic potential. 
Regarding the gelation of chitosan-GP-HEC hydrogels, it was demonstrated in the 
present study that chitosan concentration of 1.5% (w/v) in combination with 15% 
(w/v) GP and 0-0.72% (w/v) HEC all gel at 37°C providing the necessary fixation. 
This gelation temperature is ideal for injection into the body. Moreover, the gelation 
time decreases with increasing concentrations of HEC. This is in accordance with the 
studies carried out by Hoemann et al. (2007) and Li and Xu (2002). The interaction of 
negatively charged GP with highly protonated cationic chitosan through electrostatic 
attractions is one of the forces responsible for the gelation (Chenite et al., 2000). As 
suggested by Li and Xu (2002), this system is composed of molecular aggregates of 
neutral origin presented as colloidal precipitates leading to weak structure and low 
storage modulus. The neutral molecule HEC is able to bond with chitosan through 
hydrogen bonding therefore resulting in bridge formation between chitosan molecules 
(Li and Xu, 2002). Higher HEC content causes stronger hydrogels mainly due to 
higher number of hydrogen bonding in the hydrogel structure (Li and Xu, 2002). 
Faster gelation rates resulting from higher HEC content within the gels could also be 
attributed to enhanced hydrogen bonding inside the gel. 
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The presence of BCP microparticles in chitosan-GP-HEC solutions results in more 
improved gelation. In a study by Couto et al. (2009), rheological properties of 
chitosan 20/0 (w/v)-GP 16 % (w/v) hydrogels combined with 0-50% (w/w) bioactive 
glass nanoparticles of 40-100 nm diameter showed that the gelation temperature 
decreased with increasing concentrations of bioactive glass (Couto et aI., 2009). This 
in fact shows improved gelation with increasing concentrations of bioactive glass 
component. which is in agreement with the results obtained in the present study in 
which BCP microparticles improved the gelation of chitosan-GP-HEC hydrogels. As 
was suggested by Couto et al. (2009), release of ions into the hydrogel solution by 
bioactive glass nanoparticles could be the potential reason behind the improved 
gelation observed since these ions affect the hydrophilic interactions between 
chitosan chains. Similarly, in the current study, release of calcium phosphate ions into 
the chitosan-GPHEC solution could be the possible reason for the enhanced gelation 
observed in the presence of BCP microparticles. For injectable bone tissue 
engineering applications, the gelation time of a few minutes should be sufficient to 
allow hardening inside the body as mentioned previously. Chitosan 1.5% (w/v)-GP 
15% (w/v) in combination with 0.18% (w/v) HEC fits into this range therefore 
proving to be the best possible binder composition. 
With regard to degradation properties, chitosan-GP-HEC was demonstrated to be 
degradable in this study. An injectable binder needs to be degradable in order to 
create space for new bone formation when injected in to the body. Faster degradation 
is observed when the hydrogels are exposed to PBS with lysozyme in comparison 
with PBS alone. The reason why lysozyme was used in this study was that various 
studies demonstrated chitosan degradability in contact with lysozyme (Huang et al., 
2005-a; Moshfeghian et aI., 2006). More importantly, lysozyme is present in human 
plasma at around 4-13 mg/L (Henry, 1991). Therefore, in order to simulate 
physiological conditions, lysozyme (10 mg/L) was used in degradation studies. 
Furthermore, lysozyme is well-known to digest chitosan based on the amount and 
distribution of N-acetyl groups (Aiba, 1992). According to Aiba (1992), lysozyme 
identified N-acetyl-D-glucosamine sequences however, it could not operate on D-
glucosamine sequences and small portions of N-acetyl-D-glucosamine residues 
distributed at random. Lysozyme through enzymatic hydrolysis cleaves the glycosidic 
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bonds in chitosan leading to degradation products such as chitoligomers, N-acetyl-D-
glucosamine residues, and lower molecular weight chitosans (Ren et aI., 2005). It 
should also be mentioned that higher DDA chitosan has lower rate of degradation 
(Aiba, 1992: Ren et aI., 2005). 
Concerning HEC concentration and degradation properties, it was shown in the 
present study that lower HEC content leads to faster degradation when in contact with 
PBS, with or without lysozyme. Further confirmation is seen in scanning electron 
microscopy images in which chitosan-GP is degrading at a faster rate compared to 
chitosan-GP- 0.18% (w/v) HEC following 42 days of exposure with lysozyme. This 
could be attributed to the lower number of hydrogen bonds bridging chitosan 
molecules (Li and Xu, 2002) and therefore resulting in relatively weaker network 
more prone to degradation. Also, the existence of another polymer (HEC) could cause 
reduced chitosan degradation mainly due to limitation of lysozymal transport (Huang 
et aI., 200S-a). Therefore, higher concentrations of the second polymer (HEC) lead to 
lower degradation rates as observed in this study. 
Regarding the scanning electron microscopy images, it was demonstrated that such 
images validate the loss of weight both dry and wet during the course of the 
experiment. The structure gets more porous as the gels degrade. Chitosan-GP 
combined with 0-0.72% (w/v) HEC in contact with lysozyme exhibit significantly 
faster degradation rates in the first 7 days which is then followed by a steady decrease 
of percentage dry and wet weight remaining. Towards the end of the experiment, the 
degradation becomes almost negligible. This could be related to absence of acetyl 
groups needed for binding to lysozyme (Varum et aI., 1996). On the other hand, there 
is approximately similar rate of weight loss throughout the experiment when 
hydrogels are in PBS solution although the weight loss becomes insignificant near the 
end. In an study performed by Ruel-Gariepy et al. (2000), chitosan-GP exposed to 
PBS had a rapid weight loss in the first 4 hours of the experiment primarily because 
of excess GP leaching out but there was no significant weight loss afterwards during 
the 24 hour time course of the experiment (Ruel-Gariepy et aI., 2000). Furthermore, 
scanning electron microscopy images after 24 hours did not show a considerable 
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change in the structure in that study. The weight loss of chitosan-GP-HEC exposed to 
PBS seen in this study could also be related to the GP leaching out of the network. 
All the degradation characteristics of chitosan-GP-HEC strongly suggest that 
chitosan-GP-HEC is biodegradable over time without having rapid degradation 
therefore satisfying the degradability requirement of the injectable binder for bone 
tissue engineering. 
4.5 CONCLUSION 
Chitosan-GP-HEC is a promising binder material as it supports hMSCs viability, 
proliferation and osteogenic differentiation. Moreover, chitosan-GP-HEC hydrogels 
possess physiological pH levels. Chitosan-GP-HEC hydrogels are biodegradable and 
demonstrate fast gelation properties at body temperature. All the results obtained in 
this chapter indicate that chitosan-GP-HEC hydrogel is a promising binder for 
injectable tissue engineered bone application. Future studies will concentrate on the 
bone formation abilities of cells in contact with chitosan-GP-HEC hydrogels in vivo 
in order to evaluate whether chitosan-GP-HEC binder will interfere with bone 
formation in vivo. This is examined in the next chapter. 
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CHAPTER V 
IN VIVO BONE FORMATION BY 
MESENCHYMAL STEM CELLS 
ENCAPSULATED WITH CHITOSAN-BASED 
HYDROGELS 
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5.1 INTRODUCTION 
Successful in vivo bone formation involving cells, ceramIC scaffolds and binder 
depends on several factors. Binder biocompatibility, biodegradability and gelation, as 
well as survival and osteogenic differentiation of cells encapsulated within the binder 
are all important factors to allow in vivo bone formation. As mentioned in previous 
chapters, the in vitro results were particularly promising in terms of biocompatibility, 
biodegradability and gelation of chitosan-glycerol phosphate (GP)-hydroxyethyl 
cellulose (HEC) binder. Furthermore, cell survival and osteogenic differentiation 
within the binder were all adequately achieved. Nevertheless, it is necessary to 
evaluate the in vivo bone formation ability of cell (tissue )-ceramic scaffold system 
combined with chitosan-GP-HEC binder in order to understand the in vivo 
effectiveness of such a system. Therefore, in this study, following from previous 
studies (chapter 4), cells seeded on calcium phosphate ceramics and cultured for 7 
days. will be mixed with chitosan-GP-HEC hydrogel followed by in vivo 
implantation. 
The initial in vivo experiment is usually concerned with ectopic implantation within a 
small animal such as mice. This is because ectopic implantation in a place such as 
underneath the skin (subcutaneous) for bone formation removes any factor affecting 
the formation of bone and any bone formation observed is purely derived from the 
implanted cells attached to scaffolds. The choice of cells for in vivo studies is another 
crucial issue to take into account. Bone marrow derived mesenchymal stem cells from 
several species have produced bone after in vitro expansion when transplanted into 
nude mice (Ashton et al., 1984; Friedenstein et aI., 1974; Gundle et aI., 1995; 
Krebsbach et aI., 1997; Ohgushi and Okumura, 1990). However, donor variations 
associated with hMSCs would limit their applications in in vivo experiments 
(D'Ippolito et aI., 1999; Evans et aI., 1990; Mendes et aI., 2002-b). This is because in 
case of lack of bone formation, it would be difficult to know whether it was due to the 
specific donor or the failure of tissue engineering technique. Interestingly, goat bone 
marrow derived mesenchymal stem cells (gMSCs) have been frequently used for in 
vivo evaluation of bone formation (Fischer et aI., 2003; Kruyt et aI., 2003; Kruyt et 
aI., 2006). This is due to the fact that they are relatively easy to expand. In addition, 
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since the future studies in large animals following the current study are likely to take 
place in goats using gMSCs, therefore gMSCs are the ideal choice for the present 
study. 
5.1.1 Aims and Objectives 
In previous chapters, biocompatibility, gelation, and biodegradability of chitosan-GP-
HEC were established. Cell survival, growth and osteogenic differentiation in 
combination \vith chitosan-GP-HEC binder showed encouraging results. Therefore, as 
the next step, the aim of the present study was to evaluate the in vivo bone formation 
ability of gMSCs attached to BCP ceramic microparticies in combination with 
chitosan-GP-HEC binder in order to examine whether chitosan-GP-HEC binder will 
interfere with bone formation in vivo. 
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5.2 MATERIALS AND METHODS 
All chemicals were ordered from Sigma-Aldrich, UK unless otherwise indicated. 
5.2.1 Experimental Design 
The control and experimental groups are shown in Table 5.1. Goat bone marrow 
derived mesenchymal stem cells (gMSCs) (from iliac crest of adult Dutch milk goats, 
2-4 years old) were seeded on 212-300 !lm biphasic calcium phosphate (BCP) 
microparticles that were sintered at 1150°C and were composed of 80% HA and 20% 
~-TCP with a porosity of 70.8 % (Xpand Biotechnology BV, The Netherlands). 
Following this, gMSCs-BCP combination were implanted after one week with or 
without chitosan-GP-HEC binder to serve as experimental and control groups 
respectively. BCP microparticles mixed with/without chitosan-GP-HEC were also 
implanted as control groups. All four conditions within the study group were 
implanted subcutaneously in 13 nude mice based on power analysis (n=13). All the 
samples were explanted 6 weeks following implantation. The samples were analysed 
by histology and histomorphometry. 
5.2.2 Preparation of Chitosan-GP-HEC Solutions 
Chitosan powder (Kitomer, Marinard Biotech, Quebec, Canada) with a 94% degree of 
deacetylation (DDA) and a molecular weight (Mw) of 679 kDa was sterilized by 
autoclaving at 126°C for 20 minutes. Sterile chitosan powder (0.225g) was dissolved 
in 9 ml of 0.18 M hydrochloric acid. Subsequently, 1.5 g of glycerol phosphate (GP) 
was dissolved in deionized water to bring the total volume to 15 ml. A 0.2 !lm filter 
(Triple Red Laboratory, UK) was used to sterilize the GP-deionized water mixtures. 
Chitosan-hydrochloric acid and GP-deionized water solutions were placed in an ice 
bath to chill for 15 minutes to avoid gelation when combined together. The ice cold 
GP-deionized water was then added drop by drop to the ice cold chitosan solution 
with constant stirring in order to create a clear chitosan-GP solution. 
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Hydroxyethyl cellulose (HEC) was prepared (Gibco Invitrogen, UK) at the 
concentration of 0.0125 glml in a-MEM (Roughley et ai., 2006). In order to prepare 
chitosan-GP-HEC solutions, the HEC solutions were sterilized using a 0.2 /lm filter 
and then added to the chitosan-GP solution at the ratio of 0.8 ml to 4.8 ml 
respectively. The final concentration of chitosan and GP in the solutions was 1.5% 
(\'Jv) and 100/0 (w/v) respectively while the concentration of HEC was 0.18% (w/v). 
5.2.3 Cell Culture and Seeding Conditions 
Passage 2 gMSCs (1 x 105 cells) with a seeding density of about 15,000 cells/cm2 
(Fischer et al.. 2003; Kruyt et aI., 2006) were added to 100 mg of212-300 /lm BCP 
microparticles. The medium used was osteogenic differentiation culture medium 
\vhich was composed of a-MEM (Gibco Invitrogen, The Netherlands) supplemented 
with 15% (v/v) fetal bovine serum (Cambrex, The Netherlands), 0.2 mM L-ascorbic 
acid 2-phosphate (AsAP), 10-8 M dexamethasone, 10 mM ~-glycerophosphate, 2 mM 
L-glutamine (Lonza, The Netherlands), 100 U/ml Penicillin and 100 /lg/ml 
Streptomycin (Invitrogen, The Netherlands). The medium was refreshed every two 
days. gMSCs attached to BCP microparticles were cultured for 7 days in non-tissue 
culture (cells do not attach) 25 square well-plates (Greiner Bio-one, Germany) at 
37°C/5% CO2 incubator after which 1.5% (w/v) chitosan-10% (w/v) GP-0.18% HEC 
was added such that the final BCP/gel ratio was 20% (w/v). This ratio was 
detennined according to previously performed experiments in this thesis and is the 
optimal BCP/gel ratio as it involves the maximum amount of BCP microparticles 
while the binder is still injectable. 
gMSCs attached to BCP microparticles and surrounded by chitosan-GP-HEC was 
referred to as the experimental group. The control groups consisted of gMSCs 
attached to BCP microparticles without chitosan-GP-HEC, BCP mixed with chitosan-
GP-HEC, and BCP alone. A summary of different groups (control and experimental) 
is shown in Table 5.1. All the groups were implanted subcutaneously in nude mice 
and a number of samples from BCP microparticles with attached gMSCs were used 
for construct characterization in vitro. 
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T~ble 5.1- Different groups (experimental and control) implanted subcutaneously in 
mlce. 
Type of sample Sample description 
Experimental gMSCs + BCP + chitosan-GP-HEC 
Control gMSCs + BCP 
Control BCP + chitosan-GP-HEC 
Control BCP 
5.2.4 Construct Characterization In Vitro 
The number of gMSCs on BCP microparticles after 1 week of culture was evaluated 
by the colourimetric indicator Alamar Blue (SeroTec, Oxford, UK) before 
subcutaneous implantation (n=6). Constructs composed of gMSCs attached to BCP 
microparticles were washed three times with pre-warmed PBS solution. 
Consequently, 1 ml of a 5% Alamar Blue solution in culture medium (Lawson et aI., 
2004) was added to each well-plate. The plates were then incubated for 3 hours in a 
humidified atmosphere at 37°C/5% C02. Fluorescence of 100 1-11 aliquots of the 
extracted dye from each sample was determined using a Fluorimeter (Zenyth 3100 
Multimode Detector, Anthos Labtec Instruments GmbH, Austria) at excitation and 
emission wavelengths of 544 nm and 590 nm respectively. A standard calibration 
curve according to known numbers of gMSCs reacting with the Alamar Blue solution 
was used in order to quantify the number of cells present in each sample (Lawson et 
al., 2004; Li et al., 2005). 
Scanning electron microscopy images were obtained for gMSCs seeded on BCP 
microparticles after 1 week of culture (n=6). Samples of BCP microparticles with 
attached gMSCs were fixated in 10% (v/v) formalin solution for 15 minutes. 
Following fixation, the samples were exposed to increasing concentrations of ethanol 
(70%, 80%, 90%, 100%) (BDH laboratory supplies, UK). The ethanol solutions 
consisted of x% ethanol and (100-x) % distilled water. Ultimately, the drying agent, 
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hexamethyl-disilazane was added to the samples. The samples were then coated with 
a layer of gold (Agar Auto Sputter Coater, UK) and placed into the FEI INSPECT F 
Scanning Electron Microscope (The Netherlands). 
Moreover. methylene blue staining on cell-microparticle constructs was performed 
following 1 week of culture in order to analyse the attachment and distribution of 
gMSCs on BCP microparticles (n=6). The BCP microparticles with attached gMSCs 
were washed in pre-warmed PBS solution. The samples were then fixated using 10% 
(v/v) formalin solution for 15 minutes. Methylene blue (1 % w/v) solution was then 
added to the samples and left for 1-2 minutes after which the samples were rinsed 
\\ ith distilled water and viewed under Leica stereomicroscope (Leica MZ6, UK). 
5.2.5 Subcutaneous Implantation 
Based on power analysis, a total of thirteen 6 to 8 week-old nude mice (hsd-cpb 
NMRI-nu, male, Harlan, The Netherlands) were used after obtaining approval by the 
local animal care committee (n=13). The mice were anaesthetized by inhalation of 
isoflurane, oxygen and carbon dioxide through a small cap over the nose. Before 
creation of subcutaneous pockets on either side of the spine, the skin was disinfected 
with 70% ethanol. 
A small cut was made on the back of the mice using scissors. A pair of scissors with a 
blunt tip was used to create pockets underneath the skin (Figure 5.2 a). A total of 4 
pockets per mouse were created as shown in Figure 5.1. Each animal received each 
condition presented in Table 5.1 (Figure 5.2 b). Sample implantation was based on 
randomized scheme. After implantation, the pockets were closed for 6 weeks until 
explantation (Figure 5.2 c and d). 
129 
Figure 5.1- Schematic picture of a mouse. Numbers correspond to implant positions. 
Figure 5.2- Implantation images. a) Creation of subcutaneous pockets, b) 
Subcutaneous implantation, c) Animal after implantation of all 4 groups, d) Animal 
back in the cage for 6 weeks until explantation. 
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5.2.6 Explantation, Histology, and Histomorphometry 
Six weeks following implantation, the mice were sacrificed by CO2 inhalation. The 
skin was opened using scissors and samples were removed and cleared from adhering 
tissues. The samples were fixated in 1.5% (v/v) glutaraldehyde in 0.14 M cacodylate 
buffer for 2 days at 4° C. Samples were dehydrated through increasing concentrations 
of ethanol (70% 80%, 90%, 96%, 100%) and embedded in polymethylmethacrylate 
(MMA K-Plast LTI, The Netherlands). 
Bone formation was assessed through histology and histomorphometry. Using 
histological diamond saw (Leica SP1600, Leica Microsystems, Germany), three semi-
thin sections of 10 J-lm were obtained from each sample specimen. Methylene blue 
(1 % w/v) and 0.3% (w/v) basic fuchsin were used to stain the sections. Histological 
sections were examined by a light microscope (Leica DMI 4000B, Leica, UK) 
attached to Leica digital camera (Leica DFC300 FX, Leica, UK). Histomorphometry 
was performed to quantify the amount of bone formation using Adobe Photoshop 6.0 
software. The samples were blinded before the analysis. Bone formation was 
determined as the percentage of newly formed bone (B) inside the available space 
(Figure 5.3). The available space was calculated as the total implant area - the total 
BCP scaffold area (S) (Figure 5.3). 
[ll] BCP Scaffold (S) 
ffiillI Bone tissue (B) 
o Fibrous tissue 
Figure 5.3- Schematic picture of a histological section after staining. The scaffold 
area (S) and the bone area (B) are shown. The total implant area is comprised of the 
scaffold area (S), the bone area (B), and the fibrous tissue area. 
5.2.7 Statistical Analysis 
Results were analyzed using two sample two-tail Student's (-test and one-way 
analysis of variance (ANOVA) followed by a post hoc least significant difference 
(LSD) test for multiple comparisons. Data are presented in mean ± standard 
deviation. A p value of <0.05 indicated statistical significance. 
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5.3 RESULTS 
5.3.1 Construct Characterization In Vitro 
The number of cells on BCP microparticles after 7 days of culture is 2.3 ± 0.4 x 105 
cells per construct. Scanning electron microscopy images demonstrate that gMSCs 
are spread on the surface of BCP microparticles forming a layer of cells following 7 
days of culture (Figure 5.4a). Furthermore, extracellular matrix deposition on the 
surface of ceramic micro particles is apparent after 1 week of culture (Figure 5.4b). 
F · 5 4- Scanning electron microscopy images of 7 -days cultured BCP Igure . . I d b) 
. rtl·cles showing a) almost full cell coverage around the partlC e an mlcropa .. d . . . 
flattened cells together with extracellular matnx. Extracellular matnx eposlt1on IS 
shown. 
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Methylene blue staining of gMSCs attached to BCP microparticles after 1 week of 
culture demonstrates almost full coverage around the microparticles with some 
particle bridging which is a mask of cells attaching BCP microparticles together 
(Figure 5.5). Moreover, stereomicroscopy shows homogeneous cell attachment and 
distribution all over the BCP microparticles before implantation in mice (Figure 5.5). 
Figure 5.5- Stereomicroscopy of 7 -days cultured BCP microparticles stained with 
methylene blue. Cells are attached to BCP microparticles connecting one particle to 
another (i.e. particle bridging is shown). 
5.3.2 Histology and Histomorphometry 
All the implants were implanted without any surgical complications. In addition, all 
13 animals survived the 6-week in vivo implantation phase. All the samples were seen 
by macroscopic examination before explantation. Blood vessels were visible 
macroscopically around the samples when explanted after 6 weeks. 
Histology was performed on all the explanted samples. Ectopic bone formation was 
consistently observed throughout BCP microparticles in groups containing cells 
(gMSCs + BCP + chitosan-GP-HEC and gMSCs + BCP) (Figure 5.6 and 5.7). Bone 
was formed on the surface of ceramic microparticles. Both mineralized (dark red) and 
non-mineralized (light red/pink) bone was seen in both groups containing gMSCs. 
Bone marrow was also detected in all samples containing bone. Interestingly, bone 
133 
bridging between ceramic microparticles was detected on the interior and exterior of 
the samples (Figure 5.6 and 5.7). Furthermore, samples without cells (BCP mixed 
with/without chitosan-GP-HEC) did not show any sign of bone formation in all 
implanted animals instead they were filled with fibrous tissue (Figure 5.8 and 5.9). 
Figure 5.6- Bone formation between BCP micropar:icles in ~MSCs + BCP + 
chitosan-GP-HEC group after 6 week in vivo implantatIon. Bone IS coloured as dark 
red and osteoid is coloured as light red/pink. BCP microparticles, Bone, Bone 
marrow, and fibrous tissue are shown. 
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· gure 5.7- Bone formation between BCP microparticles in gMSCs + BCP group 
a 6 week in vivo implantation. Bone is coloured as dark red and osteoid is 
c loured as light red/pink. 
Figure 5.8- BCP + chitosan-GP-HEC group after 6 weeks, no bone formation was 
detected. 
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Figure 5.9- BCP group after 6 weeks, no bone formation was seen. 
gMSCs attached to BCP and combined with/without chitosan-GP-HEC show high 
levels of bone formation (24.6 ± 13.7% and 34.5 ± 10.8% respectively) in all 13 
samples and statistically there is no significant difference between these two groups 
(Figure 5.10). Moreover, gMSCs deficient groups fail to produce bone in any of the 
13 implanted mice (Figure 5.10). 
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Figure 5.10- Histomorphometry of bone in terms of percentage of bone area inside 
the available space within samples implanted in vivo for 6 weeks (n=13). The 
incidence of bone fonnation in each group is shown on the graph. 
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5.4 DISCUSSION 
The results of this study showed that gMSCs seeded onto BCP scaffolds prior to 
implantation, forms significant amount of bone in vivo. In addition, the presence of 
chitosan-GP-HEC in gMSCs-BCP constructs does not interfere with the bone 
formation process. Although the overall quantity of bone formed after 6 weeks is 
lower in the chitosan-GP-HEC group compared to the control group (gMSCs attached 
to BCP microparticles), this difference is not statistically significant. It should be 
noted that chitosan-GP-HEC was fully degraded after 6 weeks of in vivo implantation 
creating available space for bone formation. 
In this study, gMSCs were seeded onto BCP scaffolds and cultured for a week in 
medium containing 10-8 M dexamethasone and 10 mM ~-glycerophosphate in order 
to promote osteogenic differentiation (Maniatopoulos et aI., 1988). This was then 
followed by in vivo implantation. Previous work has shown the advantage of cell 
culture on the constructs before in vivo implantation since the in vitro culturing period 
allows extracellular matrix formation and differentiation of cells (Mankani et al., 
2001; Ohgushi and Caplan, 1999; Yoshikawa et al., 2000). Nevertheless, Kruyt et al. 
(2004-a) demonstrated that cells seeded onto BCP scaffolds containing 80% 
hydroxyapatite and 20% trica1cium phosphate (cubes of 7x7x7 mm) just before 
implantation produce just as much bone as the pre-culture group (cells cultured for a 
week before implantation) in intramuscular implantation in goats (Kruyt et al., 2004-
a). They attributed this to the osteoinductive nature of the scaffolds since the superior 
osteogenic properties of the pre-culture group became inappropriate regarding bone 
formation. Despite the fact that similar bone formation was observed in both groups, 
the added benefit of pre-culture technique was clear for non-osteoinductive scaffolds. 
In a different study, Mendes et al. (2002-a) seeded rat bone marrow cells at a density 
of 1 x 105 cells on HA particle of 3 x 2 x 2 mm3 dimension followed by culturing for 
5 days in vitro before in vivo implantation (Mendes et aI., 2002-a). The control 
groups consisted of7.5 x 105 (equivalent to the number of cells on HA particle seeded 
with 1 x 105 cells following 5 days of in vitro culture) and 1 x 105 cells seeded for 16 
hours on each HA particle. All the groups were implanted in rats subcutaneously for 
2, 4, 7, 9, and 12 days. The results demonstrated that after 4 days of subcutaneous 
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implantation there was statistically significantly higher quantity of bone formation in 
the cell cultured group in comparison to the cell seeded groups therefore further 
confirming the efficiency of cell culturing prior to implantation. Moreover, bone 
formation was observed earlier at day 2 of implantation in the cell cultured group 
whereas it was identified in the cell seeded groups only after 4 days of implantation 
thus demonstrating faster bone formation in the pre-cultured group. 
In this study, bone formation was observed in between ceramic microparticles within 
the gMSCs containing samples both on the interior and exterior of the samples. This 
is in contrast to the results achieved by Kruyt et al. (2006) who never observed bone 
on the exterior of the samples. Bone distribution on the interior and exterior of the 
samples could be due to the fact that gMSCs were homogeneously attached and 
distributed before implantation as evidenced by stereomicroscopy image of 7 -days 
cultured BCP microparticles stained with methylene blue (Figure 5.5). Although 
homogenous attachment and distribution of cells on microparticles was also achieved 
in the study performed by Kruyt et al. (2006), it is not clear why bone was not formed 
on the exterior of the samples. 
With regard to chitosan's ability to support bone formation, Kim et al. (2008) 
performed an study in which rat muscle-derived stem cells surrounded by 1.8% (w/v) 
chitosan-20% (w/v) GP, produced mineralized bone deposits after subcutaneous 
implantation in rats for 4 weeks (Kim et aI., 2008). This is in agreement with the 
results obtained in the current study since chitosan-GP-HEC was demonstrated to 
support bone formation in vivo when in contact with gMSCs. 
5.5 CONCLUSION 
The results obtained in this study demonstrate the osteogenic potential and bone 
formation ability of cells encapsulated in chitosan-GP-HEC hydrogel. Chitosan-GP-
HEC hydrogel supports bone formation and provides a minimally invasive option for 
bone tissue engineering. 
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CHAPTER VI 
CHITOSAN-BASED HYDROGELS UNLIKE 
HUMAN BONE MARROW DERIVED 
MESENCHYMAL STEM CELLS DO NOT 
INDUCE ANGIOGENESIS 
Published in Journal of Tissue Engineering and Regenerative Medicine (more 
details in the List of publications and conference proceedings section). 
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6.1 INTRODUCTION 
Angiogenesis is the process in which new blood vessels grow from the endothelium 
of pre-existing vasculature (Folkman and Shing, 1992). It plays an important role for 
success in bone tissue engineering approaches since bone is a highly vascularized 
tissue that needs blood vessels to supply oxygen and nutrients to the cells. Since the 
diffusion limit of oxygen is around 100-200 ~m, formation of new blood vessels is 
necessary for the tissue to grow further than this limit (A wwad et al., 1986; Carmeliet 
and Jain. 2000). This can result in major cell survival problems with regard to bone 
tissue engineered constructs that are principally used to regenerate large bony defects. 
Chitosan-based matrices have gained increasing interest in regenerative medicine as 
they can be used to prepare injectable formulations of cells combined with micron 
sized biomaterial scaffolds. The approach to injectable tissue engineered bone that 
was pursued in this study was to combine bone producing cells attached to biphasic 
calcium phosphate (BCP) microparticles surrounded by an injectable binder as 
explained in previous chapters. Advantages of this approach is that it can be applied 
in a minimally invasive manner that offers many benefits such as reduced cost, pain, 
complications, surgery time, scarring and healing period. In the current study, 
chitosan combined with glycerol phosphate (OP) and hydroxy ethyl cellulose (HEC) 
is used as the injectable binder. Chitosan is biocompatible (Hirano and Noishiki, 
1985) and biodegradable (Muzzarelli, 1997) and when combined with OP, it becomes 
thermo-sensitive in diluted acids and gels around body temperature (Chenite et aI., 
2000). Thermo-sensitivity is needed for minimally invasive applications of the 
injectable tissue engineered bone since it allows injection to the defect site followed 
by the gelation. Heavy weighted BCP microparticles tend to sink to the bottom of the 
chitosan-OP rather than remain homogeneously distributed within the gel structure. 
However, HEC improves chitosan-OP rigidity (Hoemann et al., 2002; Hoemann et 
aI., 2005; Roughley et aI., 2006) which can be useful for future incorporation of the 
BCP microparticles. 
With regard to the angiogenic potential of chitosan, there have been suggestions that 
chitosan is angiogenic (Biagini et aI., 1989; de Castro-Bernas, 2003). De Castro-
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Bernas (2003) reported chick chorioallantoic membrane (CAM) assay results 
demonstrating that chitosan stimulated neovascularization in a dose-dependent 
manner at even higher levels than the known angiogenic growth factor b-FGF (basic 
fibroblastic growth factor). Nevertheless, the study failed to mention more detailed 
information including the chitosan concentration used. In a study by Biagini et al. 
(1989), N-Carboxymethyl chitosan placed into the cornea of 10 adult rabbits induced 
neovascularisation in 7 rabbits after 30 days whereas control rabbits did not 
demonstrate any new vasculature. In their paper, Biagini et al. (1989) referred to the 
biochemical etfects of chitosan or the foreign body reaction caused by chitosan as 
possible reasons behind chitosan's induced neoangiogenesis. According to Biagini et 
al. (1989), foreign body reaction initiated by chitosan led to the presence of 
leukocytes and macrophages. It is known that angiogenesis is related to inflammation 
and inflammatory cells can function as indirect mediators of angiogenesis (Benelli et 
al.. 2002). In addition, inflammatory cells possess proteolytic enzymes able to digest 
the basal membrane which is the initial step involved in the formation of new blood 
vessels (Biagini et aI., 1989; Guo et aI., 2001). Moreover, presence of angiogenic 
stimuli leads to endothelial cell proliferation (Silver et aI., 2007). All these 
mechanisms could potentially lead to the angiogenesis observed in relation to 
chitosan. 
Interestingly, it has been reported that mesenchymal stem cells produce angiogenic 
cytokines including vascular endothelial growth factor (VEGF), b-FGF, hepatocyte 
growth factor, insulin-like growth factor 1, MCP-2 and MCP-3 (Chen et aI., 2003; 
Kamihata et aI., 2001; Kinnaird et aI., 2004; Nagaya et aI., 2004; Tang et al., 2005). 
Chitosan combined with human bone marrow derived mesenchymal stem cells 
(hMSCs) could have synergistic effects on angiogenesis and as a result enhance the 
overall angiogenic response in orthotopic defects. 
A range of in vitro and in vivo angiogenesis assays have been used in order to 
elucidate the effects of different agents on endothelial cell proliferation and blood 
vessel growth (Auerbach et aI., 2003). Most of these assays were performed on 
isolated cell preparations. However, such assays do not demonstrate the complicated 
host components and interactions that take place in the in vivo environment (Miller et 
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af., 2004). Nevertheless, in vivo small animal models are a closer estimate to the 
processes observed in humans but it should be noted that these experiments are 
expensive and time consuming (Miller et af., 2004). 
The CAM assay is an alternative to small animal models and is one of the most 
commonly used in vivo assay systems to study angiogenesis (Ribatti et af., 2000; 
Staton et af., 2004). The chick egg possesses a natural environment of growing blood 
vessels as well as all the components of the complex host interactions, and many 
angiogenic factors have been tested by this assay (Olivo et af., 1992; Ribatti et aI., 
2000~ Wilting et af., 1993; Yang and Moses, 1990). The CAM is characterized by a 
dense microvascular network which first emerges at day 3 of incubation and 
thereafter quickly develops (Ribatti et aI., 2001). It is formed when the adjacent 
mesodermal layers of the chorion and the allantois fuse and it functions as a transient 
gas exchange surface similar to the lung until the time of hatching (Dimitropoulou et 
al., 1998; Laschke and Menger, 2007; Ribatti et al., 2001). When the CAM is used as 
an assay for angiogenesis, an increased vessel density around the implant in which the 
vessels radially converge towards the centre resembling spokes in a wheel is 
associated with an angiogenic response (Ribatti et aI., 1995). The CAM assay has 
many advantages such as low cost in comparison with in vivo animal models and the 
simplicity of the preparation of the CAM vascular network. Moreover, xenografts 
from mammalian species implanted onto the CAM do not show rejection since the 
early chicken embryo does not have a complete immune system (Laschke and 
Menger, 2007). It should also be mentioned that the CAM assay has some drawbacks 
such as the limitation of its use to a time period of about 10 days, difficulty in 
detailed quantification of angiogenesis by microscopy since smaller blood vessels 
( capillaries) are not easy to visualize, and also, the CAM is composed of embryonic 
tissue that is characterized by a different growth factor profile compared to adult 
tissue (Laschke and Menger, 2007). 
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6.1.1 Aims and Objectives 
The aim of this study was to evaluate the effect of added hMSCs on the angiogenic 
potential of chitosan binder. The angiogenic response of chitosan-GP-HEC combined 
with/without hMSCs was therefore assessed using the CAM assay. For this purpose, 
hMSCs were cultured on BCP microparticies since the cells require scaffolds for 
attachment and subsequent bone deposition. 
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6.2 MATERIALS AND METHODS 
All chemicals were ordered from Sigma-Aldrich, UK unless otherwise indicated. The 
experiments were repeated twice. 
6.2.1 Preparation of Chitosan-GP-HEC Solutions 
Chitosan powder (Kitomer, Marinard Biotech, Quebec, Canada) with a 94% degree of 
deacetylation (DDA) and a molecular weight (Mw) of 679 kDa was sterilized by 
autoclaving at 126°C for 20 minutes. Sterile chitosan powder with a quantity of 
0.225g was dissolved in 9 ml of 0.18 M hydrochloric acid. Consequently, 2.25g of 
GP was dissolved in deionized water in order to bring the total hydrochloric acid and 
deionized water volume in the solutions to 15 m!. 
The GP-deionized water was filter-sterilized uSIng a 0.2 f.lm filter (Triple Red 
Laboratory, UK). Solutions of chitosan-hydrochloric acid and GP-deionized water 
were placed in an ice bath to chill for 15 minutes to avoid gelation when mixed 
together. The ice cold GP-deionized water was then added drop by drop to the ice 
cold chitosan solution with constant stirring to create a clear solution. HEC was 
added to a-MEM (Gibco Invitrogen, UK) at the concentration of 0.0125 glml 
(Roughley et aI., 2006). The HEC solution was filter-sterilized and then added to the 
chitosan-GP solution at the ratio of 0.8 ml to 4.8 ml respectively. The final 
concentrations of chitosan, GP, and HEC in the solutions were 1.5% (w/v) , 15% 
(w/v), and 0.18% (w/v) respectively. 
6.2.2 Culture of Human Mesenchymal Stem Cells on Biphasic 
Calcium Phosphate Microparticles 
Passage 2 hMSCs (from female, age 36 (iliac crest, donor 1); male, age 44 
(acetabulum, donor 2); female, age 55 (iliac crest, donor 3), Xpand Biotechnology 
BV, The Netherlands) were seeded at a density of 30,000 cells/cm2 on 212-300 Jlm 
BCP that were sintered at 1150°C and were composed of 80% hydroxyapatite and 
20% p-tricalcium phosphate with a porosity of 70.8 % (Xpand Biotechnology BV, 
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The Netherlands). The BCP microparticles with cells were kept in a humid 
atmosphere at 37°C/5% CO2 for 7 days until they were 85-90% covered with cells. 
The medium was composed of a-MEM (Gibco Invitrogen, UK) supplemented with 
10% v/v fetal bovine serum (FBS, Gibco Invitrogen, UK), 100 U/ml penicillinl100 
l-1g/ml streptomycin, 2 mM L-glutamine, 10 mM ~-glycerophosphate (BGP), 10-8 M 
dexamethasone, and 0.2 mM L-ascorbic acid 2-phosphate (AsAP) and was refreshed 
every two days. After 7 days, chitosan-GP-HEC solution was added to hMSCs 
attached to BCP microparticles such that the final BCP/gel ratio was 20% (w/v). This 
ratio was determined according to previously performed experiments and is the 
optimal BCP/gel ratio as it involves the maximum amount of BCP micropartic1es 
while the binder is still injectable. Chitosan-GP-HEC solution was also added to the 
BCP micropartic1es without hMSCs to serve as the control for the experimental group 
for the following CAM assay. 
Cell proliferation was assessed using the colourimetric indicator Alamar Blue assay 
(SeroTec, Oxford, UK). To determine the total number of cells attached to BCP 
microparticles at the time of placement on the CAM, hMSCs were washed three times 
with pre-warmed phosphate buffered saline solution (PBS). Consequently, 1 ml of a 
5% Alamar Blue solution in culture medium (Lawson et aI., 2004) was added to 
hMSCslBCP combination in the well-plate and then the plates were incubated for 3 
hours in a humidified atmosphere at 37°C/5% C02. Fluorescence of 100 1-11 aliquots 
of the extracted dye from each sample was determined using a Fluorimeter 
(FLUOstar Galaxy Fluorimeter, JENCONS-PLS, Germany) at excitation and 
emission wavelengths of 544 nm and 590 nm respectively. A standard calibration 
curve according to known numbers of hMSCs reacting with the Alamar Blue solution 
was used in order to quantify the number of cells present in each sample (Lawson et 
aI., 2004; Li et aI., 2005). 
6.2.3 CAM Assay 
Ethical approvals needed for this study were obtained prior to the experiments. 
Fertilized chicken eggs (Henry Stewart and Co, UK) were placed in an incubator at 
37°C. After 3 days a hole was created in the pointed end of the egg and 2 ml of 
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albumin was removed using a 21 G needle (Appleton Woods, UK) (Figure 6.1 a). A 
window was then made on the upper surface of the egg by removing a small 2 cm 
oval of shell, thus allowing access to the CAM. The viability of the eggs was assessed 
then the windows were sealed with adhesive tape and the eggs returned to the 
incubator (Figure 6.1 c). Figure 6.1 b shows a day 3 chicken embryo with the 
beginnings of the blood vessel network. 
Figure 6.1- Procedure for exposing and accessing the chick chorioallantoic 
membrane. Two mls of albumin is removed from 3 day old chick eggs using a 21 G 
needle and syringe (a); 3 day old chicken embryo showing the fine blood vessel 
network extending over the surface of the yolk (b); the window through the shell, 
used to gain access to the CAM, is sealed with clear tape then the egg is returned to 
the incubator (c). 
Filter paper discs with a diameter of 2 mm (Whatman, UK) were prepared and 
autoclaved at 126°C for 20 minutes. The filters were then impregnated with PBS or 
200 ng of basic fibroblastic growth factor in 10 JlI of PBS (Marks et al., 2002) (b-
FGF, SeroTec, Oxford, UK) which served as negative and positive controls 
respectively. The experimental groups consisted of filter paper discs saturated with 
chitosan-GP-HEC solutions, hMSCs attached to BCP microparticles surrounded by 
chitosan-GP-HEC solution, and BCP microparticles surrounded by chitosan-GP-HEC 
solution all prepared as explained above. The experimental groups were referred to as 
chitosan-GP-HEC, chitosan-GP-HEClhMSCs/BCP, and chitosan-GP-HEC/BCP 
respectively throughout this study. 
At day 7, control and experimental groups (10 JlI each) were placed on the CAM 
(Oates et al., 2007) based on the n numbers shown in Table 6.1. The windows were 
then sealed again with adhesive tape and returned to the incubator. At day 10, the 
images of the CAM with filter paper discs were obtained (Oates et al., 2007) using a 
Leica DC500 camera (Leica Microsystem, Milton Keynes, UK) connected to Adobe 
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Photoshop 6.0 software and attached to a Leica MZ FLIII microscope (Leica 
Microsystem, Milton Keynes, UK). Quantification of the results was performed based 
on the total number of vessels converging towards the centre of the implant in a 
spoke-wheel pattern traversing a 4mm diameter circle from the centre of the filter 
paper disc. For quantification purposes, the magnification of the images was kept 
constant. Blood vessels were quantified blindly by 3 different observers. 
Table 6.1- Table showing the n numbers for the different control and experimental 
groups in the study. 
Control and experimental groups 
Negative control 
Positive control 
Chitosan-GP-HEC 
Chitosan-GP-HEClhMSCs/BCP 
Chitosan-GP-HEC/BCP 
6.2.4 Statistical Analysis 
n number 
9 
9 
9 
3 for each donor 
9 
Results were analysed using two sample two-tail Student's (-test and one-way 
analysis of variance (ANOVA) followed by a post hoc least significant difference 
(LSD) test for multiple comparisons. Data are presented as mean ± standard 
deviation. A p value of <0.05 indicated statistical significance. 
6.3 RESULTS 
6.3.1 Culture of Human Mesenchymal Stem Cells on Biphasic 
Calcium Phosphate Microparticles 
After 7 days of culture, the total number of hMSCs attached to BCP microparticles at 
the time of placement on the CAM is 1.6 ± 0.1 x 105 for donor 1, 1.66 ± 0.05 x 10
5 
for donor 2, and 1.58 ± 0.06 x 105 for donor 3. There is no significant difference 
between different donors in terms of the number of cells on BCP microparticles after 
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7 days of culture. The standard deviations within each donor do not vary 
significantly. 
6.3.2 CAM Assay 
An increased vessel density around the implant in a spoke-wheel pattern is observed 
in the b-FGF positive control (Figure 6.2). The same enhanced vessel density in a 
spoke-wheel manner is also detected around the chitosan-GP-HEC/hMSCs/BCP 
group (Figure 6.2). Angiogenesis is thus greatly stimulated when hMSCs are added to 
the BCP microparticles and then mixed with chitosan-GP-HEC. The BCP 
microparticles without hMSCs combined with chitosan-GP-HEC do not lead to an 
enhanced angiogenic response in the CAM assay. Therefore, the stimulation of 
angiogenesis can be attributed to the presence of hMSCs in the system. The b-FGF 
shows very strong angiogenesis as expected of a positive control, however, more 
interestingly, the strength of the angiogenic reaction is similar to the chitosan-GP-
HEC/hMSCslBCP group (Figure 6.2). The comparable level of angiogenic response 
between these two groups demonstrates the efficacy and the significance of hMSCs in 
the system in terms of angiogenesis. 
There is no spoke wheel pattern observed for the chitosan-GP-HEC group (Figure 
6.2) therefore, chitosan-GP-HEC does not enhance angiogenesis. Also, the negative 
control group which is composed of the filter paper impregnated with PBS does not 
result in a spoke-wheel pattern. 
Quantitatively, significantly more converging blood vessels growing towards the 
centre of the implant are detected for the chitosan-GP-HEC/hMSCs/BCP group as 
compared to all other groups (p<O.05), except for the b-FGF positive control (Figure 
6.3). The difference between the number of converging blood vessels in the stem cell 
containing group and the rest of the groups excluding b-FGF positive control is large 
(maximum percentage difference of 61.5%). The number of blood vessels radiating 
from the centre of the implant does not show any significant difference between the 
b-FGF and the chitosan-GP-HEC/hMSCs/BCP group. 
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The number of blood vessels around the implants is slightly higher in the chitosan-
GP-HEC and the chitosan-GP-HEC/BCP groups compared to the PBS negative 
control nevertheless, these differences are not statistically significant (Figure 6.3). 
Hence, chitosan-GP-HEC and chitosan-GP-HEC/BCP without hMSCs do not result 
in enhanced angiogenic response. 
Figure 6.2- Extent of angiogenesis after ~ days in contact with. the CAM, (a) 
Negative control, (b) Positive control, (c) Chltosan-GP-HEC, (d) Chltosan-GP-HECI 
hMSCs/BCP. 
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Figure 6.3- Bar graph showing the number of blood vessels converging towards the 
centre of the implants in the different conditions. * Statistically significant difference 
(P<0.05). 
6.4 DISCUSSION 
Angiogenesis is crucial for success in bone tissue engineering since cells within bone 
tissue engineering scaffolds must be alive after implantation in order to create a 
positive effect on the formation of bone (Kruyt et aI., 2003). Implanted cells in vivo 
depend on diffusion and vascularization for the nutrient and oxygen supply. As 
mentioned before, since the diffusion process can only supply the cells within a 
maximum range of 200 J.lm (Goldstein et aI., 2001) and the initial vascularization is 
not usually optimal, the cells in the middle of large constructs have often limited 
survival (Kneser et aI., 1999). Therefore in this study, the angiogenic potential of 
chitosan and hMSCs was examined in an attempt to increase the overall angiogenic 
response in orthotopic defects. 
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The results of this study demonstrated that hMSCs attached to BCP microparticles 
and combined with chitosan-GP-HEC lead to enhanced angiogenic effect in 
comparison with the negative control and chitosan-GP-HEC ± BCP microparticles 
when placed on the CAM for 3 days. Chitosan-GP-HEC does not enhance 
angiogenesis. The angiogenic response in this study was manifest as a spoke-wheel 
pattern. The spoke-wheel pattern is a well described indicator of angiogenesis, where 
an increased density of radially converging vessels occurs around the implanted tissue 
on the CAM (Oates et aI., 2007; Ribatti et aI., 1995). 
The increased angiogenic potential of the chitosan-GP-HEClhMSCs/BCP group 
observed in this study could be due to several factors relating to the presence of 
hMSCs. Based on previous work, hMSCs secrete VEGF which can stimulate 
recruitment and proliferation of endothelial cells as well as functioning as an 
angiogenic factor in bone healing (Furumatsu et aI., 2003; Kaigler et al., 2003). As 
previously stated, mesenchymal stem cells produce angiogenic cytokines like b-FGF, 
hepatocyte growth factor, insulin-like growth factor 1, MCP-2 and MCP-3 (Chen et 
aI., 2003; Kamihata et aI., 2001; Kinnaird et al., 2004; Nagaya et aI., 2004; Tang et 
aI., 2005). Factors such as b-FGF, a-FGF, and VEGF have direct mitogenic and 
chemotactic effects for endothelial cells and encourage tube formation in vitro (Rifkin 
and Moscatelli, 1989; Thomas, 1996). VEGF is produced by osteoblasts (Deckers et 
aI., 2000; Steinbrech et aI., 1999), mesenchymal progenitor cells with an osteogenic 
phenotype (Kaigler et aI., 2003), and undifferentiated mesenchymal progenitor cells 
(Furumatsu et aI., 2003). Also, undifferentiated mesenchymal progenitor cells can 
stimulate the sprouting of blood vessels in vivo (AI-Khaldi et aI., 2003; Furumatsu et 
aI., 2003). 
According to the study performed by Potapova et al. (2007), concentrations of VEGF, 
b-FGF, angiogenin, and BMP-2 were raised from 5-20 times in hMSCs spheroid 
conditioned media (Potapova et al., 2007). The hMSCs spheroids conditioned media 
stimulated umbilical vein endothelial cell proliferation, migration, and the invasion of 
the basement membrane. Moreover, the conditioned media encouraged the survival of 
endothelial cells in vitro. This study suggests that hMSCs produce angiogenic factors 
that can stimulate endothelial cell activity. 
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Considering the fact that there are still problems about the survival of mesenchymal 
stem cells orthotopically, further approaches and strategies could be used to improve 
vascularization inside tissue engineered constructs implanted in large bony defects. 
Besides blood vessel ingrowth from the host, strategies like improvement of scaffold 
architecture to enhance the ingrowth of blood vessels (Druecke et aI., 2004; 
Karageorgiou and Kaplan, 2005; Pinney et aI., 2000; Yang et aI., 2001), addition of 
angiogenic factors (Huang et aI., 2005-b; Leach et aI., 2006; Perets et aI., 2003; 
Richardson et aI., 2001), and in vitro (Choong et aI., 2006; Rouwkema et al., 2006) 
or in vivo pre-vascularization have been studied (Akita et aI., 2004; Casabona et aI., 
1998; Kim and Kim, 2005). These strategies could be applied to mesenchymal stem 
cells in large bony defects in order to enhance cell survival. 
The results of the CAM assay regarding the angiogenic potential of chitosan 
presented in this study show a discrepancy with the work published by de Castro-
Bernas (2003) and Biagini et al. (1989), since chitosan-GP-HEC was not found to be 
angiogenic. It should be noted that de Castro-Bernas (2003) failed to mention more 
specific details like the concentration of chitosan and the time point used in their 
study therefore making an exact comparison with this study more difficult. In terms 
of the study performed by Biagini et al. (1989), 0.8% N-Carboxymethyl chitosan was 
utilized. It is apparent that the concentration of chitosan used and the composition is 
different to the current study which could have an effect in the final outcome related 
to angiogenesis. It is also possible that longer time was needed in the CAM assay in 
order to observe angiogenic response with the chitosan although this is highly 
unlikely since 10 days was enough for hMSCs to demonstrate their angiogenic 
potential. Moreover, quantifying the CAM assay after 10 days is practised by many 
researchers. Interestingly on a different account, Mochizuki et al. (2007) performed a 
study in which the AG73 peptide covalently conjugated to a chitosan membrane was 
tested for angiogenesis using the CAM assay (Mochizuki et aI., 2007). The attractive 
point about this study was the results which showed that the chitosan membrane alone 
with the concentration of 1.67% (w/v) used as the control did not show angiogenic 
activity. This is in agreement with the results of this study regarding the angiogenic 
effects of chitosan. Also, the concentration of chitosan used by Mochizuki et al. 
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(2007) is similar to the chitosan concentration of 1.5% (w/v) used in this study. Based 
on the results from the present study, it can be concluded that chitosan with the 
concentration and composition used is not angiogenic. 
The lack of angiogenic potential by chitosan is not expected to solve the cell survival 
problem in injectable bone tissue engineering. In case of the injectable tissue 
engineered bone applied orthotopically, it is likely that hMSCs would face survival 
problems despite the angiogenic potential of these cells. If chitosan was angiogenic 
then together with angiogenic potential of hMSCs, it might be possible to obtain an 
enhanced overall angiogenic response. Nevertheless, since this is not the case, the cell 
survival issue still remains to be solved. 
6.5 CONCLUSION 
Chitosan-GP-HEC gel does not demonstrate any angiogenic potential while the 
presence of hMSCs results in an increased angiogenic response following 3-day 
placement on the CAM. There are significantly more blood vessels formed for the 
group containing stem cells in comparison with other groups with the exception of b-
FGF positive control. New approaches to solve the cell survival problem in injectable 
tissue engineered bone needs to be devised. 
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CHAPTER VII 
OSTEOGENESIS BY MC3T3-El CELLS IS 
ENHANCED THROUGH CHITOSAN-BASED 
HYDROGELS 
154 
7.1 INTRODUCTION 
In previous chapters, chitosan-based hydrogels were shown to be biocompatible when 
used with goat and human bone marrow derived mesenchymal stem cells (gMSCs, 
hMSCs). They provide a promising binder material for injectable bone tissue 
engineering applications and examining the osteogenic potential of cells exposed to 
these binders would be useful for future applications of these binders. 
Various studies have shown a stimulatory effect of chitosan on bone formation 
(Klokkevold et aI., 1996; Malette et aI., 1986; Muzzarelli et al., 1994; Pang et al., 
2005). Malette et al. (1986) demonstrated increased bone regeneration in radii of dogs 
following 6 weeks treatment with chitosan. Wounds were generated through the 
cortex right into the marrow cavity. The wounds treated with saline showed a 
osteoblastic-osteoclastic remodelling sequence with callus production but wounds in 
contact with chitosan produced direct cortical bone without callus formation. In a 
different study, Klokkevold et al. (1996) assessed the in vitro effect of chitosan on 
mesenchymal stem cells in terms of osteogenic differentiation and bone formation. 
Based on this study, 2 mg/ml chitosan created significantly higher numbers of bone 
nodules than the control group. However, as the cell population was not monitored, it 
was not clear whether chitosan stimulated proliferation of cells and subsequently 
nodule formation or if it directly enhanced nodule formation and therefore 
osteogenesis. 
In addition, Pang et al. (2005) examined the effect of chitosan on bone formation in 
calvarial defects in rats and on proliferation and osteogenic differentiation of human 
periodontal ligament fibroblasts in vitro. They did not see a significant difference 
between the cell proliferation rates in the control group and the group containing 0.1 
mg/ml chitosan. In contrast, they reported that 0.1 mg/ml chitosan enhanced the 
alkaline phosphatase (ALP) activity of the human periodontal ligament fibroblasts 
while the same concentration of chitosan gave rise to significantly higher amounts of 
bone after 8 weeks of implantation in 8 mm diameter calvarial defects. In another in 
vivo study, Muzzarelli et al. (1994) reported the use of chitosan containing imidazolyl 
groups in a 7 mm diameter defect in the femoral condyle of sheep. Following 40 
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days. there was more bone formation in the defects treated with chitosan compared to 
the control however, since quantitative analysis of bone formation was not included 
in the study; it was not possible to know if the difference was statistically significant. 
In the current study, the effect of chitosan on undifferentiated preosteoblast cell line 
was evaluated in terms of osteogenic differentiation, cell proliferation and viability in 
vitro in order to examine whether chitosan has any effect on osteogenesis directly. 
7.1.1 Aims and Objectives 
The aim of the present study was to evaluate the effect of chitosan-based hydrogels 
on osteogenic properties of preosteoblast cell line (MC3T3-E1 cells). With this in 
mind, temporal assessment of MC3T3-E1 survival, growth and osteogenic 
differentiation when exposed to chitosan-containing media and control media was 
performed. pH and osmolality of different media containing chitosan in addition to 
control media was measured in order to examine whether presence of chitosan allows 
physiological pH and osmolality levels within the media. 
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7.2 MATERIALS AND METHODS 
All chemicals were ordered from Sigma-Aldrich, UK unless otherwise indicated. The 
experiments were repeated three times. The n number for all the measurements was 6. 
7.2.1 MC3T3-E 1 Cell Culture and Seeding Conditions 
Murine preosteoblast cell line, MC3T3-El cells (kindly provided by Department of 
Tissue Regeneration, Twente University, The Netherlands) were seeded at a density 
of 5 x 103 cells/cm2 (Quarles et ai., 1992) on sterile 12 well-plates (Falcon, VWR 
international, UK). The same number of cells was exposed to both control and 
experimental groups. The control groups involved the cells exposed to the 
proliferation and differentiation medium. The proliferation medium was composed of 
a-MEM (Gibco Invitrogen, UK) supplemented with 10% (v/v) FBS (FBS, Gibco 
Invitrogen, UK), and 100 Ulml penicillinll00 /lg/ml streptomycin and the 
differentiation medium consisted of a-MEM supplemented with 10% (v/v) FBS, 100 
Ulml penicillinll00 /lg/ml streptomycin, 10 mM ~-glycerophosphate and 0.2 mM L-
ascorbic acid 2-phosphate (AsAP) (Quarles et al., 1992). The medium was refreshed 
every two days. 
7.2.1.1 Preparation of Chitosan Samples 
To prepare the experimental groups, chitosan (Kitomer, Marinard Biotech, Quebec, 
Canada) with a degree of deacetylation (DDA) of 94% and a molecular weight (Mw) 
of 679 kDa was sterilized by autoclaving at 126°C for 20 minutes. Sterile chitosan 
powder (0.225g) was dissolved in 15 ml of 0.18 M hydrochloric acid and diluted to 
the following concentrations: 2 mg chitosanlml of proliferation medium, 0.05 mg 
chitosanlml of proliferation medium, and 0.005 mg chitosanlml of proliferation 
medium. The proliferation medium combined with various concentrations of chitosan 
known as the experimental groups were added to the cells in the 12 well plates. The 
medium was refreshed every two days. 
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7.2.2 MC3T3-E 1 Survival, Growth and Osteogenic 
Differentiation Study 
7.2.2.1 MC3T3-E1 Survival and Growth Study 
The viability of the cells was evaluated at days 1,3,6, 10, and 15 through live/dead 
viability staining using Calcein AM and Ethidium homodimer-2 (Molecular Probes, 
USA). Briefly, the samples were washed with pre-warmed PBS. Subsequently, 2.5 J..lI 
of both stains were mixed with 1 ml of a-MEM and applied to the samples in 250 J..lI 
volume such that the samples were covered by the staining solution. Following this, 
the samples were kept at 37°C/5% CO2 incubator for 15 minutes after which they 
were washed three times with pre-warmed a-MEM and viewed under Leica 
fluorescent microscope (Leica DMI 4000B, UK) equipped with a Leica DFC camera 
(Leica DFC 300 FX, UK). In the live/dead viability assay, metabolically active cells, 
covert Calcein AM into green fluorescent Calcein by intracellular esterases, whereas 
Ethidium homodimer enters the dead cells and binds to deoxyribonucleic acid (DNA) 
through damaged membranes. Viable and dead cells are presented as green and red 
respectively. The DNA contents of the samples were also measured at days 1, 3, 6, 
10, and 15 using the supernatant of the samples obtained in order to evaluate the 
number of cells over time. The cyquant assay kit was employed to measure the DNA 
contents following manufacturer's instructions and using a Fluorimeter. The DNA 
solution obtained was spectrometric ally analysed using emissions measured at 485 
and 520 nm by a Hitachi U- 2000 Spectrophotometer. A standard calibration curve 
based on the DNA measurements of known numbers of hMSCs was used for 
quantification of the number of cells present. 
7.2.2.2 MC3T3-E1 Osteogenic Differentiation Study 
The ALP activity and protein content were measured at days 1, 3, 6, 10, and 15. The 
samples were washed with pre-warmed PBS and stored at -80°C freezer (New 
Brunswick Scientific, USA). The samples from all time points were defrosted at once, 
lysed by the addition of 1 ml of 0.2% Triton X-100 followed by sonification (Decon 
Ultrasonics, UK). The ALP activity in the supernatant was measured as the release of 
p-nitrophenol from p-nitrophenylphosphate substrate over a period of 1 hour (AP 307 
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kit. Randox Laboratories, UK) by assessing the absorbance at 405 run wavelength on 
a ELx808 Ultra Microplate Reader (Bio-Tek Instruments, USA). A standard 
calibration curve based on the absorbance measurements of known concentrations of 
p-nitrophenol standard solution were used to compare the values obtained. The total 
protein content was evaluated with bicinchoninic acid (BCA) protein assay kit 
(product no: 23227. Pierce, USA) following manufacturer's instructions to normalize 
the ALP activity levels. This assay applies a reactive solution of bicinchoninic acid 
(BCA) and CUS04. Proteins of the cells reduce Cu2+ ions into Cu+1 ions, which make 
a complex with BCA. The absorbance was measured at 562 run wavelength on a 
ELx808 Ultra Microplate Reader. A series of bovine serum albumin (BSA) was used 
as standards. The ALP activity levels were normalized to the total protein content at 
the end of the experiment (expressed as runol P-nitrophenol/mg protein/hr). 
7.2.3 pH Measurements 
The pH of the control and experimental media were measured using an electronic pH 
meter (Fisherbrand Hydrus 300, Orin Research Incorporation, USA) to evaluate 
whether different concentrations of chitosan in the experimental groups have 
physiological pH levels. 
7.2.4 Osmolality of Various Media (Control and Experimental 
Groups) 
The osmolality of 200 !J.I aliquots of the control and experimental media were 
measured by the Advanced Osmometer (Model 3250, Advanced Instruments Inc., 
USA), in order to assess whether addition of chitosan in the media exposed to the 
cells would result in physiological osmolality. Standard osmolality solutions were 
used to calibrate the machine before performing the measurements. 
7.2.5 Statistical Analysis 
Results were analyzed using two sample two-tail Student's (-test and one-way 
analysis of variance (ANOVA) followed by a post hoc least significant difference 
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(LSD) test for multiple compansons. Data are presented In mean ± standard 
deviation. A p value of <0.05 indicated statistical significance. 
7.3 RESULTS 
7.3.1 MC3T3-E1 Survival, Growth and Osteogenic 
Differentiation 
7.3.1.1 MC3T3-E1 Survival 
The number of cells increases in all groups during the first 6 days of culture leading 
to a confluent layer of cells (Figure 7.1). However, there are significantly more viable 
cells when MC3T3-El cells are exposed to proliferation and differentiation media 
(Figure 7.1i and 7.1j). MC3T3-El cells exposed to various types of media are viable 
with limited number of dead cells following 15 days of culture (Figure 7.2). 
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Figure 7.1- MC3T3-E1 cells on tissue culture plastic at day 1 in a) 2 mg/ml chitosan, 
b) 0.05 mg/ml chitosan, c) 0.005 mg/ml chitosan, d) differentiation medium, e) 
proliferation medium; MC3T3-E1 cells on tissue culture plastic at day 6 in f) 2 mg/ml 
chitosan, g) 0.05 mg/ml chitosan, h) 0.005 mg/ml chitosan, i) differentiation medium, 
j) proliferation medium. 
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Figure 7.2- MC3T3-El cells on tissue culture plastic at day 15 in a) 2 mg/ml 
chitosan, c) 0.05 mg/ml chitosan, e) 0.005 mg/ml chitosan, g) differentiation medium, 
i) proliferation medium; dead MC3T3-El cells on tissue culture plastic at day 15 in b) 
2 mg/ml chitosan, d) 0.05 mg/ml chitosan, t) 0.005 mg/ml chitosan, h) differentiation 
medium, j) proliferation medium. 
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7.3.1.2 MC3T3-El Growth 
The number of cells exposed to different conditions was quantified based on DNA 
content measurement (Figure 7.3). The cells proliferate in all conditions throughout 
the experiment. After 6 days, cells exposed to the chitosan groups show a 
significantly reduced cell proliferation compared to the control groups. At later time 
points however, the cells demonstrate similar proliferation between different 
conditions (Figure 7.3). At days 10 and 15, the cells continue to proliferate but there 
are no significant differences between any of the groups. It should be noted that the x-
a'{is of Figure 7.3 is not linear while the y-axis is linear. 
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significantly different (P<O.05). 
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7.3.1.3 MC3T3-El Osteogenic Differentiation 
With respect to the osteogenic differentiation of MC3T3-El cells, addition of the 
osteogenic medium results in significantly higher ALP activity for all different time 
points as shown in Figure 7.4 (P<O.05). Chitosan concentrations of 2 mg/ml and 0.05 
mg/ml result in significantly higher ALP activity compared to the differentiation 
medium. The peak of ALP activity is between days 6 and 10 followed by a reduction 
at day 15. 
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7.3.2 pH Measurements 
The pH of all media are around the physiological levels (i.e. pH 7.4) except for the 2 
mg/ml chitosan group for which the pH level is 6.4 which is statistically significantly 
lower compared to the rest of the groups (Figure 7.5). 
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7.3.3 Osmolality of Various Media (Control and Experimental 
Groups) 
The osmolality values are within the physiological range (i.e. around 285 mOsmlkg 
H20 (Davies et ai., 2001)) except for the 2 mg/ml chitosan group for which the 
osmolality is statistically significantly higher compared to all the other groups. 
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165 
7.4 DISCUSSION 
The results of this study showed that chitosan concentrations of 2 mg/ml and 0.05 
mg/ml enhance the ALP activity levels of MC3T3-E1 cells compared to the control 
groups (proliferation and differentiation media). These findings support the positive 
effect of chitosan on osteogenic activity of MC3T3-E1 cells. The ALP activity trend 
in tnedia containing different chitosan concentrations is similar to the differentiation 
medium. For MC3T3-E1 cells exposed to differentiation medium and media 
containing various chitosan concentrations, the ALP activity reached its peak between 
days 3 and 6 followed by a decrease at day 10. Previous studies also observed the 
same pattern of ALP activity over time (Kim et aI., 2005; Deno et aI., 2001-b). 
MC3T3-E1 cells exposed to all groups continue to proliferate throughout the study 
\vith limited number of dead cells. The pH and osmolality of all the groups are around 
the physiological levels (i.e. pH 7.4 and osmolality around 285 mOsmlkg H20 
(Davies et aI., 2001)) except for the 2 mg/ml chitosan group. 
MC3T3-E1 cells are preosteoblastic cell line derived from neonatal mice calvaria 
which show a chronological expression of osteogenic features similar to bone 
formation in vivo (Quarles et al., 1992). In other words, alkaline phosphatase (ALP) 
production, collagen synthesis, extracellular matrix deposition and mineralization of 
extracellular matrix which are associated with different phases of osteoblast 
development are all observed when MC3T3-E1 cells are cultured with appropriate 
stimuli (e.g. ascorbate and ~-glycerophosphate) (Quarles et aI., 1992). Therefore, 
these cells provide an excellent model to study osteogenesis by an external factor. 
Pang et al. (2005) studied the effect of chitosan on proliferation and osteogenic 
differentiation of human periodontal ligament fibroblasts in vitro. They reported that 
increased concentrations of chitosan were associated with reduced cell proliferation 
with 2 mg/ml chitosan showing significantly lower cell proliferation. This is in 
accordance with our results since as shown in Figure 7.3, a reduced cell proliferation 
was observed when MC3T3-E1 cells were exposed to increasing concentrations of 
chitosan although these differences were not significant except at day 6. These 
findings suggest that when MC3T3-E1 cells are in contact with different 
166 
concentrations of chitosan, the proliferation is slowed at initial time points (i.e. day 6) 
which corresponds to the highest ALP activity levels for these groups compared to 
the control groups because cells cease to proliferate when they start to differentiate 
(Conget and Minguell, 1999). 
Chitosan has been shown to support and stimulate bone formation (Klokkevold et aI., 
1996; Malette et al., 1986; Muzzarelli et aI., 1994; Pang et aI., 2005). The results of 
this study support this since the ALP activity levels for 2 mg/ml chitosan and 0.05 
mg/ml chitosan groups are higher as compared to the control groups at almost all time 
points. This demonstrates the stimulation of osteogenic differentiation of MC3T3-El 
cells when they are in contact with the above mentioned concentrations of chitosan. 
Klokkevold et al. (1996) examined the effect of chitosan exposure on mesenchymal 
stem cells with regard to osteogenic differentiation and bone formation. Nevertheless, 
in their study, the number of cells was not counted and therefore it was not clear 
whether chitosan stimulated proliferation of cells and as a result more nodule 
formation or if it in fact increased nodule formation and consequently osteogenesis 
directly. However, the results of the current study indicate that chitosan enhances 
osteogenic differentiation of MC3T3-El cells. Moreover, freeze dried chitosan 
scaffolds have been observed to support osteoblast proliferation and differentiation 
(Seol et al., 2004). It should be noted that chitosan extracts were used in the present 
study however, both chitosan extracts and freeze dried chitosan (Seol et aI., 2004) 
support osteoblast differentiation which suggests that the osteogenic stimulation takes 
place in both forms. Also, chitosan combined with hydroxyapatite offers an excellent 
scaffold for attachment, proliferation and differentiation of goat bone marrow derived 
stromal cells (Oliveira et al., 2006). All these information confirm the positive effects 
of chitosan on osteogenesis and cell attachment. 
Comparing the results of chapter 4 with this chapter, it is noticed that the osteogenic 
differentiation of hMSCs is not enhanced when encapsulated with chitosan-GP-HEC 
which is contradictory to the results obtained when MC3T3-El cells are cultured with 
2 and 0.05 mg/ml chitosan concentrations. However, the differences observed could 
be due to different set-up, different experimental conditions or the fact that chitosan 
167 
was mixed with GP. HEC and BCP when it was in contact with hMSCs. Nonetheless, 
since the results obtained with MC3T3-El cells are different to those of hMSCs with 
regard to osteogenic differentiation, this might suggest that the results obtained form 
MC3T3-El cells might not be directly relevant regarding the clinical application of 
injectable tissue engineered bone. 
Chitosan was used in the range of 0.01-2 mg/ml in previous studies and was shown to 
be biocompatible when used within that range (Klokkevold et al., 1996; Pang et al., 
2005). Therefore, in the preset study, chitosan concentrations of 0.05 and 2 mg/ml 
were used. Low chitosan concentration of 0.005 mg/ml was also used in this study to 
examine the osteogenic potential of cells exposed to such low concentration. It should 
be noted that 0.005 mg/ml chitosan shows lower ALP activity levels in comparison 
with 2 mg/ml and 0.05 mg/ml chitosan. This might be because of the lower 
concentrations of chitosan. Even though the chitosan concentration is the lowest in 
the 0.005 mg/ml group however, it still produces higher ALP activity than the 
negative control (proliferation medium) group. Chitosan concentration of 0.05 mg/ml 
is the most favourite concentration with respect to ALP activity and osteogenic 
differentiation, pH and osmolality levels in comparison with 2 mg/ml and 0.005 
mg/ml. This is partly due to the fact that 2 mg/ml chitosan produces significantly 
lower pH levels compared to the rest of the groups as mentioned earlier. Also, the 
osmolality of the 2 mg/ml chitosan group is significantly higher relative to all the 
other groups however, the osmolality for bioencapsulation should be ideally around 
270-340 mOsm/kg H20 (Chenite et al., 2002). 
The mechanism by which chitosan stimulates osteogenic differentiation is unknown. 
Due to its N-acetylglucosamine repeating units, chitosan has structural similarity to 
glycosaminoglycans especially hyaluronic acid (Sandford, 1989) and therefore may 
imitate their functional activities (Pang et al., 2005). Hyaluronic acid facilitates 
progenitor cells migration thus assisting tissue regeneration (Zhu et aI., 2006). Also, 
chitosan has been suggested to increase the migration and differentiation of 
preosteoblastic progenitor cells (Klokkevold et al., 1996; Malette et al., 1986). 
Further studies are needed to understand chitosan's mechanism of action. 
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7.5 CONCLUSION 
Chitosan concentrations of 2 mg/ml and 0.05 mg/ml enhance the ALP activity levels 
of MC3T3-E1 cells compared to the control groups. MC3T3-E1 cells exposed to all 
groups continue to proliferate throughout the study with limited number of dead cells. 
These results support the positive effect of chitosan on osteogenic activity ofMC3T3-
E 1 cells. 
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CHAPTER VIII 
GENERAL DISCUSSION 
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8.1 GENERAL DISCUSSION 
This chapter reviews and discusses different in vitro and in vivo studies performed 
regarding the injectable tissue engineered bone formulations. Various studies 
described in this thesis (chapters 3-7) have shown that chitosan-glycerol phosphate 
(GP) is a biocompatible binder which undergoes sol-gel transition around body 
temperature. Moreover, extracts of all chitosan concentrations combined with or 
without 5% (w/v) GP and 20/0 (w/v) chitosan mixed with 10% (w/v) GP demonstrated 
up to 34% increase in proliferation rate of goat bone marrow derived mesenchymal 
stem cells (gMSCs) in comparison with the control medium. Addition of 
hydroxyethyl cellulose (HEC) to chitosan-GP hydrogels allowed cross-linking of the 
chitosan and thus enhancing gel rigidity (Hoemann et al., 2002; Hoemann et al., 
2005: Roughley et at., 2006). Furthermore, when HEC was added at 0.18% (w/v) 
concentration to 1.5% (w/v) chitosan-15% (w/v) GP, the cell survival, growth and 
osteogenic differentiation were not affected. Chitosan-GP-HEC was found to be 
degradable as well as having an increased gelation rate compared to chitosan-GP 
alone. With regard to the in vivo bone formation ability, gMSCs produced bone when 
surrounded by chitosan-GP-HEC after a 6-week subcutaneous implantation in nude 
mice which further confirmed the results obtained in vitro concerning the suitability 
of chitosan-GP-HEC as an injectable binder for bone formation. Additionally, 
chitosan-based binder was demonstrated to be non-angiogenic unlike human bone 
marrow derived mesenchymal stem cells (hMSCs) which showed angiogenic 
potential. Also, chitosan was found to enhance osteogenic activity ofMC3T3-E1 cells 
at 2 and 0.05 mg/ml concentrations. 
8.1.1 In Vitro Gelation and Degradation ofChitosan-GP ± HEC 
Chitosan-GP solutions set at 37°C as expected therefore making them suitable to act 
as an injectable tissue engineered bone binder which needs to gel at body temperature 
when applied to the defect site (chapters 3-4). In addition, chitosan-GP demonstrated 
fast gelation properties such that a gelation time of less than 1 minute was seen when 
15-20% (w/v) GP was added to 1-2% (w/v) chitosan. This is because increasing GP 
concentrations lead to reduced gelation time (chapter 3) which is in accordance with 
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the study performed by Ganji et al. (2007), nevertheless, in their study, an inverted 
test tube method was used to measure the gelation time as opposed to rheometry 
which is more accurate. 
With regard to factors influencing the gelation time, it should be noted that chitosan 
concentration is influential such that higher chitosan concentrations result in 
decreased gelation time when mixed with the same amount of GP (chapter 3). This 
pattern was also detected by Ganji et al. (2007) whereby 2% (w/v) chitosan led to 
decreased gelation time in comparison with 1 % (w/v) chitosan when mixed with 
similar GP quantities. In terms of the reasons behind this trend, it is known that 
increasing chitosan and GP concentration accelerates the gelation process owing to an 
increase of intermolecular interactions and entanglements (Cho et al., 2006). 
Moreover, in a separate study, Montembault et al. (2005) evaluated the effect of 
chitosan concentration on gelation time with no external cross-linking agents in acetic 
acid-water-propanediol solution and demonstrated that higher chitosan concentrations 
result in lower gelation time. It was then suggested that more entangled polymer 
chains were responsible for faster gelation when higher polymer concentrations were 
involved. 
To understand the influence of gelation temperature with regard to pH and GP 
concentration, Chenite et al. (2001) performed a study and observed that higher GP 
concentration which is coupled to higher pH, results in lower gelation temperature. 
They suggested that the number of charged ammonium groups on the chitosan chain 
is influential regarding the control of the gelation. A reduction in charge density on 
chitosan chains causes reduction of interchain electrostatic repulsion, thus leading to 
smaller amount of thermal energy required to start the gelation. The gelation results 
presented in chapter 3 are in agreement with this since higher GP concentration and 
thus higher pH, led to smaller addition of thermal energy necessary to initiate the 
gelation. However, chitosan solutions mixed with lower GP concentrations required 
more thermal energy which could be achieved by increasing the gelation time or 
gelation temperature. 
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In order to increase the rigidity of the chitosan-GP hydrogels such that biphasic 
calcium phosphate microparticles (BCP) could be homogeneously distributed with 
the gel network, HEC was added. The gelation time decreased significantly with 
increasing concentrations of HEC, in other words, presence of HEC increased the 
gelation rate (chapter 4). This is in agreement with the studies performed by 
Hoemann et al. (2007) and Li and Xu (2002). It should be noted that the interaction 
of negatively charged GP with highly protonated cationic chitosan through 
electrostatic attractions is one of the forces responsible for the gelation (Chenite et aI., 
2000). As suggested by Li and Xu (2002), this system is made of molecular 
aggregates of neutral origin presented as colloidal precipitates resulting in a weak 
structure and low storage modulus. The neutral molecule HEC, is capable of binding 
with chitosan through hydrogen bonding thus resulting in bridge formation between 
chitosan molecules (Li and Xu, 2002). Higher HEC content leads to stronger 
hydrogels primarily as a result of higher number of hydrogen bonding in the hydrogel 
structure (Li and Xu, 2002). Faster gelation rates which result from higher HEC 
content inside the gels could also be related to enhanced hydrogen bonding within the 
gel. 
Regarding the gelation temperature, chitosan-GP-HEC solutions gel at 37°C similar 
to chitosan-GP solutions. Therefore, the presence of HEC in chitosan-GP hydrogels is 
beneficial in tenns of increasing the integrity of the gel and decreasing the gelation 
time while still being able to undergo gelation at 37°C. Gelation time of a few 
minutes is suitable for injectable applications of tissue engineered bone which is 
achieved in this thesis (chapters 3-4). 
Other than having the appropriate gelation times, chitosan-GP ± HEC hydrogels have 
physiological pH levels which is needed when cells are combined with such 
hydrogels as explained in section 8.1.2. 
The other important characteristic of an injectable binder is the biodegradability, 
since an injectable binder for tissue engineered bone needs to degrade in a timely 
fashion after being placed in the defect in order to create space for bone formation. 
Nonetheless, it should not have rapid degradation since injectable binders have to 
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remain for days and not hours. The degradation behaviour of chitosan-GP ± HEC 
hydrogels was evaluated in chapter 4. Lysozyme was used in the degradation medium 
at 10 mg/L to ilnitate physiological conditions in which lysozyme is present in plasma 
at around 4-13 mg/L (Henry, 1991). The pH of the phosphate buffered saline (PBS) 
and PBS combined with lysozyme solutions in degradation studies was around the 
physiological level throughout the experiment demonstrating that the degradation 
products of chitosan-GP-HEC maintain the pH at physiological range. Lower HEC 
concentrations resulted in faster degradation rates when chitosan-GP-HEC hydrogels 
were exposed to PBS or PBS mixed with lysozyme. Moreover, additional 
confirmation was seen in scanning electron microscopy images in which chitosan-GP 
was degrading at a faster rate in comparison with chitosan-GP-0.18% (w/v) HEC 
after 42 days of exposure with lysozyme. This could be related to the lower number 
of hydrogen bonds bridging chitosan molecules (Li and Xu, 2002) and thus leading to 
relatively weaker network more subject to degradation. Also, the existence of another 
polymer i.e. HEC could cause reduced chitosan degradation primarily because of 
limitation of lysozymal transport (Huang et al., 200S-a). 
The degradation results in chapter 4 showed that presence of lysozyme lead to higher 
degradation rates. Lysozyme is well-known to digest chitosan according to the 
amount and distribution of N-acetyl groups (Aiba, 1992). In addition, several studies 
have shown degradability of chitosan in contact with lysozyme (Huang et aI., 200S-a; 
Moshfeghian et aI., 2006). As presented in chapter 4, the percentage dry and wet 
weight remaining for chitosan-GP ± HEC hydrogels decreased throughout the 42 day 
period (without having rapid degradation) which was further evidenced by scanning 
electron microscopy images showing the external morphology of the gels over the 42 
days. Based on the results obtained in this thesis (chapter 4), chitosan-GP ± HEC 
binders meet the degradability requirement for application as a tissue engineered bone 
binder. Also, in the in vivo bone formation study, the behaviour of chitosan-GP-HEC 
binder was further evaluated in terms of in vivo degradation, which is discussed in 
section 8.1.3. 
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8.1.2 In Vitro Cell Survival, Growth and Osteogenic 
Differentiation of Mesenchymal Stem Cells Combined with 
Chitosan-GP-HEC 
The biocompatibility of the injectable tissue engineered bone binder is of paramount 
importance since the binder is required to be in contact with the bone producing cells 
and hence it must not be toxic to the cells. Moreover, an ideal binder should allow 
cell survival, growth and differentiation towards the osteogenic lineage when 
surrounding the cells. All these features were investigated in chapters 3-4. 
Initially, the biocompatibility of chitosan-GP was studied in chapters 3-4 followed by 
chitosan-GP-HEC. The results of chapter 3 showed improved cell proliferation 
relative to the control ranging from 18-34% with extracts from 0.5-2% (w/v) chitosan 
mixed with 5% (w/v) GP. Chitosan-GP extracts with higher concentrations of 
chitosan resulted in more cell proliferation. For example, in the case of extracts from 
10% (w/v) GP combined with chitosan, there was improved cell proliferation with 
2% (w/v) chitosan and decreased cell proliferation with 0.5-1.5% (w/v) chitosan. As 
previously discussed, this could possibly be due to two reasons. Firstly, it could be 
because of higher chitosan concentrations requiring more GP to react with the amine 
group as the electrostatic interactions between the chitosan and the GP is one of the 
forces involved in gel formation (Chenite et aI., 2000). When more GP is reacting 
with the chitosan, there would thus be less leaching to the outside medium which is 
the extraction medium and therefore better cell growth response. Secondly, higher 
chitosan concentrations result in higher degradation products and thus stimulating 
higher cell growth. Concerning the second point, chitosan has been shown to cause 
enhanced cell proliferation response as Howling et al. (2001) studied the effect of 
chitin and chitosan on the proliferation of human skin fibroblasts and keratinocytes. 
They observed about 50% increase in the proliferation rate of fibroblasts over the 
control group when they were treated with an initial chitosan concentration of 50 
Ilg/ml in culture media. The mechanism by which chitosan stimulates cell growth is 
unknown nevertheless, chitosan may indirectly enhance fibroblast proliferation 
through the formation of poly-electrolyte complexes with serum components like 
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heparin (Mori et aI., 1997), or potentiating growth factors like platelet derived growth 
factor (Inui et aI., 1995). 
After learning about the positive response of chitosan-GP hydrogels with regard to 
biocompatibility as discussed above, it was important to know the biocompatibility of 
the hydro gels when HEC was added. As explained before, HEC was added to 
chitosan-GP hydrogels to improve the rigidity of the gels so that BCP microparticles 
could be distributed homogenously within the gel network. Various tests were 
performed in chapter 4 to investigate cell survival, growth and osteogenic 
differentiation of mesenchymal stem cells when in contact with chitosan-GP-HEC 
hydrogels. 
With respect to direct contact biocompatibility tests, cells exposed to higher 
concentrations of HEC were not growing as well as the control and the groups 
containing 0 and 0.18% (w/v) HEC as observed by the significantly lower number of 
cells in these groups (chapter 4). As suggested by Hoemann et al. (2007), HEC 
contains glyoxal. Glyoxal is a toxic by-product of advanced glycation endproducts 
(AGE) (Shangari et al., 2003) which has caused apoptosis following extended contact 
with lung epithelial cells at 0.1 mM concentration (Kasper et al., 2000). Higher HEC 
concentrations therefore having higher glyoxal levels give rise to higher cytotoxicity 
response and thus cell death which is the reason behind lower cell growth observed. 
The pH values of 1.5% (w/v) chitosan-15% (w/v) GP combined with 0.18% (w/v) 
HEC was around the physiological range. Based on the biocompatibility and pH 
results, chitosan concentration of 1.5% (w/v) mixed with 15% (w/v) GP and 0.18% 
(w/v) HEC was chosen as the ideal composition for hMSCs survival, growth and 
osteogenic differentiation studies. 
Live/dead staining using Calcein AM and Ethidium homodimer-2 proved that hMSCs 
attached to BCP microparticles exposed to 1.5% chitosan-15% GP-0.18% HEC 
proliferate and remain viable after 7 days of culture. In addition, only limited number 
of dead cells was detected when the cells were surrounded by chitosan-GP-HEC. This 
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was comparable to the control group which was composed of cells attached to BCP 
microparticles without chitosan-GP-HEC. The result of live/dead staining further 
confirmed the suitability of chitosan-GP-HEC hydrogels in terms of maintaining cell 
viability. 
When the number of cells exposed to chitosan-GP-HEC was quantified, the results 
showed that the cells grow in BCP microparticles group mixed with or without 
chitosan-GP-HEC. With respect to the osteogenic differentiation, hMSCs produced 
significantly higher ALP activity when cultured in osteogenic medium as compared 
to the basic medium. In addition, chitosan-GP-HEC did not have any negative effect 
on hMSCs' osteogenic differentiation. These achievements are crucial for injectable 
tissue engineered bone binders since such binders should allow cell survival, growth 
and osteogenic differentiation when in contact with the cells. 
8.1.3 In Vivo Bone Formation Ability of Mesenchymal Stem 
Cells Surrounded by Chitosan-GP-HEC 
Following the successful survival and osteogenic differentiation of mesenchymal 
stem cells in contact with chitosan-GP-HEC hydrogels in vitro, the in vivo bone 
formation ability of mesenchymal stem cells surrounded by chitosan-GP-HEC was 
investigated. It is important to examine whether a certain tissue engineered product is 
functional in vivo since in vivo animal experiments are closer estimate of what 
actually happens inside the body as compared to in vitro experiments. In case of bone 
tissue engineering, the functionality of the product is assessed based on its bone 
formation ability in vivo. 
gMSCs were cultured on BCP microparticles for 7 days before implantation. Cell 
seeding on the constructs in vitro before in vivo implantation allows extracellular 
matrix formation and differentiation of cells (Kruyt et aI., 2004-a; Mankani et al., 
2001; Ohgushi and Caplan, 1999; Yoshikawa et al., 2000). This was indeed the case 
since gMSCs formed a layer of cells and produced extracellular matrix on the surface 
of BCP ceramic microparticles after 7 days of culture in vitro (chapter 5). Following 
implantation in nude mice, ectopic bone formation was consistently observed 
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throughout BCP microparticles in gMSCs containing groups in the presence and 
absence of chitosan-GP-HEC. Furthermore, control groups without cells did not show 
any sign of bone formation in all implanted animals instead they were filled with 
fibrous tissue. The results of this study showed that the presence of chitosan-GP-HEC 
in gMSCs-BCP constructs did not interfere with the bone formation process. 
Although the overall quantity of bone formed after 6 weeks was lower in the 
chitosan-GP-HEC group compared to the control group (gMSCs attached to BCP 
microparticles) however, this difference was not statistically significant. Also, 
chitosan-GP-HEC was degraded after 6 weeks, creating more space for bone 
formation. This further confirmed that chitosan-GP ± HEC binders have the 
degradation characteristics needed for minimally invasive applications of tissue 
engineered bone as previously discussed in section 8.1.1. 
With respect to the ability of chitosan-GP to support osteogenic differentiation, Kim 
et al. (2008) reported an study in which rat muscle-derived stem cells surrounded by 
1.8% (w/v) chitosan-20% (w/v) GP, produced mineralized bone deposits after 
subcutaneous implantation in rats for 4 weeks (Kim et al., 2008). Similarly in chapter 
5 study, chitosan-GP-HEC supported bone formation in vivo following the 
stimulation of gMSCs into the osteogenic lineage. Furthermore, according to Cho et 
al. (2008), rat bone marrow mesenchymal stem cells attached and proliferated when 
suspended in 1.8% (w/v) chitosan mixed with 20% GP (w/v) (Cho et aI., 2008). 
Immunohistochemical visualization verified that the cells remain viable in the gel for 
at least 28 days following implantation. This supports the fact that chitosan gel is 
biocompatible as proved in chapter 5 study by the bone formation that occurred in the 
presence of chitosan-GP-HEC. 
This successful in vivo experiment further confirmed the results obtained in vitro 
concerning the biocompatibility of chitosan-GP-HEC hydrogels as well as the ability 
of such hydrogels to support osteogenic differentiation. 
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8.1.4 Angiogenic Potential of Chitosan-based Binders 
Angiogenesis plays an important role for success in bone tissue engineering 
approaches since bone is a highly vascularized tissue that needs blood vessels to 
supply oxygen and nutrients to the cells. Since the diffusion limit of oxygen is around 
1 00-200 ~lm, formation of new blood vessels is necessary for the tissue to grow 
further than this limit (A wwad et aI., 1986; Carmeliet and Jain, 2000). This can result 
in major cell survival problems with regard to bone tissue engineered constructs that 
are principally used to regenerate large bony defects. 
With regard to the angiogenic potential of chitosan, there have been suggestions that 
chitosan is angiogenic (Biagini et aI., 1989; de Castro-Bernas, 2003). The angiogenic 
response of chitosan-GP-HEC combined with and without hMSCs was therefore 
examined in chapter 6 using the chick chorioallantoic membrane (CAM) assay. 
Chitosan-GP-HEC gel did not show any angiogenic potential whereas the presence of 
hMSCs gave rise to an enhanced angiogenic response when placed on the CAM for 3 
days. Quantitatively, significantly more blood vessel formation was observed for the 
stem cell containing group as compared to all other groups (p<0.05), except for b-
FGF positive control. The results indicated that the chitosan-GP-HEC binder did not 
contribute to enhanced angiogenesis and that the presence of hMSCs improved 
. . 
angIogenesIs. 
The absence of angiogenic potential by chitosan is not expected to solve the cell 
survival problem in injectable bone tissue engineering. If chitosan was angiogenic 
then in case of injectable tissue engineered bone applied orthotopically, it might have 
been possible to solve the cell survival problem. Nonetheless, since this was not the 
case the cell survival issue still remains to be solved. Despite the fact that hMSCs , 
support angiogenesis, when placed in a defect, the rate of blood vessel formation 
might not be enough to speed up vasculature inside the tissue engineered bone 
therefore leading to a possible problem with regard to cell survival. However, this 
needs to be verified by implantation of injectable tissue engineered bone formulations 
in critical size defects. Previous studies demonstrated that cells survive in critical size 
defects such as the study performed by Brodke et al. (2006). This study showed that 
demineralized bone chips combined with osteoprogenitor cells and implanted in 
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critical size defects in canine model result in bone bridging across the defect in all 
animals after 16 weeks (Brodke et aI., 2006). Similar results were also obtained when 
autografts were implanted in the defects but in the control group (demineralized bone 
chips without cells) only 500/0 of the defects were healed. The interesting point about 
this study is that the cells seeded on the demineralized bone chips survived in critical 
size defects and led to bone bridging and complete healing. Even though this study 
shows that the cells survive in critical size defects in canine model nevertheless , 
Meijer et al. (2008) demonstrated that cell survival was an issue in the clinical study 
that was carried out which resulted in bone formation in only 1 patient (Meijer et al., 
2008). Having such contradictory results regarding cell survival, it is therefore 
necessary to implant injectable tissue engineered bone in critical size defects. If cell 
survival is found to be affected in critical size defects despite the angiogenic abilities 
of hMSCs, then further approaches and strategies could be used to improve 
vascularization inside tissue engineered constructs implanted in large bony defects. 
Besides blood vessel ingrowth from the host, strategies like improvement of scaffold 
architecture to enhance the ingrowth of blood vessels (Druecke et al., 2004; 
Karageorgiou and Kaplan, 2005; Pinney et al., 2000; Yang et al., 2001), addition of 
angiogenic factors (Huang et al., 2005-b; Leach et al., 2006; Perets et al., 2003; 
Richardson et al., 2001), and in vitro (Choong et al., 2006; Rouwkema et al., 2006) 
or in vivo pre-vascularization have been studied (Akita et al., 2004; Casabona et al., 
1998; Kim and Kim, 2005). 
8.1.5 Osteogenic Potential of Cells Exposed to Chitosan-based 
Binders 
With regard to the stimulatory effect of chitosan on bone formation, various studies 
have been performed (Klokkevold et al., 1996; Malette et al., 1986; Muzzarelli et al. , 
1994; Pang et al., 2005). Klokkevold et al. (1996) assessed the effect of chitosan on 
mesenchymal stem cells in terms of osteogenic differentiation and bone formation. 
Based on this study, 2 mg/ml chitosan created significantly higher number of bone 
nodules than the control group. However, since the number of cells was not 
monitored, it is not clear whether chitosan stimulated proliferation of cells and as a 
result more nodule formation or if it in fact enhanced nodule formation and therefore 
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osteogenesis directly. To investigate this further, the effect of chitosan on MC3T3-E1 
cells was evaluated in chapter 7 in terms of osteogenic differentiation, cell 
proliferation and viability in vitro. 
Live/dead staining USIng Calcein AM and Ethidium homodimer-2 indicated that 
MC3T3-E1 cells exposed to 2, 0.05 and 0.005 mg chitosanlml continue to proliferate 
throughout the study with limited number of dead cells observed. With respect to the 
osteogenic differentiation of MC3T3-E 1 cells, chitosan concentrations of 2 mg/ml 
and 0.05 mg/ml resulted in significantly higher ALP activity compared to the 
differentiation medium. These findings support the positive effect of chitosan on 
osteogenic activity of MC3T3-E 1 cells. 
The mechanism by which chitosan stimulates osteogenic differentiation is unknown 
however, due to its N-acetylglucosamine repeating units, chitosan has structural 
similarity to glycosaminoglycans especially hyaluronic acid (Sandford, 1989) and 
therefore may imitate their functional activities (Pang et at., 2005). Hyaluronic acid 
facilitates progenitor cells migration therefore assisting tissue regeneration (Zhu et 
at., 2006). Also, chitosan has been suggested to increase the migration and 
differentiation of preosteoblastic progenitor cells (Klokkevold et at., 1996; Malette et 
al., 1986). Future studies are needed to further understand chitosan's mechanism of 
action. 
Comparing the results of chapter 4 with chapter 7, it is noticed that the osteogenic 
differentiation of hMSCs was not enhanced when encapsulated with chitosan-GP-
HEC (chapter 4) which is contradictory to the results obtained when MC3T3-E1 cells 
were cultured with 2 and 0.05 mg/ml chitosan concentrations. However, the 
differences observed could be due to different set-up, different experimental 
conditions or the fact that chitosan was mixed with GP, HEC and BCP when it was in 
contact with hMSCs. Nevertheless, since the results obtained with MC3T3-E1 cells 
are different to those of hMSCs with regard to osteogenic differentiation, this might 
suggest that the results obtained from MC3T3-E1 cells might not be directly relevant 
regarding the clinical application of injectable tissue engineered bone. Also, hMSCs 
are closer to the final application of injectable tissue engineered bone compared to 
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MC3T3-E1 cells. In any case, even though chitosan-GP HEC t nh . 
- was no e anclng the 
osteogenic differentiation of hMSCs, at least it was not preventing it which indicates 
that it is a promising binder for tissue engineered bone. 
8.1.6 Future Work and General Considerations 
Injectable tissue engineered bone is a relatively new concept in the field of bone 
tissue engineering. It is a promising approach to overcome some of the drawbacks 
associated with traditional bone tissue engineering techniques since it offers 
minimally invasive strategy to repair and regenerate bone defects. This technology 
could be applied to various clinical conditions such as spinal fusion and skull defects. 
Also, chitosan-GP-HEC binder which surrounds the tissue engineered bone could be 
used to deliver growth factors to the injury site. In addition, it could offer benefits 
such as cell protection from harsh haematoma (with high potassium concentration 
toxic to cells) which is formed in osseous defects after an injury (Street et al., 2000). 
Many interesting novel facts were discovered during the course of this thesis with 
regard to biocompatibility, gelation and degradation of chitosan-GP ± HEC binders as 
well as survival, osteogenic differentiation and in vivo bone formation of cells 
exposed to chitosan-GP-HEC binders. Nonetheless, more experiments are necessary 
before injectable tissue engineered bone could be used clinically. For example, in 
terms of future experiments, injectable tissue engineered bone should be applied in 
critical size bone defects in animals such as goats so that the success of such approach 
could be tested in critical size defects. If cell survival is indeed an issue in such 
critical size defects, then new effective approaches will be necessary to enhance 
angiogenesis in injectable tissue engineered bone constructs since chitosan-GP-HEC 
did not have inherent angiogenic properties. Suggestions regarding this matter were 
made in section 8.1.4. Moreover, hMSCs should be used in addition to gMSCs in 
preclinical in vivo experiments since the application of injectable tissue engineered 
bone is patient-oriented. For instance, hMSCs could be used in ectopic implantation 
in nude mice model. Unfortunately, hMSCs cannot be applied in critical size defects 
in animals such as goats because of immune rejection but they could be used in 
critical size defects in nude mice or rats. Following successful preclinical tests, 
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clinical trials using injectable tissue engineered bone would be the next step. If all the 
necessary regulatory approval is obtained and all the additional requirements are met 
then with a robust planning scheme it becomes possible to test injectable tissue 
engineered bone in patients with bone related medical conditions such as spinal 
fusion or skull defects. 
The studies in this thesis focused on the biological and material aspects of injectable 
bone tissue engineering as opposed to the mechanical aspects. It is of paramount 
importance that the cells inside the injectable tissue engineered bone constructs 
survive and produce bone when implanted in defects. In line with this requirement, 
the biological and material aspects of such constructs were the subject of 
investigation in this thesis. Therefore, the potential use for these constructs would be 
non load-bearing applications such as spinal fusion and skull defects. It should be 
noted that the current golden standard therapy for bone repair and regeneration 
(autografts) are applied to the defects in the form of bone chips without having much 
mechanical properties. Even though these bone chips lack sufficient mechanical 
properties, they are still the best solution available for bone regeneration. It is 
therefore debatable how relevant the mechanical properties are with regard to bone 
defects. Nevertheless, it is a promising solution when tissue engineered bone 
constructs perform well both biologically and mechanically. 
The current tissue engineering strategies for bone repair and regeneration including 
the approach used in this thesis, involves direct osteogenic differentiation. It should 
be noted that the natural healing response of the body in case of fracture is also 
through endochondral bone formation as mentioned in the introduction of this thesis 
(chapter 1). It is therefore reasonable to combine tissue engineering techniques with 
natural healing response of the body (endochondral bone formation) when devising 
strategies to regenerate bone defects in future. 
8.2 CONCLUDING REMARKS 
The studies described in this thesis contributed to further understanding of injectable 
applications of tissue engineered bone. A promising binder was discovered for 
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minimally invasive applications of tissue engineered bone with successful in vitro and 
in vivo results. Chitosan-GP-HEC was shown to be biocompatible and biodegradable 
with quick gelation properties at body temperature. Mesenchymal stem cells 
remained viable when surrounded by the gel and underwent osteogenic differentiation 
when supplied with the right stimuli. In vivo experimentation in mice was another 
success after bone formation was observed in cell containing groups in the presence 
or absence of the chitosan-GP-HEC. This further demonstrated the suitability of 
chitosan-GP-HEC for injectable bone tissue engineering applications. 
In addition, chitosan produced positive results regarding enhancement of osteogenic 
activity and it was shown to be non-angiogenic. Despite all the novel successful 
results obtained during the course of this thesis, however, more investigations and 
studies (e.g. evaluation of cell survival in injectable tissue engineered bone implanted 
in critical size defects) are necessary before we witness clinical applications of 
injectable tissue engineered bone. 
184 
LIST OF PUBLICATIONS AND 
CONFERENCE PROCEEDINGS 
PUBLICATIONS 
Ahmadi, R. & de Bruijn, J.D. 2008, "Biocompatibility and gelation of chitosan-
glycerol phosphate hydrogels" , Journal of Biomedical Materials Research Part A, 
vol. 86(3). pp. 824-32. 
Ahmadi, R. & de Bruijn, J.D. 2007, "Chitosan based delivery systems for injectable 
tissue engineered bone: human mesenchymal stem cell survival, proliferation and 
osteogenic differentiation", TERMIS-EU Meeting Abstracts, London, UK, Tissue 
Engineering, vol. 13(7), pp. 1655. 
Ahmadi, R., Zhou, M., & de Bruijn, J.D. 2005, "The use of thermo-sensitive chitosan 
as an injectable carrier for bone tissue engineering", European Cells and Materials, 
vol. 1 0, Suppl.2, pp. 61. 
Ahmadi, R., Bums, AJ., & de Bruijn, J.D. 2009, "Chitosan-based hydro gels do not 
induce angiogenesis", Journal of Tissue Engineering and Regenerative Medicine. 
Reviewing Experience: 
Reviewer for Tissue Engineering and Journal of Tissue Engineering and 
Regenerative Medicine. 
185 
CONFERENCE PROCEEDINGS 
Oral Presentations: 
Oral presentation at World Biomaterials Congress 2008 entitled "Angiogenesis in 
chitosan-based injectable systems", Amsterdam, The Netherlands. 
2 Oral presentations at European Society for Biomaterials Conference (ESB) 2007 
entitled "Chitosan based delivery systems for injectable tissue engineered bone" and 
"Degradation and gelation behaviour of chitosan based delivery systems", Brighton, 
United Kingdom. 
Oral presentation at Tissue Engineering and Regenerative Medicine International 
Society (TERMIS) 2007 entitled "Chitosan based delivery systems for injectable 
tissue engineered bone: human mesenchymal stem cell survival, proliferation and 
osteogenic differentiation", London, United Kingdom. 
Oral presentation at 10M3 Materials Congress 2006 entitled "The use of thermo-
sensitive chitosan as an injectable carrier for bone tissue engineering", London, 
United Kingdom. 
Poster Presentations: 
Poster presentation at World Biomaterials Congress 2008 entitled "Osteogenesis of 
MC3T3-E1 cells is enhanced by chitosan-based polymeric system", Amsterdam, The 
Netherlands. 
Poster presentation at London Technology Network (L TN) 2007 entitled "(Bone) 
Tissue engineering and adult stem cell technology", London, United Kingdom. 
Poster presentation at European Society for Biomaterials Conference (ESB) 2005 
entitled "The use of thermo-sensitive chitosan as an injectable carrier for bone tissue 
engineering", Sorrento, Italy. 
186 
Poster presentation at Tissue and Cell Engineering Society (TCES) 2005 entitled 
"The use of thermo-sensitive chitosan as an injectable carrier for bone tissue 
engineering", London, United Kingdom. 
187 
REFERENCES 
Aiba S. 1 ~92, Studies on chitosan: 4. Lysozymic hydrolysis of partially N-acetylated 
chitosans, Int J Bioi Macromol, 14: 225-228. 
Akita S, T~ai N, Myoui A, Nishikawa M, Kaito T, Takaoka K, Yoshikawa H. 2004, 
CapIllary ves~el n~two.rk integration by inserting a vascular pedicle enhances 
bone fonna~Ion In yssue-engineered bone using interconnected porous 
hydroxyapatIte ceramICS, Tissue Eng, 10: 789-795. 
AI-Khaldi A, Eliopoulos N, Martineau D, Lejeune L, Lachapelle K, Galipeau J. 2003, 
Postnatal bone marrow stromal cells elicit a potent VEGF-dependent 
neoangiogenic response in vivo, Gene Ther, 10: 621-629. 
Altman GH, Horan RL, Martin I, Farhadi J, Stark PR, Volloch V, Richmond JC, 
Vunjak-Novakovic G, Kaplan DL. 2002, Cell differentiation by mechanical 
stress, Faseb J, 16: 270-272. 
Angennann P, Jepsen OB. 1991, Procurement, banking and decontamination of bone 
and collagenous tissue allografts: guidelines for infection control, J Hosp 
Infect, 17: 159-169. 
Ashton BA, Eaglesom CC, Bab I, Owen ME. 1984, Distribution of fibroblastic 
colony-fonning cells in rabbit bone marrow and assay of their osteogenic 
potential by an in vivo diffusion chamber method, Calcif Tissue Int, 36: 83-
86. 
Athanasiou KA, Zhu C, Lanctot DR, Agrawal CM, Wang X. 2000, Fundamentals of 
biomechanics in tissue engineering of bone, Tissue Eng, 6: 361-381. 
Auerbach R, Lewis R, Shinners B, Kubai L, Akhtar N. 2003, Angiogenesis assays: a 
critical overview, Clin Chem, 49: 32-40. 
Augst AD, Kong HJ, Mooney DJ. 2006, Alginate hydrogels as biomaterials, 
Macromol Biosci, 6: 623-633. 
Awwad HK, el Naggar M, Mocktar N, Barsoum M. 1986, Intercapillary distance 
measurement as an indicator of hypoxia in carcinoma of the cervix uteri, Int J 
Radiat Oncol Bioi Phys, 12: 1329-1333. 
Balk ML, Bray J, Day C, Epperly M, Greenberger J, Evans CH, Niyibizi C. 1997, 
Effect of rhBMP-2 on the osteogenic potential of bone marrow stromal cells 
from an osteogenesis imperfecta mouse (oim), Bone, 21: 7-15. 
Bancroft GN, Mikos AG. 2001, 'Bone tissue engineering by cell transplantation' in 
Tissue engineering for therapeutic use 5, eds. Ikada Y, Ohshima N, Elsevier 
Science, New York; 151-163. 
Banwart JC, Asher MA, Hassanein RS. 1995, Iliac crest bone graft harvest donor site 
morbidity. A statistical evaluation, Spine, 20: 1055-1060. . 
Baranowski TJ, Jr., Black J, Brighton CT, Friedenberg ZB. 1983, Electncal 
osteogenesis by low direct current, J Orthop Res, 1: 120-128.. . 
Bauer TW, Muschler GF. 2000, Bone graft materials. An overvIew of the baSIC 
science, Clin Orthop Relat Res: 10-27. . . 
Benelli R, Morini M, Carrozzino F, Ferrari N, Minghelh S, SantI L, Cassatella M, 
Noonan DM, Albini A. 2002, Neutrophils as a key cellular target for 
188 
angiostatin: implications for regulation of angiogenesis and inflammation 
Faseb J. 16: 267-269. ' 
Beresford IN, Bennett JH, Devlin C, Leboy PS Owen ME 1992 E ·d £ 
. I.. ,. ,VI ence or an lnver~e re atlonshlp between the differentiation of adipocytic and osteogenic 
cells l.n rat marrow stromal cell cultures, J Cell Sci, 102 ( Pt 2): 341-351. 
Berger J .. Relst M, Mayer JM, Felt 0, Gurny R. 2004, Structure and interactions in 
Chlt~S~ hydro gels formed by complexation or aggregation for biomedical 
apphcatlons, Eur J Ph arm Biopharm, 57: 35-52. 
Bernick S. Paule W, Ertl D, Nishimoto SK, Nimni ME. 1989, Cellular events 
associated with the induction of bone by demineralized bone J Orthon Res 7· 
1-11. ' y, . 
Bhardwaj R. Blanchard J. 1996, Controlled-release delivery system for the alpha-
MSH analog melanotan-I using poloxamer 407, J Pharm Sci, 85: 915-919. 
Biagini G. Pugnaloni A, Frongia G, Gazzanelli G, Lough C, Muzzarelli RAA. 1989, 
'N -Carboxymethyl chitosan induces neovascularization' in Chitin and 
Chitosan, eds. Skjak-Braek G, Anthonsen T, Sandford P, Elsevier Applied 
Science, London and New York; 671-677. 
Birrell F, Johnell 0, Silman A. 1999, Projecting the need for hip replacement over the 
next three decades: influence of changing demography and threshold for 
surgery, Ann Rheum Dis, 58: 569-572. 
Bobyn JD, Mortimer ES, Glassman AH, Engh CA, Miller JE, Brooks CEo 1992, 
Producing and avoiding stress shielding. Laboratory and clinical observations 
of noncemented total hip arthroplasty, Clin Orthop Relat Res: 79-96. 
Bolander ME, Balian G. 1986, The use of demineralized bone matrix in the repair of 
segmental defects. Augmentation with extracted matrix proteins and a 
comparison with autologous grafts, J Bone Joint Surg Am, 68: 1264-1274. 
Bolland BJ, Tilley S, New AM, Dunlop DG, Oreffo RO. 2007, Adult mesenchymal 
stem cells and impaction grafting: a new clinical paradigm shift, Expert Rev 
Med Devices, 4: 393-404. 
Bostman OM. 1991, Osteolytic changes accompanying degradation of absorbable 
fracture fixation implants, J Bone Joint Surg Br, 73: 679-682. 
Bostman OM, Paivarinta U, Partio E, Manninen M, Vasenius J, Majola A, Rokkanen 
P. 1992, The tissue-implant interface during degradation of absorbable 
polyglycolide fracture fixation screws in the rabbit femur, Clin Orthop Relat 
Res: 263-272. 
Braddock M, Houston P, Campbell C, Ashcroft P. 2001, Born again bone: tissue 
engineering for bone repair, News Physiol Sci, 16: 208-213. 
Brekke JH, Toth JM. 1998, Principles of tissue engineering applied to programmable 
osteogenesis, J Biomed Mater Res, 43: 380-398. 
Brighton CT, Cronkey JE, Osterman AL. 1976, In vitro epiphyseal-plate growth in 
various constant electrical fields, J Bone Joint Surg Am, 58: 971-978. 
Brighton CT, Friedenberg ZB. 1974, Electrical stimulation and oxygen tension, Ann 
NY Acad Sci, 238: 314-320. . 
Brodke D, Pedrozo HA, Kapur TA, Attawia M, Kraus KH, Holy CE, Kadlyaia S, 
Bruder SP. 2006, Bone grafts prepared with selective cell retention technology 
heal canine segmental defects as effectively as autograft, J Orthop Res, 24: 
857-866. . 
Brown KL, Cruess RL. 1982, Bone and cartilage transplantation in orthopaedIc 
surgery. A review, J Bone Joint Surg Am, 64: 270-279. 
189 
Buckwalter JA, Glimcher MJ Cooper RR Recker R 1995 B B' I J B 
Joint Surg. Am, 77: 1276 _ 1289.' " one IOOgy, . one 
Burg KJ. ~orte~ S, Kellam JF. 2000, Biomaterial developments for bone tissue 
engineenng, Biomaterials, 21: 2347-2359. 
Buttery LD, Bourne S, Xy?OS JD,. ~ood H, Hughes FJ, Hughes SP, Episkopou V, 
Polak JM. 2001, DIfferentIatIon of osteoblasts and in vitro bone formation 
fro~ murine embryonic stem cells, Tissue Eng, 7: 89-99. 
Calvo p, VIla-Jato JL. M.Alonso MJ. 1997, Evaluation of cationic polymer-coated 
nanocapsules as ocular drug carriers, Int J Pharm, 153: 41-50. 
Caplan ~1. 2005, ~eview: mesenchymal stem cells: cell-based reconstructive therapy 
In orthopedIcs, Tissue Eng, 11: 1198-1211. 
Caplan AI, Bruder SP. 2001, Mesenchymal stem cells: building blocks for molecular 
medicine in the 21 st century, Trends Mol Med, 7: 259-264. 
Carmeliet p, Jain RK. 2000, Angiogenesis in cancer and other diseases, Nature, 407: 
249-257. 
Casabona F, Martin I, Muraglia A, Berrino P, Santi P, Cancedda R, Quarto R. 1998, 
Prefabricated engineered bone flaps: an experimental model of tissue 
reconstruction in plastic surgery, Plast Reconstr Surg, 101: 577-581. 
Cattermole HR, Hardy JR, Gregg P J. 1996, The footballer's fracture, Br J Sports Med, 
30: 171-175. 
Chandy T, Sharma CPo 1990, Chitosan--as a biomaterial, Biomater Artif Cells Artif 
Organs, 18: 1-24. 
Chen G, Hoffman AS. 1995, Graft copolymers that exhibit temperature-induced 
phase transitions over a wide range of pH, Nature, 373: 49-52. 
Chen J, Li Y, Katakowski M, Chen X, Wang L, Lu D, Lu M, Gautam SC, Chopp M. 
2003, Intravenous bone marrow stromal cell therapy reduces apoptosis and 
promotes endogenous cell proliferation after stroke in female rat, J Neurosci 
Res, 73: 778-786. 
Cheng SL, Yang JW, Rifas L, Zhang SF, Avioli LV. 1994, Differentiation of human 
bone marrow osteogenic stromal cells in vitro: induction of the osteoblast 
phenotype by dexamethasone, Endocrinology, 134: 277-286. 
Chenite A, Buschmann MD, Wang D, Chaput C, Kandani N. 2001, Rheological 
characterisation of thermo gelling chitosanlglycerol-phosphate solutions, 
Carbohydrate Polymers 46: 39-47 
Chenite A, Chaput C, Combes C, Selmani A, Fayrouze J. 2002, Temperature-
controlled pH-dependent formation of ionic polysaccharide gels, United States 
Patent, Patent number: 6,344,488. 
Chenite A, Chaput C, Wang D, Combes C, Buschmann MD, Hoemann CD, Leroux 
JC, Atkinson BL, Binette F, Selmani A. 2000, Novel injectable neutral 
solutions of chitosan form biodegradable gels in situ, Biomaterials, 21: 2155-
2161. 
Chevrier A, Hoemann CD, Sun J, Buschmann MD. 2007, Chitosan-g~yce.rol 
phosphate/blood implants increase cell recruitme?t, transient vascularizatI.o~ 
and subchondral bone remodeling in drilled cartIlage defects, Osteoarthritis 
Cartilage, 15: 316-327. 
Cho J, Heuzey M, Begin A, Carreau P. 2006, Chitosan and gl~cero~hosphate 
concentration dependence of solution behaviour and gel pOInt USIng small 
amplitude oscillatory rheometry, Food Hydrocolloids, 20: 936-945 
190 
Cho MH, .Kim KS, Ahn I-:IH,. Kim MS, Kim SH, Khang G, Lee B, Lee HB. 2008, 
Chltosan g.el a~ an In sItu-forming scaffold for rat bone marrow mesenchymal 
stem cells In VIVO, Tissue Eng Part A, 14: 1099-1108. 
Choong CS. Hutmac~er DW, Triffitt JT. 2006, Co-culture of bone marrow fibroblasts 
and e~dot~ehal ce~ls on modified polycaprolactone substrates for enhanced 
potentI~ls In bone tIssue engineering, Tissue Eng, 12: 2521-2531. 
Civin CI, Tnschmann T,. Kadan NS, Davis J, Noga S, Cohen K, Duffy B, 
G~oenewe~en 1, WIley J, Law P, Hardwick A, Oldham F, Gee A. 1996, 
HIghly punfied CD34-positive cells reconstitute hematopoiesis J Clin Oncol 
1~: 2224-2233. ' , 
Collett J. Cra~ford A, H.atton PV, Geoghegan M, Rimmer S. 2007, Thermally 
responsIve polymerIC hydrogel brushes: synthesis, physical properties and use 
for the culture of chondrocytes, J R Soc Interface, 4: 117-126. 
Collis L. Hall C, Lange L, Ziebell M, Prestwich R, Turley EA. 1998, Rapid 
hyaluronan uptake is associated with enhanced motility: implications for an 
intracellular mode of action, FEBS Lett, 440: 444-449. 
Conget PA, Minguell JJ. 1999, Phenotypical and functional properties of human bone 
marrow mesenchymal progenitor cells, J Cell Physiol, 181: 67-73. 
Cook AD, Hrkach JS, Gao NN, Johnson 1M, Pajvani DB, Cannizzaro SM, Langer R. 
1997, Characterization and development of RGD-peptide-modified poly(lactic 
acid-co-Iysine) as an interactive, resorbable biomaterial, J Biomed Mater Res, 
35: 513-523. 
Couto DS, Hong Z, Mano JF. 2009, Development of bioactive and biodegradable 
chitosan-based injectable systems containing bioactive glass nanoparticles, 
Acta Biomater, 5: 115-123. 
Crompton KE, Prankerd RJ, Paganin DM, Scott TF, Home MK, Finkelstein DI, 
Gross KA, Forsythe JS. 2005, Morphology and gelation of thermo sensitive 
chitosan hydrogels, Biophys Chem, 117: 47-53. 
Czyz J, Wiese C, Rolletschek A, Blyszczuk P, Cross M, Wobus AM. 2003, Potential 
of embryonic and adult stem cells in vitro, Bioi Chem, 384: 1391-1409. 
D'Ippolito G, Schiller PC, Ricordi C, Roos BA, Howard GA. 1999, Age-related 
osteogenic potential of mesenchymal stromal stem cells from human vertebral 
bone marrow, J Bone Miner Res, 14: 1115-1122. 
Daculsi G. 1998, Biphasic calcium phosphate concept applied to artificial bone, 
implant coating and injectable bone substitute, Biomaterials, 19: 1473-1478. 
Daculsi G, LeGeros RZ, Nery E, Lynch K, Kerebel B. 1989, Transformation of 
biphasic calcium phosphate ceramics in vivo: ultrastructural and 
physicochemical characterization, J Biomed Mater Res, 23:.883-894. . 
Damien CJ, Parsons JR. 1991, Bone graft and bone graft substItutes: a reVIew of 
current technology and applications, J Appl Biomater, 2: 187-208. 
Datamonitor-Publications, 2002. Market Dynamics: Bone Substitutes and Growth 
Factors; Can BMPs Become the New Gold Standard? Ref. Code DMHC 
1812. 
Davies A, Blakeley A, Kidd C. 2001, Human Physiology, Churchill Livingstone, 
ISBN 0443 045593: 762. 
De Bari C, Dell'Accio F, Tylzanowski P, Luyten FP. 2001, Multipotent mesenchymal 
stem cells from adult human synovial membrane, Arthritis Rheum, 44: 1928-
1942. 
191 
de Brui~n JD. 1?93, Calci~m phosphate biomaterials: bone-bonding and 
bIodegradatIon propertIes, PhD thesis. Leiden University Leiden The 
Netherlands. ' , 
de Castro.-~ernas ~C. 2003, Angiotherapeutics from natural products: from bench to 
chnIcs? Clzn Hemorheol Microcirc, 29: 199-203. 
de Groot K, Geesi~ R, Klein CPAT, Serekian P. 1987, Plasma sprayed coatings of 
hydroxyapatIte, J Biomed Mater Res, 21: 1375-1381. 
de Vernejoul ~C. ~ 996, ~ynamics of bone remodelling: biochemical and 
pathophYSIologIcal basIs, Eur J Clin Chem Clin Biochem, 34: 729-734. 
Deckers MM, Karperien M, van der Bent C, Yamashita T, Papapoulos SE, Lowik 
CWo 2000, Expression of vascular endothelial growth factors and their 
. receptors during osteoblast differentiation, Endocrinology, 141: 1667-1674. 
DesaI SD, Blanchard 1. 1998, In vitro evaluation of pluronic F127-based controlled-
release ocular delivery systems for pilocarpine, J Pharm Sci, 87: 226-230. 
Dimitropoulou C, Malkusch W, Fait E, Maragoudakis ME, Konerding MA. 1998, 
The vascular architecture of the chick chorioallantoic membrane: sequential 
quantitative evaluation using corrosion casting, Angiogenesis, 2: 255-263. 
Dinarvand R, D'Emanuel A. 1995, The use of thermoresponsive hydrogels for on-off 
release of molecules, J Control Release, 36: 221-227. 
Dong J, Uemura T, Shirasaki Y, Tateishi T. 2002, Promotion of bone formation using 
highly pure porous beta-TCP combined with bone marrow-derived 
osteoprogenitor cells, Biomaterials, 23: 4493-4502. 
Druecke D, Langer S, Lamme E, Pieper J, Ugarkovic M, Steinau HU, Homann HH. 
2004, Neovascularization of poly( ether ester) block-copolymer scaffolds in 
vivo: long-term investigations using intravital fluorescent microscopy, J 
Biomed Mater Res A, 68: 10-18. 
Dupraz A, Delecrin J, Moreau A, Pilet P, Passuti N. 1998, Long-term bone response 
to particulate injectable ceramic, J Biomed Mater Res, 42: 368-375. 
Dupraz A, Nguyen TP, Richard M, Daculsi G, Passuti N. 1999, Influence of a 
cellulosic ether carrier on the structure of biphasic calcium phosphate ceramic 
particles in an injectable composite material, Biomaterials, 20: 663-673. 
Eggli PS, Muller W, Schenk RK. 1988, Porous hydroxyapatite and tricalcium 
phosphate cylinders with two different pore size ranges implanted in the 
cancellous bone of rabbits. A comparative histomorphometric and histologic 
study of bony ingrowth and implant substitution, Clin Orthop Relat Res: 127-
138. 
Elisseeff J, Puleo C, Yang F, Sharma B. 2005, Advances in skeletal tissue 
engineering with hydrogels, Orthod Craniofac Res, 8: 150-161. 
Ema H, Suda T, Nakauchi H, Nakamura Y, Iwama A, Imagawa S, Akutsu M, Kano 
Y, Kato S, Yabe M, et al. 1991, Multipotent and committed CD34+ cells in 
bone marrow transplantation, Jpn J Cancer Res, 82: 547-552. 
Enneking WF, Eady JL, Burchardt H. 1980, Autogenous cortical bone grafts in the 
reconstruction of segmental skeletal defects, J Bone Joint Surg Am, 62: 1039-
1058. 
Erbe EM, Marx JG, Clineff TD, Bellincampi LD. 2001, Potential of an ultraporous 
beta-tricalcium phosphate synthetic cancellous bone void filler and bone 
marrow aspirate composite graft, Eur Spine J, 10 Suppl2: S141-146. 
Evans CE, Galasko CS, Ward C. 1990, Effect of donor age on the growth in vitro of 
cells obtained from human trabecular bone, J Orthop Res, 8: 234-237. 
192 
Farrell E, Byrne EM, Fische~ J, O'Brien FJ, O'Connell BC, Prendergast PJ, Campbell 
V A. 2007, A comp~nson of the osteogenic potential of adult rat mesenchymal 
stem cells cultured In 2-D and on 3-D collagen glycosaminoglycan scaffolds 
Technol Health Care, 15: 19-31. ' 
Fawcett ~~, Raviola E. 1994, Bloom and Fawcett, A textbook of histology, 12th 
edItIon ed. Chapman and Hall. 
Felt 0, C~el A, Baehni P, Buri P, Gumy R. 2000, Chitosan as tear substitute: a 
wettIng agent endowed with antimicrobial efficacy J Ocul Pharmacol Ther 
16: 261-270. " 
Felt 0, F~rrer ~, Mayer JM, Plazonnet B, Buri P, Gumy R. 1999, Topical use of 
chitosan In ophthalmology: tolerance assessment and evaluation of precorneal 
retention, Int J Pharm, 180: 185-193. 
Ferrari G, ~l~sella-De Angelis G, Coletta M, Paolucci E, Stomaiuolo A, Cossu G, 
MavIho F. 1998, Muscle regeneration by bone marrow-derived myogenic 
progenitors, SCience, 279: 1528-1530. 
Filgueiras MR, La Torre G, Hench LL. 1993, Solution effects on the surface reactions 
of a bioactive glass, J Biomed Mater Res, 27: 445-453. 
Fischer EM, Layrolle P, Van Blitterswijk CA, De Bruijn JD. 2003, Bone formation 
by mesenchymal progenitor cells cultured on dense and microporous 
hydroxyapatite particles, Tissue Eng, 9: 1179-1188. 
Folkman J, Shing Y. 1992, Angiogenesis, J Bioi Chem, 267: 10931-10934. 
Fraser JR, Laurent TC, Laurent UB. 1997, Hyaluronan: its nature, distribution, 
functions and turnover, J Intern Med, 242: 27-33. 
Frayssinet P, Trouillet JL, Rouquet N, Azimus E, Autefage A. 1993, Osseointegration 
of macroporous calcium phosphate ceramics having a different chemical 
composition, Biomaterials, 14: 423-429. 
Fredericks DC, Bobst JA, Petersen EB, Nepola JV, Dennis JE, Caplan AI, Burgess 
A V, Overby RJ, Schulz OH. 2004, Cellular interactions and bone healing 
responses to a novel porous tricalcium phosphate bone graft material, 
Orthopedics, 27: sI67-173. 
Freed LE, Vunjak-Novakovic G, Biron RJ, Eagles DB, Lesnoy DC, Barlow SK, 
Langer R. 1994, Biodegradable polymer scaffolds for tissue engineering, 
Biotechnology (N J), 12: 689-693. 
Friedenberg ZB, Brighton CT. 1974, Electrical fracture healing, Ann N Y Acad Sci, 
238: 564-574. 
Friedenstein AJ, Chailakhjan RK, Lalykina KS. 1970, The development of fibroblast 
colonies in monolayer cultures of guinea-pig bone marrow and spleen cells, 
Cell Tissue Kinet, 3: 393-403. 
Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV. 
1974 Stromal cells responsible for transferring the microenvironment of the 
, . . . 
hemopoietic tissues. Cloning in vitro and retransplantatlon In VIVO, 
Transplantation, 17: 331-340. . . 
Friedenstein AJ, Piatetzky S, II, Petrakova KV. 1966, OsteogenesIs In transplants of 
bone marrow cells J Embryol Exp Morphol, 16: 381-390. 
Furumatsu T Shen ZN 'Kawai A, Nishida K, Manabe H, Oohashi T, Inoue H, 
Nino~iya Y. 2003, Vascular endothelial growth factor principally acts a~ the 
main angiogenic factor in the early stage of human osteoblastogenesIs, J 
Biochem, 133: 633-639. 
193 
Ganji F, ~bdekhodaie ~J, Ramazani A. 2007, Gelation time and degradation rate of 
. chltosan-based Injectable hydrogel, J Sol-Gel Sci Techn 42' 47-53 
GauthIer 0, B~i~ D, Griman~i G, Aguado E, Bouler JM, Weis~ P, Daculsi G. 1999-b, 
A new .lnJectable calclu~ P?osphate biomaterial for immediate bone filling of 
. extractIon sockets: a p.rehmlnary study in dogs, J Periodontol, 70: 375-383. 
GauthIer 0, Bouler JM, WeIss P Bosco J Daculsi G Aguado E 1999 K' . 
, . ' , , . -a, InetIc ~tudy of. bone Ingrowth and ceramic resorption associated with the 
l~plantatIon of different injectable calcium-phosphate bone substitutes, J 
Blomed Mater Res, 47: 28-35. 
Gepstein L. 2002, Derivation and potential applications of human embryonic stem 
cells. eirc Res, 91: 866-876. 
Gitelis S, Saiz P. 2002, What's new in orthopaedic surgery J Am Coli Surg 194: 788-
791. " 
Glowacki J, Mizuno S, Greenberger JS. 1998, Perfusion enhances functions of bone 
marrow stromal cells in three-dimensional culture, Cell Transnlant 7: 319-
326. r , 
Goldstein AS, Juarez TM, Helmke CD, Gustin MC, Mikos AG. 2001, Effect of 
convection on osteoblastic cell growth and function in biodegradable polymer 
foam scaffolds, Biomaterials, 22: 1279-1288. 
Goldstein SA. 2002, Tissue engineering: functional assessment and clinical outcome, 
Ann N Y Acad Sci, 961: 183-192. 
Gotherstrom C, Ringden 0, Westgren M, Tammik C, Le Blanc K. 2003, 
Immunomodulatory effects of human foetal liver-derived mesenchymal stem 
cells, Bone Marrow Transplant, 32: 265-272. 
Grimandi G, Weiss P, Millot F, Daculsi G. 1998, In vitro evaluation of a new 
injectable calcium phosphate material, J Biomed Mater Res, 39: 660-666. 
Gundle R, Joyner CJ, Triffitt JT. 1995, Human bone tissue formation in diffusion 
chamber culture in vivo by bone-derived cells and marrow stromal fibroblastic 
cells, Bone, 16: 597-601. 
Guo YL, Wang S, Colman RW. 2001, Kininostatin, an angiogenic inhibitor, inhibits 
proliferation and induces apoptosis of human endothelial cells, Arterioscler 
Thromb Vasc Bioi, 21: 1427-1433. 
Hardwick C, Hoare K, Owens R, Hohn HP, Hook M, Moore D, Cripps V, Austen L, 
Nance DM, Turley EA. 1992, Molecular cloning of a novel hyaluronan 
receptor that mediates tumor cell motility, J Cell Bioi, 117: 1343-1350. 
Hardy RR, Malissen B. 1998, Lymphocyte development. The (knock-) ins and outs of 
lymphoid development, Curr Opin Immunol, 10: 155-157. 
Harlan D M, Kirk AD. 1999, The future of organ and tissue transplantation: can T-cell 
costimulatory pathway modifiers revolutionize the prevention of graft 
rejection?, Jama, 282: 1076-1082. . . 
Haynesworth SE, Goshima J, Goldberg VM, Caplan AI. 1992, Charactenzatlon of 
cells with osteogenic potential from human marrow, Bone, 13: 81-88. 
Hee CK, Jonikas MA, Nicoll SB. 2006, Influence of three-dimensional scaffold on 
the expression of osteogenic differentiation markers by human dermal 
fibroblasts, Biomaterials, 27: 875-884. 
Hench LL Wilson 1. 1984 Surface-active biomaterials, Science, 226: 630-636. 
Heng BC,' Cao T, Stanton'LW, Robson P, Olsen B. ~OO~, Strat.egi~s for directing. the 
differentiation of stem cells into the osteogenic hneage In vItro, J Bone Mzner 
Res, 19: 1379-1394. 
194 
Henry JB. 1991, Clinical Diagnosis and Management by Laboratory Meth d ,18th 
ed. ed. Saunders: Philadelphia. 0 s 
Hirano S, ~oishiki Y. 1985, The blood compatibility of chitosan and N-acylchitosans 
J Blomed Mater Res, 19: 413-417. ' 
Hoemann CD, Chenite A, Sun J, Hurtig M, Serreqi A, Lu Z, Rossomacha E, 
Buschmann MI? 2007, Cytocompatible gel formation of chitosan-glycerol 
phosphate solutIons supplemented with hydroxyl ethyl cellulose is due to the 
presence of glyoxal, J Biomed Mater Res A, 83: 521-529. 
Hoemann CD, Sun J, C~zanowski V, Buschmann MD. 2002, A multivalent assay to 
de.te~t glycosaminoglycan, protein, collagen, RNA, and DNA content in 
mIlhgram samples of cartilage or hydrogel-based repair cartilage Anal 
Biochem,300: 1-10. ' 
Hoemann CD, Sun J, Legare A, McKee MD, Buschmann MD. 2005, Tissue 
engineering of cartilage using an injectable and adhesive chitosan-based cell-
delivery vehicle, Osteoarthritis Cartilage, 13: 318-329. 
Holy CE, JFialkov JA, Schoichet MS, Davies JE. 2000, 'In vivo models for bone 
tissue engineering constructs' in Bone engineering eds. Davies JE, em squared 
incorporated, Toronto; 496-504. 
Howling GI, Oettmar PW, Goddard PA, Hampson FC, Domish M, Wood EJ. 2001, 
The effect of chitin and chitosan on the proliferation of human skin fibroblasts 
and keratinocytes in vitro, Biomaterials, 22: 2959-2966. 
Huang Y, Onyeri S, Siewe M, Moshfeghian A, Madihally SV. 2005-a, In vitro 
characterization of chitosan-gelatin scaffolds for tissue engineering, 
Biomaterials, 26: 7616-7627. 
Huang YC, Kaigler 0, Rice KG, Krebsbach PH, Mooney DJ. 2005-b, Combined 
angiogenic and osteogenic factor delivery enhances bone marrow stromal cell-
driven bone regeneration, J Bone Miner Res, 20: 848-857. 
Hutmacher OW, Goh JC, Teoh SH. 2001, An introduction to biodegradable materials 
for tissue engineering applications, Ann A cad Med Singapore, 30: 183-191. 
In 't Anker PS, Scherjon SA, Kleijburg-van der Keur C, Noort WA, Claas FH, 
Willernze R, Fibbe WE, Kanhai HH. 2003, Amniotic fluid as a novel source 
of mesenchymal stem cells for therapeutic transplantation, Blood, 102: 1548-
1549. 
Inui H, Tsujikubo M, Hirano S. 1995, Low molecular weight chitosan stimulation of 
mitogenic response to platelet-derived growth factor in vascular smooth 
muscle cells, Bioscience, biotechnology, and biochemistry, 59: 2111-2114 
Ishaug SL, Payne RG, Yaszemski MJ, Aufdemorte TB, Bizios R, Mikos AG. 1996, 
Osteoblast migration on poly(alpha-hydroxy esters), Biotechnol Bioeng, 50: 
443-451. 
Ishikawa K, Ueyama Y, Mano T, Koyama T, Suzuki K, Matsu~ura T. 1999,. S.e~f­
setting barrier membrane for guided tissue regeneratIon method: I~tIal 
evaluation of alginate membrane made with sodium alginate and calcIum 
chloride aqueous solutions, J Biomed Mater Res, 47: 111-115. 
Jaiswal N, Haynesworth SE, Caplan AI, Bruder SP. 1997, Osteogenic.dif~erentiation 
of purified, culture-expanded human mesenchymal stem cells In VItro, J Cell 
Biochem, 64: 295-312. 
Jarcho M. 1981, Calcium phosphate ceramics as hard tissue prosthetics, Clin Orthop 
Relat Res: 259-278. 
195 
Jarcho M .. 19~6, Biomaterial aspects of calcium phosphates. Properties and 
applIcahons, Dent Clin North Am, 30: 25-47. 
Jarcho M, Kay JF, Gumaer KI Doremus RH Drobeck HP 1977 T' 11 1 d 
' , " Issue, ce u ar an 
subcellular events at a bone-ceramic hydroxylapatite interface J Bioeng l' 
79-92. ' , . 
Jarry C, Chaput C, ~h.eni~e A, Renaud MA, Buschmann M, Leroux JC. 2001, Effects 
of steam stenhzahon on thermogelling chitosan-based gels, J Biomed Mater 
Res, 58: 127-135. 
Jeong ~'. Bae YH, Lee DS, Kim SW. 1997, Biodegradable block copolymers as 
Injectable drug-delivery systems, Nature, 388: 860-862. 
Jeong B, <?ut~wska .A. 200~, L~ssons from nature: stimUli-responsive polymers and 
then bIomedIcal applIcahons, Trends in biotechnology, 20: 305-311. 
Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, 
Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low 
WC, Largaespada DA, Verfaillie CM. 2002-a, Pluripotency of mesenchymal 
stem cells derived from adult marrow, Nature, 418: 41-49. 
Jiang Y. Vaessen B, Lenvik T, Blackstad M, Reyes M, Verfaillie CM. 2002-b, 
Multipotent progenitor cells can be isolated from postnatal murine bone 
marrow, muscle, and brain, Exp Hematol, 30: 896-904. 
Jilka RL. 2003, Biology of the basic multicellular unit and the pathophysiology of 
osteoporosis, Med Pediatr Oncol, 41: 182-185. 
Johansson G, Persson C. 2003, Development of injectable formulations of tissue-
engineered bone, Master's Thesis. Chalmers University of Technology, 
Goteborg, Sweden. 
Johnston TP, Miller SC. 1989, Inulin disposition following intramuscular 
administration of an inulinlpoloxamer gel matrix, Journal of parenteral 
science and technology 43: 279-286 
Johnston TP, Punjabi MA, Froelich CJ. 1992, Sustained delivery of interleukin-2 
from a poloxamer 407 gel matrix following intraperitoneal injection in mice, 
Pharm Res, 9: 425-434. 
Jukes JM, Both SK, Leusink A, Sterk LM, van Blitterswijk CA, de Boer J. 2008, 
Endochondral bone tissue engineering using embryonic stem cells, Proc Natl 
A cad Sci USA, 105: 6840-6845. 
Junqueira LC, Carneiro J, Kelley RO. 1998, Basic Histology, 9th edition ed. Appleton 
and Lange. 
Kaigler D, Krebsbach PH, Polverini PJ, Mooney DJ. 2003, Role of v~scular 
endothelial growth factor in bone marrow stromal cell modulatIon of 
endothelial cells, Tissue Eng, 9: 95-103. 
Kamihata H, Matsubara H, Nishiue T, Fujiyama S, Tsutsumi Y, Ozono R, ~asak~ H, 
Mori Y, Iba 0, Tateishi E, Kosaki A, Shintani S, Murohara T, ImaIzum~ T, 
Iwasaka T. 2001, Implantation of bone marrow monon.uclear cel~s In~o 
ischemic myocardium enhances collateral perfusion and reg~onal ~ctIon .VIa 
side supply of angioblasts, angiogenic ligands, and cytokines, CirculatIOn, 
104: 1046-1052. 
Karageorgiou V, Kaplan D. 2005, Porosity of 3D biomaterial scaffolds and 
osteogenesis Biomaterials, 26: 5474-5491. 
Kasper M, Roehlecke C, Witt M, Fehrenbach H, Hofer A, ~iyata T, Weige~ C, Funk 
RH, Schleicher ED. 2000, Induction of apoptoslS by glyoxal In human 
196 
:~~ryonic lung epithelial cell line L132, Am J Respir Cell Mol Bioi, 23: 485-
Kawaguchi J, Mee .PJ, Smith A? 2005, Osteogenic and chondrogenic differentiation ~~;~bryomc stem cells m response to specific growth factors, Bone, 36: 758-
Khor E, Lim L Y. 2003, Implantable applications of chitin and chitosan Biomaterials 
24: 2339-2349. ' , 
Kim KS, Lee J~, A~ HH,. L~e JY, Khang G, Lee B, Lee HB, Kim MS. 2008, The 
osteogenIc dIfferentIatIon of rat muscle-derived stem cells in vivo within in 
situ-forming chitosan scaffolds, Biomaterials, 29: 4420-4428. 
Kim WS., K~m HK. 2005, Tissue engineered vascularized bone formation using in 
VIVO Implanted osteoblast-polyglycolic acid scaffold, J Korean Med Sci 20: 
479-482. ' 
Kim YS, Lim JY, Donahue HJ, Lowe TL. 2005, Thermoresponsive terpolymeric 
films applicable for osteoblastic cell growth and noninvasive cell sheet 
harvesting, Tissue Eng, 11: 30-40. 
Kinnaird T, Stabile E, Burnett MS, Lee CW, Barr S, Fuchs S, Epstein SE. 2004, 
Marrow-derived stromal cells express genes encoding a broad spectrum of 
arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through 
paracrine mechanisms, Cire Res, 94: 678-685. 
Klein CPo Driessen AA, de Groot K, van den Hooff A. 1983, Biodegradation 
behavior of various calcium phosphate materials in bone tissue, J Biomed 
Mater Res, 17: 769-784. 
Klein CP, Patka P, den Hollander W. 1989, Macroporous calcium phosphate 
bioceramics in dog femora: a histological study of interface and 
biodegradation, Biomaterials, 10: 59-62. 
Klokkevold PR, Vandemark L, Kenney EB, Bernard GW. 1996, Osteogenesis 
enhanced by chitosan (poly-N-acetyl glucosaminoglycan) in vitro, J 
Periodontol, 67: 1170-1175. 
Knabe C, Driessens FC, Planell JA, Gildenhaar R, Berger G, Reif D, Fitzner R, 
Radlanski RJ, Gross U. 2000, Evaluation of calcium phosphates and 
experimental calcium phosphate bone cements using osteogenic cultures, J 
Biomed Mater Res, 52: 498-508. 
Kneser U, Kaufmann PM, Fiegel HC, Pollok JM, Kluth D, Herbst H, Rogiers X. 
1999, Long-term differentiated function of heterotopically transplanted 
hepatocytes on three-dimensional polymer matrices, J Biomed Mater Res, 47: 
494-503. 
Kneser U, Voogd A, Ohnolz J, Buettner 0, Stangenberg L, Zhang YH, Stark GB, 
Schaefer DJ. 2005, Fibrin gel-immobilized primary osteoblasts in calcium 
phosphate bone cement: in vivo evaluation with regard to application as 
injectable biological bone substitute, Cells Tissues Organs, 179: 158-169. 
Knowledge-Enterprises, 1998. Overview of the US joint replacement market. Inc. 
Publications. 
Knowledge-Enterprises, 2002. The Worldwide Orthopaedic Market-2001-2002. Inc. 
Publications. 
Kokubo T. 1991, Bioactive glass ceramics: properties and applications, Biomaterials, 
12: 155-163. 
Krebsbach PH, Kuznetsov SA, Satomura K, Emmons RV, Rowe. DW, Robey PG. 
1997, Bone formation in vivo: comparison of osteogenesIs by transplanted 
197 
~~~~e and human marrow stromal fibroblasts, Transplantation, 63: 1059-
Kruyt Me, de Bruijn 10, .Wilson CE, ~ner FC, van B1itterswijk CA, Verbout AJ, 
Dhert. WJ. 2003, V~abl~ osteogenIc cells are obligatory for tissue-engineered 
ectopIc bo~~ formatIon In goats, Tissue Eng, 9: 327-336. 
Kruyt MC, de Bru1Jn JD, Yuan H, van Blitterswijk CA Verbout AJ Oner FC Dhert 
WJ. ?004-a, Optimization of bone tissue engin:ering in goais: a pero;erative see~Ing method using cryopreserved cells and localized bone formation in 
CalCIum phosphate scaffolds, Transplantation, 77: 359-365. 
Kruyt MC. D~e~ W!, Oner C, van Blitterswijk CA, Verbout AJ, de Bruijn JD. 2004-
b. OptImIzatIon of bone-tissue engineering in goats, J Biomed Mater Res B 
Appl Biomater, 69: 113-120. 
Kruyt ~~. Persson C, Johansson G, Dhert WJ, de Bruijn JD. 2006, Towards 
Injectable cell-based tissue-engineered bone: the effect of different calcium 
phosphate microparticles and pre-culturing, Tissue Eng, 12: 309-317. 
Lane JM. Sandhu HS. 1987, Current approaches to experimental bone grafting, 
Orthop Clin North Am, 18: 213-225. 
Lane JM. Tomin E, Bostrom MP. 1999, Biosynthetic bone grafting, Clin Orthop 
Relat Res: SI07-117. 
Langer R, Vacanti JP. 1993, Tissue engineering, Science, 260: 920-926. 
Laschke MW, Menger MD. 2007, In vitro and in vivo approaches to study 
angiogenesis in the pathophysiology and therapy of endometriosis, Hum 
Reprod Update, 13: 331-342. 
Lawson MA, Barralet JE, Wang L, Shelton RM, Triffitt JT. 2004, Adhesion and 
growth of bone marrow stromal cells on modified alginate hydro gels, Tissue 
Eng~ 10: 1480-1491. 
Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. 2003, 
Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and 
mitogenic responses independently of the major histocompatibility complex, 
Scand J Immunol, 57: 11-20. 
Leach JK, Kaigler D, Wang Z, Krebsbach PH, Mooney DJ. 2006, Coating ofVEGF-
releasing scaffolds with bioactive glass for angiogenesis and bone 
regeneration, Biomaterials, 27: 3249-3255. 
Lee OK, Kuo TK, Chen WM, Lee KD, Hsieh SL, Chen TH. 2004, Isolation of 
multipotent mesenchymal stem cells from umbilical cord blood, Blood, 103: 
1669-1675. 
Lewandrowski KU, Gresser JD, Wise DL, Trantol DJ. 2000, Bioresorbable bone graft 
substitutes of different osteoconductivities: a histologic evaluation of 
osteointegration of poly(propylene glycol-co-fumaric acid)-based cement 
implants in rats, Biomaterials, 21: 757-764. . 
Li J, Xu Z. 2002, Physical characterization of a chitosan-based hydrogel dehvery 
system, J Pharm Sci, 91: 1669-1677. ... 
Li Z, Ramay HR, Hauch KD, Xiao D, Zhang M. 2005, Chitosan-aiginate hybnd 
scaffolds for bone tissue engineering, Biomaterials, 26: 3919-3928. 
Lindenhayn K, Perka C, Spitzer R, Heilmann. H, :o~er.ening K, Mennicke J, 
Sittinger M. 1999, Retention of hyaluronIC aCId In algInate beads: aspects for 
in vitro cartilage engineering, J Biomed Mater Res, 44: 149-155. 
198 
Liu G. Zhao L Zhang W Cui L L' W C Y 
. tl b" ,IU, ao . 2008, Repair of goat tibial defects '7~ lone marrow stromal cells and beta-tricalcium phosphate J Mater Sci 
lHater Med, 19: 2367-2376. ' 
Luginbuehl V. Wenk E, Koch.A, G~der B, Merkle HP, Meinel L. 2005, Insulin-like 
growth f~ctor I-releasIng aiginate-tricalciumphosphate composites for bone 
regeneratIon, Ph arm Res, 22: 940-950. 
Luo Y. Kirker. KR: ,~restwich GD. 2001, 'Modification of natural polymers: 
hyaluro~Ic aCid In Methods of Tissue Engineering, eds. Atala A Lanza RP 
AcademIc Press,539-553. ' , 
Malard 0, Bouler JM, ~uicheux J, Heymann D, Pilet P, Coquard C, Daculsi O. 1999, 
Int1ue?ce of bI?hasic c~lcium phosphate granulometry on bone ingrowth, 
c~ranl1c resorptIon, and Int1ammatory reactions: preliminary in vitro and in 
VIVO study. J Biomed Mater Res, 46: 103-111. 
Malette :VG. Quigley HJ, Adickes ED. 1986, 'Chitosan Effect in Vascular Surgery, 
TIssue Culture.and Tissue Regeneration' in Chitin in Nature and Technology, 
eds. Muzzarelh R, Jeuniaux C, Oooday OW, Plenum Press New York 435-
442. ' , 
Maniatopoulos C, Sodek J, Melcher AH. 1988, Bone formation in vitro by stromal 
cells obtained from bone marrow of young adult rats, Cell Tissue Res, 254: 
317-330. 
Mankani MH, Kuznetsov SA, Fowler B, Kingman A, Robey PO. 2001, In vivo bone 
fonnation by human bone marrow stromal cells: effect of carrier particle size 
and shape, Biotechnol Bioeng, 72: 96-107. 
Marcacci M, Kon E, Moukhachev V, Lavroukov A, Kutepov S, Quarto R, 
Mastrogiacomo M, Cancedda R. 2007, Stem cells associated with 
macroporous bioceramics for long bone repair: 6- to 7 -year outcome of a pilot 
clinical study, Tissue Eng, 13: 947-955. 
Marks MG, Shi J, Fry MO, Xiao Z, Trzyna M, Pokala V, Ihnat MA, Li PK. 2002, 
Effects of putative hydroxylated thalidomide metabolites on blood vessel 
density in the chorioallantoic membrane (CAM) assay and on tumor and 
endothelial cell proliferation, Bioi Pharm Bull, 25: 597-604. 
Martin I, Muraglia A, Campanile 0, Cancedda R, Quarto R. 1997, Fibroblast growth 
factor-2 supports ex vivo expansion and maintenance of osteogenic precursors 
from human bone marrow, Endocrinology, 138: 4456-4462. 
Meijer GJ, de Bruijn JD, Koole R, van Blitterswijk CA. 2008, Cell based bone tissue 
engineering in jaw defects, Biomaterials, 29: 3053-3061. 
Mendes SC. 2002, Cultured bone on biomaterial substrates: a tissue engineering 
approach to treat bone defects, PhD thesis. University of Twente, the 
Netherlands. 
Mendes SC, Sleijster M, Van Den Muysenberg A, De Bruijn JD, Van Blitterswijk 
CA. 2002-a, A cultured living bone equivalent enhances bone formation when 
compared to a cell seeding approach, J Mater Sci Mater Med, 13: 575-581. 
Mendes SC, Tibbe JM, Veenhof M, Bakker K, Both S, Platenburg PP, Oner FC, de 
Bruijn JD, van Blitterswijk CA. 2002-b, Bone tissue-engineere~ .implants 
using human bone marrow stromal cells: effect of culture condItIons and 
donor age, Tissue Eng, 8: 911-920. .... 
Mendes SC, Tibbe JM, Veenhof M, Both S, Oner FC, van BlitterswIJ~ CA, de ~ruIJn 
JD. 2004, Relation between in vitro and in vivo osteogenIC potentIal of 
199 
~~~~ed human bone marrow stromal cells, J Mater Sci Mater Med, 15: 1123-
Middletdon .JC, Ti.pton A!. 2000, Synthetic biodegradable polymers as orthopedic 
eVIces, Blomaterzals, 21: 2335-2346 
Miller WJ, Kayton ML, Patton A O'Connor'S He M Vu H B 'bak G L D 
. ' , .' ,aI ov , orang , ~eze:lc V. Kohn E, Alexander HR, StIrling D, Payvandi F, Muller GW 
LIbu~h SK. 200~, A novel technique for quantifying changes in vascula; 
denSIty. endotheh~l cell ~roli~eration and protein expression in response to 
modulators of angIogenesIs USIng the chick chorioallantoic membrane (CAM) 
assay, J Transl Med, 2: 4. 
Mistry A~. Mikos AG. 2005, Tissue engineering strategies for bone regeneration, Adv 
Blochem Eng Biotechnol, 94: 1-22. 
Miyazaki S, Suisha F, Kawasaki N, Shirakawa M, Yamatoya K, Attwood D. 1998, 
Thermally reversible xyloglucan gels as vehicles for rectal drug delivery, J 
Control Release, 56: 75-83. 
Mochizuki M, Philp D, Hozumi K, Suzuki N, Yamada Y, Kleinman HK, Nomizu M. 
2007. Angiogenic activity of syndecan-binding laminin peptide AG73 
(RKRLQVQLSIRT), Arch Biochem Biophys, 459: 249-255. 
Molinaro G. Leroux JC, Damas J, Adam A. 2002, Biocompatibility of 
thermo sensitive chitosan-based hydrogels: an in vivo experimental approach 
to injectable biomaterials, Biomateria/s, 23: 2717-2722. 
Montembault A, Viton C, Domard A. 2005, Rheometric study of the gelation of 
chitosan in a hydroalcoholic medium, Biomateria/s, 26: 1633-1643. 
Montjovent MO, Mathieu L, Hinz B, Applegate LL, Bourban PE, Zambelli PY, 
Manson JA, Pioletti DP. 2005, Biocompatibility of bioresorbable poly(L-
lactic acid) composite scaffolds obtained by supercritical gas foaming with 
human fetal bone cells, Tissue Eng, 11: 1640-1649. 
Mori T, Okumura M, Matsuura M, Deno K, Tokura S, Okamoto Y, Minami S, 
Fujinaga T. 1997, Effects of chitin and its derivatives on the proliferation and 
cytokine production of fibroblasts in vitro, Biomateria/s, 18: 947-951. 
Moshfeghian A, Tillman J, Madihally SV. 2006, Characterization of emulsified 
chitosan-PLGA matrices formed using controlled-rate freezing and 
lyophilization technique, J Biomed Mater Res A, 79: 418-430. 
Mueller SM, Glowacki 1. 2000, 'Construction and regulation of 3-dimensional bone 
tissue in vitro' in Bone Engineering, eds. Davies JE, Toronto: em squared 
incorporated, Toronto; 473-487. 
Mueller SM, Mizuno S, Gerstenfeld LC, Glowacki 1. 1999, Medium perfusion 
enhances osteogenesis by murine osteosarcoma cells in three-dimensional 
collagen sponges, J Bone Miner Res, 14: 2118-2126. 
Musaro A, Giacinti C, Borsellino G, Dobrowolny G, Pelosi L, Cairns L, Ottolenghi S, 
Cossu G Bernardi G, Battistini L, Molinaro M, Rosenthal N. 2004, Stem cell-
mediated muscle regeneration is enhanced by local isoform of insulin-like 
growth factor 1, Proc Natl A cad Sci USA, 101: 1206-1210. . 
Muzzarelli RA. 1997, Human enzymatic activities related to the therapeutIc 
administration of chitin derivatives, Cell Mol Life Sci, 53: 131-140. 
Muzzarelli RA, Mattioli-Belmonte M, Tietz C, Biagini R, Ferioli G, Brunelli MA, 
Fini M, Giardino R, Hari P, Biagini G. 1994, Stimulatory effect on bone 
formation exerted by a modified chitosan, Biomaterials, 15: 1075-1081. 
200 
Nagaya N, Fujii T, Iwase T, Ohgushi H, Itoh T Uematsu M Yam . h' MM' H 
Kang'lwa K K't S 20 ' ,agis I , on , (. .' I amura: 04, I?tra~enous administration of mesenchymal 
stem cells l~prove~ cardIac functIon In rats with acute myocardial infarction 
through angIogenesIS and myogenesis, Am J Physiol Heart Circ PhlJsiol 287' 
H2670-2676. ;.T , • 
Nery EB, LeGeros RZ, L.ynch. KL, ~ee K. 1992, Tissue response to biphasic calcium 
phosphate ceramIC With dIfferent ratios of HA/beta TCP in periodontal 
osseous defects, J Periodontol, 63: 729-735. 
Notingher I, Jell G, Lohbauer U, Salih V, Hench LL. 2004 In situ non-invasive 
spe~tral . discrimination between bone cell phenot~pes used in tissue 
engineenng, J Cell Biochem, 92: 1180-1192. 
Oates M: Che~ R, Duncan M, Hunt JA. 2007, The angiogenic potential of three-
dImensIonal open porous synthetic matrix materials, Biomaterials 28: 3679-
3686. ' 
Ohgushi H, Caplan AI. 1999, Stem cell technology and bioceramics: from cell to 
gene engineering, J Biomed Mater Res, 48: 913-927. 
Ohgushi H, Okumura M. 1990, Osteogenic capacity of rat and human marrow cells in 
porous ceramics. Experiments in athymic (nude) mice, Acta Orthop Scand, 
61: 431-434. 
Ohtsuki C, Kushitani H, Kokubo T, Kotani S, Yamamuro T. 1991, Apatite formation 
on the surface of Ceravital-type glass-ceramic in the body, J Biomed Mater 
Res, 25: 1363-1370. 
Okano T, Bae YH, Jacobs H, Kim SW. 1990, Thermally on-off switching polymers 
for drug permeation and release, Journal of Controlled Release 11: 255-265. 
Oliveira JM, Rodrigues MT, Silva SS, Malafaya PB, Gomes ME, Viegas CA, Dias 
IR, Azevedo JT, Mano JF, Reis RL. 2006, Novel hydroxyapatite/chitosan 
bilayered scaffold for osteochondral tissue-engineering applications: Scaffold 
design and its performance when seeded with goat bone marrow stromal cells, 
Biomaterials, 27: 6123-6137. 
Olivo M, Bhardwaj R, Schulze-Osthoff K, Sorg C, Jacob HJ, Flamme I. 1992, A 
comparative study on the effects of tumor necrosis factor-alpha (TNF -alpha), 
human angiogenic factor (h-AF) and basic fibroblast growth factor (bFGF) on 
the chorioallantoic membrane of the chick embryo, Anat Rec, 234: 105-115. 
Oonishi H, Kushitani S, Yasukawa E, Iwaki H, Hench LL, Wilson J, Tsuji E, 
Sugihara T. 1997, Particulate bioglass compared with hydroxyapatite as a 
bone graft substitute, Clin Orthop Relat Res: 316-325. 
Oreffo RO, Triffitt JT. 1999, Future potentials for using osteogenic stem cells and 
biomaterials in orthopedics, Bone, 25: 5S-9S. 
Palmer WK, Emeson EE, Johnston TP. 1998, Poloxamer 407-induced atherogenesis 
in the C57BL/6 mouse, Atherosclerosis, 136: 115-123. 
Pang EK, Paik JW, Kim SK, Jung UW, Kim CS, Cho KS, Kim CK, ~hoi. SH. 2005, 
Effects of chitosan on human periodontal ligament fibroblasts In VItro and on 
bone formation in rat calvarial defects, J Periodontol, 76: 1526-1533. 
Park DJ, Choi BH, Zhu SJ, Huh JY, Kim BY, Lee SH. 2005, Injectable bo~e using 
chitosan-alginate gel/mesenchymal stem cellslBMP-2 compOSItes, J 
Craniomaxillofac Surg, 33: 50-54. 
Park JK, Chang HN. 2000, Microencapsulation of microbial cells, Biotechnol Adv, 
18: 303-319. 
201 
Patashnik S, Rabinovich L Golomb G 1997 P . 
. ? . . ,reparatton and evaluation of chitosan 
mIcro spheres containIng blSphosphonates, J Drug Target, 4: 371-380. 
Pec EA, Wout ZG, JohnstO? TP. 1:92, Biological activity of urease formulated in 
~~~~xamer 407 after lntrapentoneal injection in the rat, J Pharm Sci, 81: 626-
Pelletier A, Lemire I,. Syguch J. 1990, Chitinlchitosan transformation by thermo-
mechano-c?en:l1cal . treatment including characterization by enzymatic 
depolymenzatIon, Biotechnology and bioengineering, 36: 310-315 
Perets A, Baruch Y, ~ e~sbuch F, Shoshany G, Neufeld G, Cohen S. 2003, Enhancing 
!he vasc~larlzatIon of three-dimensional porous alginate scaffolds by 
IncorporatIng controlled release basic fibroblast growth factor micro spheres J 
Biomed Mater Res A, 65: 489-497. ' 
Peter SJ, Lu L, Kim DJ, Mikos AG. 2000, Marrow stromal osteoblast function on a 
poly(propylene fumarate )lbeta-tricalcium phosphate biodegradable 
orthopaedic composite, Biomaterials, 21: 1207-1213. 
Pinney E, Liu K, Sheeman B, Mansbridge J. 2000, Human three-dimensional 
fibroblast cultures express angiogenic activity, J Cell Physiol, 183: 74-82. 
Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman 
MA, Simonetti DW, Craig S, Marshak DR. 1999, Multilineage potential of 
adult human mesenchymal stem cells, Science, 284: 143-147. 
Potapova lA, Gaudette GR, Brink PR, Robinson RB, Rosen MR, Cohen IS, Doronin 
SV. 2007, Mesenchymal stem cells support migration, extracellular matrix 
invasion, proliferation, and survival of endothelial cells in vitro, Stem Cells, 
25: 1761-1768. 
Prevot M. Dejugnat C, Mohwald H, Sukhorukov GB. 2006, Behavior of temperature-
sensitive PNIPAM confined in polyelectrolyte capsules, Chemphyschem, 7: 
2497-2502. 
Prockop DJ. 1997, Marrow stromal cells as stem cells for nonhematopoietic tissues, 
Science, 276: 71-74. 
Prolo DJ, Rodrigo JJ. 1985, Contemporary bone graft physiology and surgery, Clin 
Orthop Relat Res: 322-342. 
Qian Y, Yao G, Lin Z, Chen J, Fan Y, Davey T, Xu J, Zheng M. 2009, Natural bone 
collagen scaffold combined with OP-1 for bone formation induction in vivo, J 
Biomed Mater Res B Appl Biomater. 
Quarles LD, Yohay DA, Lever LW, Caton R, Wenstrup RJ. 1992, Distinct 
proliferative and differentiated stages of murine MC3T3-E1 cells in culture: 
an in vitro model of osteoblast development, J Bone Miner Res, 7: 683-692. 
Ratner BD, Hoffman AS. 1976, 'Synthetic hydrogels for biomedical applications' in 
Hydrogels for medical and related applications, eds. Andrade JD, American 
Chemical Society, Washington; 1-36. . ' 
Ren D, Yi H, Wang W, Ma X. 2005, The enzymatic degradatton and swel~lng 
properties of chitosan matrices with different degrees of N -acetylatton, 
Carbohydr Res, 340: 2403-2410. . 
Reubinoff BE Pera MF Fong CY, Trounson A, Bongso A. 2000, EmbryonIC stem 
cell li~es from' human blastocysts: somatic differentiation in vitro, Nat 
Biotechnol, 18: 399-404. . 
Reyes M, Verfaillie CM. 2001, Characterization of multipotent adult ~roge~ltor cells: 
a subpopulation of mesenchymal stem cells, Ann N Y Acad SCI, 938. 231-233, 
discussion 233-235. 
202 
Ribatti D. Nico B, Vacca A, Roncali L, Burri PH D1onov V 2001 Ch . 11 t' b'l1 'J. ,onoa an OIC me~ rane .capi ~y bed: a useful target for studying angiogenesis and anti-
. . angIogenesIs In VIVO, Anat Rec, 264: 317-324. 
Rlbath D, yrbinati C, Nico B, Rusn~ti .M, ~oncali L, Presta M. 1995, Endogenous 
basIc fibrobl?st gro~h factor IS ImplIcated in the vascularization of the chick 
. . embryo chonoallantolc membrane, Dev BioI, 170: 39-49. 
RibattI D .. Vacca. A, Roncali L, Dammacco F. 2000, The chick embryo 
cho~Ioallan~oIc membrane as a model for in vivo research on anti-
angIogenesIs, Curr Pharm Biotechnol, 1: 73-82. 
Richards ~, Huibregts~ BA, Caplan AI, Goulet JA, Goldstein SA. 1999, Marrow-
denved progenItor cell injections enhance new bone formation during 
distraction, J Orthop Res, 17: 900-908. 
Richardson TP, Peters MC, Ennett AB, Mooney DJ. 2001, Polymeric system for dual 
growth factor delivery, Nat Biotechnol, 19: 1029-1034. 
Rifkin DB, Moscatelli D. 1989, Recent developments in the cell biology of basic 
fibroblast growth factor, J Cell BioI, 109: 1-6. 
Ripamonti U, Ramoshebi LN, Matsaba T, Tasker J, Crooks J, Teare J. 2001, Bone 
induction by BMPs/OPs and related family members in primates, J Bone Joint 
Surg Am, 83-A Suppll: SI16-127. 
Rosenberg A. 1999, 'Bones, joints, and soft tumors' 6th edition ed in Robins 
pathological basis of disease, eds. Cotran RS, Kumar V, Collin T, W.B. 
Saunders, Philadelphia; 1215-1268. 
Roughley P, Hoemann C, DesRosiers E, Mwale F, Antoniou J, Alini M. 2006, The 
potential of chitosan-based gels containing intervertebral disc cells for nucleus 
pulposus supplementation, Biomaterials, 27: 388-396. 
Rou\vkema J, de Boer J, Van Blitterswijk CA. 2006, Endothelial cells assemble into a 
3 -dimensional prevascular network in a bone tissue engineering construct, 
Tissue Eng, 12: 2685-2693. 
Ruel-Gariepy E, Chenite A, Chaput C, Guirguis S, Leroux J. 2000, Characterization 
of thermo sensitive chitosan gels for the sustained delivery of drugs, Int J 
Pharm, 203: 89-98. 
Sandford P. 1989, 'Chitosan: commercial uses and potential applications' in Chitin 
and Chitosan, eds. Skjak-Braek G, Anthonsen T, Sandford P, Elsevier 
Applied Science, London and New York; 51-70. 
Schmitz JP, Hollinger JO. 1986, The critical size defect as an experimental model for 
craniomandibulofacial nonunions, Clin Orthop Relat Res: 299-308. 
Schwartz RE, Reyes M, Koodie L, Jiang Y, Blackstad M, Lund T, Lenvik T, Johnson 
S, Hu WS, Verfaillie CM. 2002, Multipotent adult progenitor cells from bone 
marrow differentiate into functional hepatocyte-like cells, J Clin Invest, 109: 
1291-1302. 
Seol YJ, Lee JY, Park YJ, Lee YM, Young K, Rhyu IC, Lee SJ, Han SB, Chung ~P. 
2004, Chitosan sponges as tissue engineering scaffolds for bone formatIon, 
Biotechnol Lett, 26: 1037-1041. . 
Seshi B, Kumar S, Sellers D. 2000, Human bone marrow stromal cell: coexpreSSIon 
of markers specific for multiple mesenchymal cell lineages, Blood Cells Mol 
Dis, 26: 234-246. 
Shamblott MJ Axelman J, Wang S, Bugg EM, Littlefield JW, Donovan PJ, 
Blume~thal PD, Huggins GR, Gearhart JD. 1998, Derivation of pluripotent 
203 
stem cells from cultured human primordial germ cells Proc Natl A d ('I • US 
A, 95: 13726-13731. ,  DCI 
Shangari ~, ~ruce WR, Poon ~, O'Bri~n Pl. 2003, Toxicity of glyoxals--role of 
oXldatIve stress, metabohc detoxlfication and thiamine deficiency Biochem 
Soc Trans, 31: 1390-1393. ' 
Sikavitsas VI. Temenoff lS, Mikos AG. 2001, Biomaterials and bone 
mechanotransduction, Biomaterials, 22: 2581-2593. 
Silver KL, Kain KC Liles we. 2007, Endothelial activation and dysregulation: A 
common pathway to organ injury in infectious diseases associated with 
systemic inflammation, Drug Discov Today Dis Mech, 4: 215-222. 
Sims CD, Butler PE, Cao YL, Casanova R, Randolph MA, Black A, Vacanti CA, 
Yaremchuk MJ. 1998, Tissue engineered neocartilage using plasma derived 
. polymer substrates and chondrocytes, Plast Reconstr Surg, 101: 1580-1585. 
Smlth A. 1998, Cell therapy: in search of pluripotency, Curr Bioi, 8: R802-804. 
Smith A. 2001, 'Embryonic stem cells' in Stem cell biology, eds. Marshak DR, 
Gardner RL, Gottlieb D, Cold Spring Harbor Laboratory Press, New York; 
205-230. 
Solchaga LA, Dennis lE, Goldberg VM, Caplan AI. 1999, Hyaluronic acid-based 
polymers as cell carriers for tissue-engineered repair of bone and cartilage, J 
Orthop Res, 17: 205-213. 
Solchaga LA, Gao 1, Dennis lE, Awadallah A, Lundberg M, Caplan AI, Goldberg 
VM. 2002, Treatment of osteochondral defects with autologous bone marrow 
in a hyaluronan-based delivery vehicle, Tissue Eng, 8: 333-347. 
Solter D, Gearhart 1. 1999, Putting stem cells to work, Science, 283: 1468-1470. 
Song 1. Sub CH, Park VB, Lee SH, Yoo NC, Lee lD, Kim KH, Lee SK. 2001, A 
phase IIlIa study on intra-articular injection of holmium-166-chitosan 
complex for the treatment of knee synovitis of rheumatoid arthritis, Eur J 
Nucl Med, 28: 489-497. 
Soria B, Skoudy A, Martin F. 2001, From stem cells to beta cells: new strategies in 
cell therapy of diabetes mellitus, Diabetologia, 44: 407-415. 
Sorlier P, Denuziere A, Viton C, Domard A. 2001, Relation between the degree of 
acetylation and the electrostatic properties of chitin and chitosan, 
Biomacromolecules, 2: 765-772. 
South-Paul lE. 2001, Osteoporosis: part I. Evaluation and assessment, Am Fam 
Physician, 63: 897-904, 908. 
Spangrude Gl, Heimfeld S, Weissman IL. 1988, Purification and characterization of 
mouse hematopoietic stem cells, Science, 241: 58-62. 
Staton CA, Stribbling SM, Tazzyman S, Hughes R, Brown Nl, Lewis CEo 2004, 
Current methods for assaying angiogenesis in vitro and in vivo, Int J Exp 
Pathol, 85: 233-248. . 
Steinbrech DS, Mehrara Bl, Saadeh PB, Chin G, Dudziak ME, Ge?"ets RP, Glttes 
GK, Longaker MT. 1999, Hypoxia regulates VEGF expreSSlon and cellular 
proliferation by osteoblasts in vitro, Plast Reconstr Surg, 104: 738-747. 
Street 1 Winter D, Wang lH, Wakai A, McGuinness A, Redmond HP. 2000, Is 
human fracture hematoma inherently angiogenic?, Clin Orthop Relat Res: 
224-237. . I 
Strobel ES, Gay RE, Greenberg PL. 1986, Characterization of ~he in VltrO stroma 
microenvironment of human bone marrow, Int J Cell Cloning, 4: 341-356. 
204 
Strong DM, Frie~laender GE. To~ford WW, Springfield DS, Shives IC, Burchardt 
H, . ~nnekln~ WF. Mankin HJ. 1996, Immunologic responses in human 
recIpients of osseous and osteochondral allografts Clin Orthon Relat Res' 
107-114. ' y . 
Suh lK: Matt~ew. HW .. 2000. Application of chitosan-based polysaccharide 
blomatenals In cartIlage tissue engineering: a review Biomaterials 21' 2589-
2598. ' , . 
Tang YL. Zhao Q. Qin X, Shen L, Cheng L, Ge 1, Phillips MI. 2005, Paracrine action 
enhances the effects of autologous mesenchymal stem cell transplantation on 
vascular regeneration in rat model of myocardial infarction, Ann Thorac Surg 
80: 229-236~ discussion 236-227. ' 
Temenof! lS, Lu L. Mikos AG. 2000, 'Bone-tissue engineering using synthetic 
biodegradable polymer scaffolds' in Bone Engineering, eds. Davies lE, 
Toronto: em squared incorporated454-461. 
Temenoff lS, Mikos AG. 2000, Injectable biodegradable materials for orthopedic 
tissue engineering, Biomaterials, 21: 2405-2412. 
Thomas KA. 1996, Vascular endothelial growth factor, a potent and selective 
angiogenic agent, J Bioi Chem, 271: 603-606. 
Thomson lA, Itskovitz-Eldor 1, Shapiro SS, Waknitz MA, Swiergiel 11, Marshall VS, 
10nes 1M. 1998, Embryonic stem cell lines derived from human blastocysts, 
Science, 282: 1145-1147. 
Trivedi N~ Keegan M, Steil GM, Hollister-Lock 1, Hasenkamp WM, Colton CK, 
Bonner-Weir S, Weir GC. 2001, Islets in alginate macrobeads reverse diabetes 
despite minimal acute insulin secretory responses, Transplantation, 71: 203-
21l. 
Trombi L, Mattii L, Pacini S, D'Alessandro D, Battolla B, Orciuolo E, Buda G, Fazzi 
R. Galimberti S, Petrini M. 2008, Human autologous plasma-derived clot as a 
biological scaffold for mesenchymal stem cells in treatment of orthopedic 
healing, J Orthop Res, 26: 176-183. 
Tuli R, Seghatoleslami MR, Tuli S, Wang ML, Hozack W1, Manner P A, Danielson 
KG, Tuan RS. 2003, A simple, high-yield method for obtaining multipotential 
mesenchymal progenitor cells from trabecular bone, Mol Biotechnol, 23: 37-
49. 
Tung CYM, Dynes Pl. 1982, Relationship between visco-elastic properties and 
gelation in thermosetting systems, Journal of Applied Polymer Science, 27: 
569-574 
Uchida N, Weissman IL. 1992, Searching for hematopoietic stem cells: evidence that 
Thy-1.1Io Lin- Sca-1 + cells are the only stem cells in C57BL/Ka-Thy-1.1 
bone marrow, J Exp Med, 175: 175-184. . . . 
Ueno A, Kitase Y, Moriyama K, Inoue H. 2001-b, MC3T3-E1-cond~tIo~ed medlum-
induced mineralization by clonal rat dental pulp cells, Matrix BIOI, 20: 347-
355. d h r 
Ueno H, Mori T, Fujinaga T. 2001-a, Topical formulations and woun ea Ing 
applications of chitosan, Adv Drug Deli~ Rev, 5~: 105-115. . 
Urist MR, Strates BS. 1971, Bone morphoge~etIc proteIn,. J Dent Res,.50 .. 1392-1.4?6. 
Vacanti lP, Langer R. 1999, Tissue engineenng: the. design and fabncatI.on of hVlng 
replacement devices for surgical reconstruction and transplantation, Lancet, 
354 Suppll: SI32-34. 
205 
Vallet-Regi ~, Gonzalez-Calbet JM. 2004, Calcium phosphates as substitution of 
bone ttssues, Progress in Solid State Chemistry, 32: 1-31. 
VandeVord PJ: Matthew ~W, DeS~I~~ SP, Mayton L, Wu B, Wooley PH. 2002, 
Evaluatton of the blocompattblhty of a chitosan scaffold in mice, J Biomed 
l\/ater Res. 59: 585-590. 
Varum KM, Ho.lme HK, Iz.ume M, Stokke BT, Smidsrod O. 1996, Determination of 
enzymattc hydrolysIs specificity of partially N-acetylated chitosans Biochim 
Biophys Acta. 1291: 5-15. ' 
Vehof JW. Haus MT. de Ruijter AE, Spauwen PH, Jansen JA. 2002 Bone formation 
in transforming growth factor beta-I-loaded titanium fiber me~h implants Clin 
Oral Implants Res, 13: 94-102. ' 
Vermonden ~. Fedorovich NE, van Geemen D, Alblas J, van Nostrum CF, Dhert WJ, 
Hennink. WE. 2008, Photopolymerized thermo sensitive hydrogels: synthesis, 
degradatton, and cytocompatibility, Biomacromolecules, 9: 919-926. 
Verzijl N. Bank RA, TeKoppele JM, DeGroot 1. 2003, AGEing and osteoarthritis: a 
different perspective, Curr Opin Rheumatol, 15: 616-622. 
Vilquin JT, Rosset P. 2006, Mesenchymal stem cells in bone and cartilage repair: 
current status, Regen Med, 1: 589-604. 
Vunjak-Novakovic G, Martin I, Obradovic B, Treppo S, Grodzinsky AJ, Langer R, 
Freed LE. 1999, Bioreactor cultivation conditions modulate the composition 
and mechanical properties of tissue-engineered cartilage, J Orthop Res, 17: 
130-138. 
Walker PR, Saas P, Dietrich PY. 1997, Role of Fas ligand (CD95L) in immune 
escape: the tumor cell strikes back, J Immunol, 158: 4521-4524. 
Wang C, Duan Y, Markovic B, Barbara J, Howlett CR, Zhang X, Zreiqat H. 2004, 
Phenotypic expression of bone-related genes in osteoblasts grown on calcium 
phosphate ceramics with different phase compositions, Biomaterials, 25: 
2507-2514. 
Wang L, Shelton RM, Cooper PR, Lawson M, Triffitt JT, Barralet JE. 2003-b, 
Evaluation of sodium alginate for bone marrow cell tissue engineering, 
Biomaterials, 24: 3475-3481. 
Weinand C, Pomerantseva I, Neville CM, Gupta R, Weinberg E, Madisch I, Shapiro 
F, Abukawa H, Troulis MJ, Vacanti JP. 2006, Hydrogel-beta-TCP scaffolds 
and stem cells for tissue engineering bone, Bone, 38: 555-563. 
Weinreb M, Shinar D, Rodan GA. 1990, Different pattern of alkaline phosphatase, 
osteopontin, and osteocalcin expression in developing rat bone visualized by 
in situ hybridization, J Bone Miner Res,S: 831-842. 
Weiss MJ, Orkin SH. 1996, In vitro differentiation of murine embryonic stem cells. 
New approaches to old problems, J Clin Invest, 97: 591-~95. . . 
Weissman IL. 2000, Translating stem and progenitor cell bIology to the chnIc: 
barriers and opportunities, Science, 287: 1442-1446. 
Westphal CH, Leder P. 1997, Transposon-generated 'knock-out' and 'knock-in' gene-
targeting constructs for use in mice, Curr BioI, 7: 530-533. 
Whang K, Tsai DC, Nam EK, Aitken M, Spragu~ SM, Patel PK, Heal~ KE. 1998, 
Ectopic bone formation via rhBMP-2 dehvery from porous bioabsorbable 
polymer scaffolds, J Biomed Mater Res, 42: 491-499 .. 
Wikesjo UM, Sorensen RG, Wozney JM .. 2?01,. Au~me~tatton of a~veol~r bone and 
dental implant osseointegration: chnical Imphcattons of studIes WIth rhBMP-
2, J Bone Joint Surg Am, 83-A Suppll: SI36-145. 
206 
Wilting J, Chri.st B. Bokeloh M, Weich HA. 1993, In vivo effects of vascular 
endothehal growth factor on the chicken chorioallantoic membrane C II 
Tissue Res, 274: 163-172. ' e 
Wu J, Su Z, ~a GH. ~006, A thermo- and pH-sensitive hydrogel composed of 
quaternized chitosan/glycerophosphate, International Journal of 
Pharmaceutics, 315: 1-11 
Wu W. Ch~n F, Liu ~. Ma Q, Ma? T. 2007, Autologous injectable tissue-engineered 
cartIlage by uSIng platelet-nch plasma: experimental study in a rabbit model J 
Oral Maxillofac Surg. 65: 1951-1957. ' 
Yamad~ y. Ueda M. Na!ki T, Takahashi M, Hata K, Nagasaka T. 2004, Autogenous 
I?Jectable bo~e for re~eneration with mesenchymal stem cells and platelet-
nch plasma: hssue-engineered bone regeneration, Tissue Eng, 10: 955-964. 
Yang EY, M~ses !lL. 199?, Tr~sforming growth factor beta I-induced changes in 
cell nugrahon. prohferahon, and angiogenesis in the chicken chorioallantoic 
membrane,JCell Bioi, 111: 731-741. 
Yang S, Leong KF, Du Z, Chua CK. 2001, The design of scaffolds for use in tissue 
engineering. Part I. Traditional factors, Tissue Eng, 7: 679-689. 
Yaszemski MJ. Payne RG, Hayes WC, Langer R, Mikos AG. 1996-a, Evolution of 
bone transplantation: molecular, cellular and tissue strategies to engineer 
human bone, Biomaterials, 17: 175-185. 
Yaszemski MJ, Payne RG, Hayes WC, Langer RS, Aufdemorte TB, Mikos AG. 
1995, The Ingrowth of New Bone Tissue and Initial Mechanical Properties of 
a Degrading Polymeric Composite Scaffold, Tissue Engineering 1: 41-52. 
Yoo JU, Barthel TS, Nishimura K, Solchaga L, Caplan AI, Goldberg VM, Johnstone 
B. 1998, The chondrogenic potential of human bone-marrow-derived 
mesenchymal progenitor cells, J Bone Joint Surg Am, 80: 1745-1757. 
Yoshikawa T, Ohgushi H, Nakajima H, Yamada E, Ichijima K, Tarnai S, Ohta T. 
2000, In vivo osteogenic durability of cultured bone in porous ceramics: a 
novel method for autogenous bone graft substitution, Transplantation, 69: 
128-134. 
Yoshikawa T, Ohgushi H, Tarnai S. 1996, Immediate bone forming capability of 
prefabricated osteogenic hydroxyapatite, J Biomed Mater Res, 32: 481-492. 
Younger EM, Chapman MW. 1989, Morbidity at bone graft donor sites, J Orthop 
Trauma, 3: 192-195. 
Yuan H, Li Y, de Bruijn JD, de Groot K, Zhang X. 2000, Tissue responses of calcium 
phosphate cement: a study in dogs, Biomaterials, 21: 1283-~290. 
Yuan H, Yang Z, De Bruij JD, De Groot K, Zhang X. 2001, Matenal-dependent bone 
induction by calcium phosphate ceramics: a 2.5-year study in dog, 
Biomaterials, 22: 2617-2623. 
Zan J, Zhu D, Tan F, Jiang G, Lin Y, Ding F. 2006, Prep~ration of thermo sensitive 
chitosan formulations containing 5-FluorouracIl/poly-3-hydroxybutyrate 
microparticles used as injectable drug delivery system, Chinese Journal of 
Chemical Engineering, 14: 235-241 . 
Zhu H, Mitsuhashi N, Klein A, Barsky LW, Weinberg K, Barr ML, Demetnou A, Wu 
GD. 2006, The role of the hyaluronan receptor CD44 in mesenchymal stem 
cell migration in the extracellular matrix, Stem Cells, 24: 928-935. 
Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang 11, Mi~uno H: Alfo?so ZC, Fraser 
JK, Benhaim P, Hedrick MH. 2002, Human adIpose tIssue IS a source of 
multipotent stem cells, Mol Bioi Cell, 13: 4279-4295. 
207 
